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Abstract
Diabetes mellitus is a globally growing disease with more than 180 million
cases worldwide and no cure exists. In order to minimize the many medi-
cal complications, tight glucose monitoring has been shown to be the best
alternative. Many diabetics require insulin injections to regulate their glu-
cose level and, as of today, the insulin quantity to be delivered can only be
determined on the basis of finger stick measurements. Such measurements
are painful and insufficient, and therefore continuous glucose monitoring
systems are necessary. A few devices are recently available for 2 - 7 days
of use, but since these devices adopt a semi-invasive principle, they are not
suited for long term (e.g. 1 year) monitoring. In practice, it is necessary for
a long term sensor to be implanted and such a device does not exist yet.
A novel method has been recently developed in our laboratory to con-
tinuously monitor the glucose concentration in the subcutaneous intersti-
tial fluid. The method uses an implanted rotating microviscometer to mea-
sure the viscosity variations of a glucose-sensitive fluid due to the glucose
concentration changes. The present work investigates solutions for a bio-
compatible interface between the living tissues and the sensitive fluid en-
closed in the device. Because the sensitive fluid contains two necessary
molecules, dextran and concanavalin A, the interface has to selectively re-
tain these two solutes whilst being permeable to glucose.
On the basis of the requirements of the sensor, a wide literature search
and theoretical considerations, two selective interfaces have been selected
among the most actual technologies: hybrid membranes composed of a
nanoporous alumina membrane coated with poly(poly(ethylene glycol) me-
thacrylate) (PPEGMA) brushes and nanoporous polyethylene films, which
have different advantages from each other. A theoretical model for the tran-
sient diffusion of a solute through membranes permitted to quantify the
membrane performance.
Both selective interfaces have been characterized systematically and their
selectivity to a test protein has been demonstrated. Furthermore, the link
between the diffusion rate of glucose and the protein retention threshold
has been highlighted, which enabled to determine the membrane perfor-
mance without complex analysis. The optimized hybrid porous alumina-
PPEGMA selective interface revealed sufficient retention properties of dex-
tran and ConA in diffusion cells over 48 hours.
In a second step, the hybrid selective interface has been integrated to a
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latest implantable sensor demonstrator and the interface performance has
been investigated under an environment mimicking the in vivo conditions.
Since the integrated demonstrator showed a good ability to respond to glu-
cose variations in vitro, the system has been transferred for in vivo experi-
mentation. An in vivo test has been carried out over 5 days in a rat model,
and the implantation as well as the transcutaneous data acquisition have
been successfully demonstrated. Finally, the sensor capability to respond
to glucose variation in a rat model has been shown and solutions for further
development of the device are proposed.
Keywords: biofouling, biocompatibility, continuous glucose monitor-
ing, Concanavalin A, dextran, dialysis, glucose concentration sensing, gly-
cemia, glucose affinity sensor, selective interface, microviscometer, nano-
porous membrane, long term implantable sensor, biosensor, interstitial im-
plantable sensor, diabetes management, membrane, in vivo, minimally in-
vasive, molecular selectivity, diabetes technology, coaxial viscometer.
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Résumé
Le diabète est une maladie grandissante qui s’étend à 180 millions de cas
dans le monde et aucun remède n’existe. Afin de minimiser les nombreuses
complications, il a été démontré qu’une gestion fine de la glycémie reste
la meilleure alternative. Beaucoup de diabétiques ont besoin d’injections
d’insuline pour réguler leur glycémie et, de nos jours, le dosage ne peut
être déterminé qu’en se basant sur des mesures par prélèvement d’une
goutte de sang. De telles mesures sont douloureuses et insuffisantes. Par
conséquent, un système qui mesure en continu la glycémie est nécessaire.
Quelques dispositifs sont disponibles depuis peu pour une utilisation sur 2
à 7 jours, mais puisque ceux-ci ont recours à une méthode semi-invasive, ils
ne sont pas adaptés à une utilisation à long terme (p. ex. 1 an). En pratique,
il est nécessaire qu’un capteur long terme soit implanté, et un tel appareil
n’existe pas encore.
Une nouvelle méthode a été récemment mise au point dans notre lab-
oratoire pour mesurer en continu la concentration de glucose dans le flu-
ide interstitiel sous-cutané. La méthode utilise un implant qui consiste en
un micro-viscosimètre rotatif pour mesurer les variations de viscosité d’un
fluide sensible aux changements de concentration de glucose. Le travail
présenté examine des solutions pour une interface biocompatible entre les
tissus vivants et le fluide sensible contenu dans le dispositif. Puisque le
liquide sensible contient deux molécules indispensables, le dextrane et la
concanavaline A, l’interface doit sélectivement retenir ces deux composants
tout en étant perméable au glucose.
En se basant sur les besoins du capteur, une recherche littéraire élargie
et des considérations théoriques, deux interfaces sélectives ont été choisies
parmi les technologies les plus récentes : des membranes hybrides com-
posées d’une membrane en alumine revêtue de poils en poly(poly(ethylene
glycol) methacrylate) (PPEGMA) et des films de polyéthylène nanoporeux,
qui présentent chacun des avantages différents. Un modèle théorique pour
la diffusion transitoire d’un soluté au travers d’une membrane nous a per-
mis de quantifier les performances des interfaces.
Les deux interfaces sélectives ont été caractérisées systématiquement et
leur sélectivité à une protéine test a été démontrée. De plus, le lien entre
le taux de diffusion du glucose et le seuil de rétention d’une protéine a été
mis en avant, ce qui a permis de déterminer la performance de la mem-
brane sans une analyse complexe. L’interface sélective hybride composée
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d’alumine poreuse et de PPEGMA a présenté des propriétés de rétention
suffisantes du dextrane et de la concanavaline A dans des cellules de diffu-
sion sur 48 heures.
Dans un deuxième temps, l’interface sélective hybride a été intégrée à
un nouveau démonstrateur du capteur de glucose implantable. La per-
formance de l’interface a été examinée dans un environnement imitant les
conditions in vivo. Etant donné que le démonstrateur intégré a montré une
bonne capacité à répondre aux variations de glucose in vitro, le système
a été transféré pour une expérimentation in vivo. Ce test a été effectué
sur une durée de 5 jours dans un modèle de rat, l’implantation ainsi que
l’acquisition de données transcutanée ont été démontrés avec succès. Fi-
nalement, la capacité du capteur à répondre aux variations de glycémie
dans un modèle de rat a été montrée. Des solutions pour un futur développe-
ment du dispositif sont proposées.
Mots clés: bioencombrement, biocompatibilité, mesure de glucose en
continu, concanavaline A, dextrane, dialyse, détection de la concentration
de glucose, glycémie, capteur de glucose, interface sélective, micro-viscosi-
mètre, membrane nanoporeuse, capteur implantable long terme, biocap-
teur, capteur implantable sous-cutané, gestion du diabète, membrane, in
vivo, peu invasif, sélectivité moléculaire, technologie du diabète, viscosimè-
tre coaxial.
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Chapter 1
Introduction
1.1 Background & motivations
The World Health Organization1 (WHO) estimates that more than 180 mil-
lion people worldwide have diabetes. This number is likely to more than
double by 2030. The world prevalence is mapped in figure 1.1. In 2005,
an estimated 1.1 million people died from diabetes type 1. Almost 80% of
diabetes deaths occur in low and middle-income countries. Almost half of
diabetes deaths occur in people under the age of 70 years; 55% of diabetes
deaths are in women. WHO projects that diabetes deaths will increase by
more than 50% in the next 10 years without urgent action. Most notably,
diabetes deaths are projected to increase by over 80% in upper-middle in-
come countries between 2006 and 2015. In many countries in Asia, the Mid-
dle East, Oceania and the Caribbean, diabetes affects 12-20% of the adult
population.
Diabetes is increasing faster in the world’s developing economies than
in developed countries. The developing countries will bear the brunt of this
epidemic in the 21st century, with 80% of all new cases of diabetes expected
to appear in the developing countries by 2025. If present trends persist, by
2025 the majority will be in the 45-64 age group. In a generation, diabetes
has had a six-fold increase. Seven out of ten countries with the highest
number of people living with diabetes are in the developing world. With
an estimated 35 million people with diabetes, India has the world’s largest
diabetes population.
Diabetes is a silent epidemic that claims as many lives each year as
HIV/AIDS. In 2007, diabetes caused 3.5 million deaths globally2.
Diabetes mellitus can now be found in almost every population in the
world and epidemiological evidence suggests that, without effective pre-
vention and control programmes, diabetes will likely continue to increase
1http://www.who.int
2http://www.worlddiabetesfoundation.org
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The top 10 countries, 
in numbers of people 
with diabetes, are:
India   
China
USA    
Indonesia
Japan
Pakistan
Russia  
Brazil   
Italy
Bangladesh
Year     2000    2030
Ranking Country People with diabetes (millions)
1  India   31.7    79.4
2  China   20.8    42.3
3 United States of America 17.7    30.3
Figure 1.1: World map of the diabetes prevalence in the active population.
Source: World Health Organization
globally.
Before insulin was discovered in 1921, diabetes was a deadly illness.
Today, there is still no cure for diabetes, the best way to avoid health com-
plication is to manage the illness through tight glucose monitoring together
with insulin injections. Less acute cases of type 2 diabetes can manage it
through an adapted diet and lifestyle, or simple oral medication can be
prescribed.
The first company to introduce a blood glucose measurement system
for home use was A.R.M. in 19653. The Dextrostix were paper strips cov-
ered with a chemical reagent whose color was changing with the addition
of a drop of blood. The reaction had to be timed for one minute, and was
then washed off. The strip developed a color which was compared to a
3http://www.mendosa.com/history.htm
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worldwide list.
Source: http://www.mendosa.com/noninvasive_glucose.pdf
color chart for glucose concentration determination. The system was not
quantitative, but gave an approximation of the blood glucose level. In ad-
dition, it was more designed for physician’s office than home use. Later
in 1970, realizing that the Dextrostix were difficult to read, Anton Hubert
Clemens developed a reflectance meter. The instrument measured the color
of the reflected light from the Dextrostix strips and made their use more
convenient.
Today, at the beginning of the 21st century, not much has changed in
the world of glucose measuring techniques. Of course, the meters have be-
come more accurate, smaller and require less blood volume. But there is
still no painless solution commercially available to measure the blood glu-
cose concentration. The research for an alternative method, which would
prevent diabetics to prick their fingers, has been going on for the last 30
years. Today the motivation is growing drastically, and it becomes an ev-
idence if one looks at the increasing number of filed patents in the United
States on the topic of non-invasive glucose measuring methods, see figure
1.2.
It stands to reason that the motivation toward better glucose measuring
techniques is also economical. In 2007, the glucose monitoring market is
estimated worldwide to over six billion US dollars and it is obvious that
3
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the massive demand from patients will guarantee an immediate financial
success for the organization that finally finds a solution.
As actual non-invasive measuring method fail providing a reliable de-
vice, research groups are focusing on long-term implantable glucose sen-
sors, also called minimally invasive. Such a device would allow a con-
stant monitoring of the human glycemia and would considerably improve
the quality of life of diabetics. Moreover, it would generalize the real-time
closed-loop insulin regulation. Such a system, joining a glucose sensor and
an insulin pump, is called an artificial pancreas.
In 2008 no one has succeeded in bringing a long-term implantable glu-
cose sensor to commercial realization. Most insulin dependent diabetics
still rely on 2 - 6 glucose measurements per day to manage their insulin in-
jections, like thirty years ago. Therefore a implantable device would repre-
sent a major breakthrough in the diabetes management and overall health
of the patients.
Our team, through the Implantable GLUcose Sensor (IGLUS) project,
aims at the realization of such a long-term implantable glucose sensor.
1.2 Diabetes
In this section, an overview of diabetes is presented. We intend to give basic
information about the disease and its different forms, and shortly present
the different complications.
Diabetes mellitus is recognized as a group of heterogeneous disorders
with the common elements of hyperglycaemia and glucose intolerance due
to insulin deficiency, impaired effectiveness of insulin action, or both.
Diabetes mellitus is classified on the basis of aetiology and clinical pre-
sentation of the disorder into three main types: Type 1 diabetes, Type 2
diabetes, gestational diabetes and other specific types4.
1.2.1 Type 1
Type 1 diabetes results from cellular-mediated autoimmune destruction of
pancreatic islet β-cells causing the loss of insulin production. It ranks as
the most common chronic childhood disease in developed nations, but oc-
curs at all ages and the clinical presentation can vary with age. Figure 1.3
presents a schematic of the the glucose regulation.
Type 1 diabetes in an adult may masquerade as Type 2 diabetes at pre-
sentation with a slow deterioration in metabolic control, and subsequent
progression to insulin dependency. This form is called latent autoimmune
4http://www.eatlas.idf.org
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Figure 1.3: The pancreas has many islets that contain insulin-producing β-
cells and glucagon-producing α-cells. Insulin and glucagon have opposite
effects on liver and other tissues for controlling blood-glucose levels.
Source: http://health.howstuffworks.com/diabetes1.htm
diabetes mellitus in adults (LADA). LADA falls within Type 1 autoimmune
diabetes, but in a slowly progressive form, in the new WHO classification.
The predominant cause of hyperglycaemia in Type 1 diabetes is the au-
toimmune destruction of the β-cells, which leads to absolute dependence
on insulin treatment and a high rate of complications typically occurring at
relatively young ages.
1.2.2 Type 2
Type 2 diabetes is characterized by insulin resistance and relative insulin
deficiency, either of which may be present at the time that diabetes becomes
clinically manifest. The specific reasons for the development of these ab-
normalities are not yet known.
The diagnosis of Type 2 diabetes usually occurs after the age of 40 years
although the age of onset is often a decade earlier in populations with a
high diabetes prevalence. People with Type 2 diabetes may not show any
symptoms for many years and the diagnosis is often made from associated
complications or incidentally through an abnormal blood or urine glucose
test.
Type 2 diabetes is often, but not always, associated with obesity, which
5
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itself can cause insulin resistance and lead to elevated blood sugar levels. It
is strongly familial, but major susceptibility genes have not yet been iden-
tified. In contrast to Type 1 diabetes, persons with Type 2 diabetes are not
dependent on exogenous insulin and are not ketosis-prone, but may re-
quire insulin for control of hyperglycaemia if this is not achieved with diet
alone or with oral hypoglycaemic agents.
Type 2 diabetes constitutes about 85% to 95% of all diabetes in devel-
oped countries, and accounts for an even higher percentage in developing
countries. It is now a common and serious global health problem, which,
for most countries, has evolved in association with rapid cultural and social
changes, ageing populations, increasing urbanization, dietary changes, re-
duced physical activity and other unhealthy lifestyle and behavioural pat-
terns.
1.2.3 Gestational
The most widely accepted definition of gestational diabetes mellitus (GDM)
is "carbohydrate intolerance of varying degrees of severity with onset or
first recognition during pregnancy". This definition applies regardless of
whether insulin is used for treatment or the condition persists after preg-
nancy. It does not exclude the possibility that unrecognized glucose intol-
erance may have occurred before the pregnancy.
It is widely believed that differences in reported prevalence of GDM
parallel the differences that have been found in the frequency of Type 2
diabetes among different populations. Nonetheless GDM is increasing in
prevalence in concert with the worldwide rise in Type 2 diabetes.
1.2.4 Complications of diabetes
While insulin allows a person with Type 1 diabetes to stay alive, it does not
cure the disease, nor does it prevent the development of serious complica-
tions, which can be many and varied. High blood sugar levels eventually
damage blood vessels, nerves, and organ systems in the body. Among the
potential complications of diabetes are:
Cardiovascular disease
Cardiovascular disease, a range of blood vessel system diseases that in-
cludes both stroke and heart attack, is the major cause of death in people
with diabetes. The two most common types of cardiovascular disease are
coronary heart disease, caused by fatty deposits in the arteries that feed the
heart, and hypertension, or high blood pressure. Research shows that peo-
ple with diabetes are more likely to have high cholesterol and hypertension,
both of which cause damage to the cells lining the artery walls. Researchers
6
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think high blood glucose contributes to both of these conditions.
Hypoglycemia
Hypoglycemia, low blood sugar, is a dangerous condition for people with
diabetes. It can be triggered by not eating often enough, eating too little
food, too much physical activity without eating, or too much insulin. Peo-
ple with diabetes can usually tell when their blood sugar is low. But the
more episodes of hypoglycemia you have, the harder it gets for your body
to detect the next episode. In severe forms, hypoglycemia can lead to un-
consciousness or even death. For patients with Type 1 diabetes, fear of
hypoglycemia is a major obstacle to maintaining tight blood glucose con-
trol.
Nephropathy
Diabetic kidney disease, also known as diabetic nephropathy, is one of the
most common and most devastating complications of diabetes. It is a slow
deterioration of the kidneys and kidney function which, in severe cases,
can eventually result in kidney failure, also known as end-stage renal dis-
ease, or ESRD. About one third of people with Type 1 diabetes develop
nephropathy.
Neuropathy
Neuropathy, or nerve damage, affects more than 60% of people with Type
1 diabetes. The impact of nerve damage can range from slight inconve-
nience to major disability and even death. Diabetic neuropathy leads to loss
of feeling and sometimes pain and weakness in the feet, legs, hands, and
arms, and is the most common cause of amputations not caused by accident
in the United States. In one type of neuropathy, known as autonomic neu-
ropathy, high glucose levels injure the autonomic nervous system, which
controls bodily functions such as breathing, circulation, urination, sexual
function, temperature regulation, and digestion. Autonomic neuropathy
may result in various types of digestive problems, diarrhea, erectile dys-
function, a rapid heartbeat, and low blood pressure.
Retinopathy
Diabetic retinopathy is the most common and serious eye-related compli-
cation of diabetes. It is a progressive disease that destroys small blood ves-
sels in the retina, eventually causing vision problems. In its most advanced
form (known as "proliferative retinopathy") it can cause blindness. Nearly
all people with Type 1 diabetes show some symptoms of diabetic retinopa-
thy, usually after about 20 years of living with diabetes; approximately 20
to 30% of them develop the advanced form.
1.2.5 Glucose concentration range in blood
The blood glucose concentration (or blood sugar concentration or glucose
level) is tightly regulated in the human body. In non-diabetics, the concen-
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Figure 1.4: Glycemia evolution of a diabetic over one day. The green
points represent the points-in-time monitoring obtained with finger-stick
measurements, and the blue curve the real glycemia.
tration is maintained between 4 and 8 mM (72 to 144 mg/dl). The total
amount of glucose in the circulating blood is therefore between 3.3 to 7 g
(assuming an ordinary adult blood volume of 5 l). This amount is rather
low compared to the body needs. As a comparison, 1dl of Coca-Cola has
30 g of sugar. As a general rule, the glucose concentration is at its lowest
level in the morning before the first meal, and rises after every meal.
Diabetics have a much broader range of blood glycemia depending on
the way they manage the condition. If not or poorly controlled, the blood
glucose level can, in extreme cases, reach 50 mM (900 mg/dl). An example
of the glycemia excursion of a diabetic over day is depicted in figure 1.4.
Hypoglycemia is defined below a threshold of 4 mM (72 mg/dl). Above
a concentration of 8 mM (144 mg/dl), it is considered as a hyperglycemia.
In between, the term normoglycemia is used. There is no absolute defini-
tion for the two thresholds, since these values can differ slightly depending
on the patient and physician.
Commercially available strip glucose meters have a typical measuring
range of 0.6 to 33.3 mM (10-600 mg/dl).
1.3 Needs for glucose regulation
Many of the complications of diabetes can be prevented through tight con-
trol of glucose levels. Two landmark studies on diabetes treatment were
the Diabetes Control and Complications Trial (DCCT), completed by the
National Institutes of Health in 1993 among 1’400 Type 1 diabetes patients,
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and the United Kingdom Prospective Diabetes Study (UKPDS) completed
in 1998 with 5’000 Type 2 diabetes patients. These studies demonstrated
that tight glucose control, involving various therapeutic interventions as
well as three or more glucose measurements daily, substantially reduced
morbidity and mortality among these diabetes patient populations.
In addition, the DCCT showed that intensive glucose control dramati-
cally delays or prevents the eye, nerve, and kidney complications of Type
1 diabetes. A paradigm shift in the way Type 1 diabetes is controlled was
based on this finding. As researchers continued to follow study partic-
ipants, they found that tight glucose control also prevents or delays the
cardiovascular complications of Type 1 diabetes, such as heart attack and
stroke5.
Even before a closed-loop artificial pancreas is available, continuous
glucose monitoring (CGM) is expected to help people with diabetes bet-
ter manage glucose levels. In fact, clinical studies [21] have shown that
patients using CGMs spend much more time in the normal glucose range
compared with patients using conventional finger-stick blood glucose meth-
ods. With tighter control, as measured by long-term hemoglobin A1c test-
ing, their risk of complications should drop dramatically.
1.4 The market
In 2007 the glucose monitoring market is estimated worldwide to be over
six billion dollars. Earlier, in 2004, the market was estimated at 5 billions,
mostly shared by four big companies as presented in figure 1.5.
As for the economic burden of the disease, 5 to 10% of the world’s
healthcare budget is currently spent on diabetes, and by 2025 this figure
could reach 40% in some countries if predictions of diabetes prevalence are
fulfilled6. Most of the economic costs of diabetes are attributable to the
various complications linked to it, with up to two-thirds of people with di-
abetes in certain countries developing serious chronic complications. The
American Diabetes Association estimated in 2007 diabetes costs to be $174
billion each year for the United States, $58 billion thereof generated by indi-
rect costs. Health expenditure due to diabetes for Europe was $120 billion
in 2007. While increasing in incidence, diabetes already represents a sub-
stantial burden to health systems. For Switzerland, costs caused by this
disease currently represent 5 - 10% of the health expenses. A device that
can lower the costs is ensured to rapidly take market shares.
5Source: http://www.nih.gov
6Source: http://www.idf.org
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Figure 1.5: Glucose test sensor market in 2004. Source: Abbott Laborato-
ries.
1.5 This work
As described in section 1.1, diabetes mellitus is a globally growing disease.
In order to minimize the medical complications, tight glucose monitoring
is required. As of today, however, the insulin quantity to be delivered can
only be determined on the basis of finger stick measurements. CGM de-
vices are recently available for 2 - 7 days of use, but since these devices
adopt a semi-invasive principle, they are not suited for long term (e.g. 1
year) monitoring. In practice, it is necessary for a long term sensor to be
implanted and such a device does not exist yet.
The IGLUS is an implant type sensor and is meant for a continuous use
over 1 year. The original idea of the IGLUS comes from Dr. Sigi Straessler,
Dr. med. Klaus Ganz and Prof. Dr. Peter Ryser, and has been engineered
by members of the Laboratoire de Production Microtechnique at EPFL.
The work presented in this thesis intends to develop a molecular selec-
tive interface (SI) for the IGLUS which is based on a glucose-sensitive fluid
containing dextran and concanavalin A. The SI is one of the biggest pieces
of the puzzle for the IGLUS to function, and is essential to be understood
to design an optimum system. One of the other important pieces is a mi-
croviscometer, which was thoroughly investigated in a previous work [22],
and consists of a novel method to continuously monitor the viscosity vari-
ations of the sensitive fluid due to the glucose concentration changes. The
last piece of the puzzle is the sensitive fluid (SF).
Deeper in details, this work aims to select a better membrane for the
IGLUS and to give tools for this purpose. We focused on the realization of a
working IGLUS demonstrator in vitro, which is then applied to in vivo stud-
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ies. In order to select an optimum membrane, the functioning of every com-
ponent of the sensor must be well understood. Another task of this work
is to choose the best known technologies for each component and integrate
them to build the IGLUS demonstrator. The vision of the overall project
is to create a commercial product, and therefore the choices must integrate
existing and suitable technologies for production. The chosen SIs charac-
terized in this work are a hybrid membrane composed of a nanoporous
alumina membrane coated with poly(poly(ethylene glycol) methacrylate)
brushes (PPEGMA) and a nanoporous polyethylene (PE) film. The hybrid
membrane was developed by Dr. Laurent Lavanant in the laboratory of
Prof. Dr. Harm-Anton Klok. And the PE films were developed by Prof. Dr.
Hiroki Uehara.
In the following, a state-of-the-art in glucose measuring technologies
is presented to start with, and the IGLUS concept and functioning are de-
scibed. Then the basics and requirements to design the SI are introduced
and followed by the results of characterization of the chosen SI through
glucose diffusion and protein retention measurements in diffusion cells.
Afterwards, the in vitro assessment of the SI on a latest IGLUS demonstra-
tor is discussed. The last part of this work describes the first application of
the IGLUS to in vivo environment and the related results are analyzed for
future improvement.
11
Chapter 1. Introduction
12
Chapter 2
State of the art in glucose
measuring technologies
2.1 Introduction
The glucose concentration in the body can be measured by various tech-
niques, which are applied either to the interstitial fluid or to the blood.
They can be summarized in 3 groups: electrochemical, spectroscopic and
mechanical methods.
Nowadays, the standard measuring technique is the test strip, which re-
lies on an electrochemical principle. Since a blood sample must be taken for
every measurement, the method is painful and the frequency of measure-
ments is limited. The only potential commercially available alternatives are
semi-invasive needle sensors. These are quite new and cannot replace the
test strips at present. The barriers are both scientific and regulatory1. In-
deed their reliability is not sufficient and reference measurements still need
to be done using strips. Due to the infection risks, the semi-invasive nee-
dle sensors are short-term sensors (2 - 7 days). A long-term solution can
only be achieved with an implantable sensor, but no commercial product is
available, nor any FDA2 or CE3 approved device. As discussed in section
1.3, continuous glucose monitoring (CGM) sensors represent the optimal
way for glycemia regulation. It stands to reason that a long-term CGM
sensor would make very rich its inventors. Often companies prematurely
disclosed that they were close to a solution, but were not. Now, diabetics,
investors and researchers are suspiciously awaiting a working device for
over thirty years [23]. It is difficult to gather reliable information from the
1http://www.jdrf.org
2U.S. Food and Drug Administration, responsible agency for the safety regulation of
medical devices in USA.
3"Conformité Européenne", certification required for medical devices in the European
Union.
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Figure 2.1: Schematic of the different glucose measuring techniques and
the key commercial products [1].
web sites of companies, therefore the present state-of-the-art is based on sci-
entific publications. Web sites are solely useful to have an overview of the
current products, as they tend to be too optimistic for marketing purposes.
However an independent web site keeps an objective list of the current
companies working on glucose monitoring: http://www.mendosa.com/-
meters.htm.
The different glucose measuring techniques and their related commer-
cially available devices are briefly described in the following sections. Fig-
ure 2.1 describes the different glucose measuring techniques together with
the key commercial products.
2.2 Electrochemical test strips
In 2008, the only reliable and approved glucose measurement for diabetes
management is the electrochemical test strip. This method requires the pa-
tient to take a blood sample of 0.3 to 1 µl (depending on devices) and place
it on a disposable test strip, which is connected to an electronic device (me-
ter) for data acquisition. The test strip contains a capillary that absorbs a
reproducible amount of blood on an enzyme electrode containing glucose
oxidase (GO). The enzyme is reoxidized with an excess of ferrocyanide ion
as schematized in figure 2.2. The total charge passing through the electrode
is measured and is proportional to the concentration of glucose. Some glu-
cose meters use another enzyme, the glucose dehydrogenase (GD).
Over twenty five different meters are available commercially. But four
14
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Figure 2.2: The electrochemical reaction in a glucose monitoring test strip
[2].
Table 2.1: Recent strip glucose meter from the four market leaders. GO
and GD stand for glucose oxidase and glucose dehydrogenase respectively.
Brand Glucose meter Blood
sample
Chemical
reaction
Roche
diagnostics
Accu-chek
Aviva/Advantage
0.6 µl GO
Abbott
diabetes care
FreeStyle/Flash/
Freedom
0.3 µl GD
Bayer Contour/Breeze 2 0.6/1 µl GO
Lifescan UltraSmart/
UltraMini
1 µl GO
major companies share almost 90% of the market. The latest glucose meters
from these companies are listed in table 2.1. The accuracy of such meters is
approximatively ±15%. This gives an estimate of the required accuracy for
glucose sensors.
Some recent glucose meters, like the Precision Xtra from Abbott Di-
abetes Care, integrate the measurement of β-hydroxybutyrate (β-ketone)
concentration in the blood to detect ketoacidosis, because diabetic ketoaci-
dosis is a life-threatening complication if not treated. Urine ketone test
strips are the only alternative.
2.3 Non-invasive sensors
As people suffering from diabetes need to measure frequently their glyce-
mia frequently, a system capable of a painless and continuous measure-
ment is highly demanded. It would avoid the pain caused by the finger
pricking and allow a tight control of the glycemia. A measuring method
which does not mechanically penetrate the skin or a body cavity is com-
monly named non-invasive. Such a method would highly ease and en-
hance the diabetes management or at least increase patients’ compliance.
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Table 2.2: Non-invasive optical, acoustic and electromagnetic glucose de-
tection methods.
Technique Definition Ref.
Polarimetry A reflected polarized light beam,
usually through the eye, contains in-
formation on the glucose concentra-
tion.
[26, 27, 28]
Near Infrared
(NIR) absorption
and scattering
Absorption or emission in the 0.7 to
2.5 µm region of the spectrum.
[29, 30, 31,
32]
Raman
spectroscopy
Probes the vibrational modes of glu-
cose with inelastic scattering of light.
[33, 34, 35,
36]
Photoacoustic The photoacoustic effect is based on
the generation of acoustic waves as a
consequence of light absorption.
[37, 38, 39,
40, 41]
Optical coherent
tomography
Low-coherence interferometry with
backscattered light from the tissue
using super bright LEDs or lasers
with extremely short pulses. The
light spectrum is in the range of 10
- 15 µm.
[42, 43, 44]
Impedance
spectroscopy
Dielectric investigation of cellular
membranes (influenced by glu-
cose). Electromagnetic frequency
spectrum: 1 to 200 MHz.
[45, 46, 47]
Currently developed non-invasive methods are mainly spectroscopic
and of the following types: optical, acoustic and electric. The general mea-
surement principle can be summarized as follows: a zone of skin or of the
eye is probed by sending a signal, and a signature is detected within the
response, which is obtained either by reflection, diffusion or scattering. D-
glucose can be detected through numerous spectroscopic signatures, but
the difficulty is to extract its signature in the complex environment that is
the body. The usual test sites are finger tips, forearm, ear lobe and eye.
Many different non-invasive techniques have been reviewed [24, 25] and
an overview is presented in table 2.2.
Though many different spectroscopic techniques exist, none has been
successfully integrated in a commercial working glucose meter yet. All
methods suffer from the fact that glucose has a chemical composition sim-
ilar to other components of its environment, and do not have the property
to show an important response to any of the methods. In other word, none
of these techniques is sufficiently selective to glucose to precisely detect its
16
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presence.
The only non-invasive glucose sensor that currently has an FDA ap-
proval is the GlucoWatch G2 Biographer from Cygnus. The device requires
a daily calibration and is only meant to monitor the glycemia trends. One
limitation is that the GlucoWatch system is not able to cope with sweat at
the measurement site. Due to such limitations, the product is no longer on
the market.
Besides these methods, other approaches to non-invasive glucose mon-
itoring are investigated. Some try to extract a small sample of interstitial
fluid through the skin by applying vacuum4 through the skin. Others ap-
ply a small electric current to the skin (ionophoresis) [31, 48, 49, 50, 51]. It
results that uncharged particles such as glucose are carried by electroos-
mosis to the cathode. However, as it is the case for the GlucoWatch, the
skin is often covered by sweat or other secretions which interfere with the
measurements, therefore the device requires recurrent calibrations.
2.4 Semi-invasive sensors
Semi-invasive glucose sensors are external devices with a probe inserted
through the skin into the subcutaneous tissues. In general, the probe con-
sists of a flexible needle or thin flexible probe and is disposed after a limited
time, between one to seven days for the actual sensors. The measurement
in the interstitial fluid of the subcutaneous tissue is suitable because it has
been demonstrated that there is a good correlation between the glucose
concentration in the interstitial fluid and the blood glucose concentration
[52, 53]. This correlation is subject to a lag time of 5 to 30 minutes depend-
ing on the implantation site.
The existing sensors employ different measuring methods. One cate-
gory measures the glucose concentration at the tip of a needle while an-
other extract a small amount of interstitial fluid. A third category uses a
dialysis type needle.
Needle type sensors are now present on the market, but only available
under medical prescription. Health care professionals use them for their
diabetic patients in order to have a clearer view of the glycemia evolu-
tion throughout the day. The system gives a continuous glycemic profile
which fills in the gaps left by punctual measurements, and can reveal hid-
den patterns, like frequent episodes of hypoglycemia (see figure 1.4). But,
at present, it is not meant for an every day use.
Needle glucose sensors still suffer from a poor reliability and accuracy,
especially in the hypoglycemic range [54, 55]. Even though several prod-
ucts have obtained the CE mark or FDA certification, they are not approved
4http://www.iit.edu/∼ipro331f04/ultrasound.html
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Figure 2.3: Dexcom STS semi-invasive electrochemical sensor. The image
on the right shows the sensor and the flexible needle which is inserted into
the skin.
to replace the finger stick method, only to supplement it or to serve as "glu-
cose trend monitors".
Besides the motivation to replace daily glucose testing, efforts have
been taken to develop a reliable short-term glucose sensor for use in clinical
environment, especially in intensive care units.
The main recent semi-invasive techniques and products are given be-
low and are separated in three categories: electrochemical, optical and me-
chanical methods.
2.4.1 Electrochemical needle glucose sensors
All FDA or CE approved devices are listed in table 2.3 and are based on
the glucose oxidase (GO) electrochemical method, which is described in
section 2.2. Electrochemical sensors are known to be a rapid and rather
reliable method in the short-term range. The accuracy of the cited contin-
uous glucose sensors is in the range of 14-20% [56]. As an example, the
minimally invasive sensor from Dexcom is shown in figure 2.3.
The GlucoDay from Menarini is particular because it uses the combina-
tion of two dialysis membranes and a GO-based sensor. A dialysis hollow
fiber (regenerated cellulose) with a molecular weight cut-off (MWCO) of
15 - 20 kDa is inserted subcutaneously. A perfusion solution flows in the
fiber and transports the glucose to the GO electrochemical sensor. The GO
probe is covered with a second dialysis membrane (cellulose ester) with a
MWCO of 100 Da, which prevents some interferant constituents of the in-
terstitial fluid (ascorbic and uric acid) from reaching the electrode. In sum-
mary, the GlucoDay distributes the dialysis process to two membranes, the
hollow fiber having a high MWCO and a high diffusivity to glucose, and
a membrane with a very low MWCO (very selective) and a poor glucose
diffusivity. The slow glucose diffusivity of the latter membrane is not an is-
sue since it directly covers the probe and hence the response time remains
18
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Table 2.3: Semi-invasive sensors: FDA or CE approved continuous glucose
monitoring devices. GO stands for glucose oxidase.
CGMS Gold GlucoDay-S Guardian TGMS
Company Medtronic Menarini Medtronic
Approval 1999 FDA 2002 CE 2004 FDA
Method GO µ-electrode Dialysis + GO GO µ-electrode
Life time 72 h 48 h 72 h
Calibration 4/day first day 4/day
Test freq. 5 min 5 min 5 min
Guardian RT STS Sensor FreeSytle Navigator
Company Medtronic DexCom Abbott
Approval 2005 FDA 2006 FDA 2008 FDA
Method GO µ-electrode GO probe GO probe
Life time 72 h 7 days 5 days
Calibration max 5/day every 12h 4 /5 days
Test freq. 5 min 5 min 1 minute
rapid.
2.4.2 Optical needle glucose sensors
The optical needle glucose sensor developed by Ballerstadt et al. [57] is
based on a fluorescence measurement. The principle is based on the re-
versible binding of fluorescent-labeled concanavalin A (ConA) to glucose
inside a colored Sephadex bread [58]. The fluorescent dye Alexa647 is
grafted to ConA and emits in the red visible light range (670 nm). The
fluorescent compound is placed at the tip of a glucose permeable needle
which is connected through an optical fiber to an external electronic de-
vice. The company BioTex5 is currently developing the device. The current
restriction of the method are the long-term stability and the decay of the
fluorescence intensity.
Pasic et al. [59, 60] proposed to measure the interstitial glucose concen-
tration using a dialysis hollow fiber coupled to a fiber optics sensor. The
glucose level is detected via oxygen consumption which occurs as a con-
sequence of the enzymatic reaction between glucose and immobilized GO.
Using an optical fiber, the probe is connected to an oxygen meter that uses
a phase-shift method for the determination of the luminescence decay time
which is then converted to oxygen concentration. A representation of the
probe is given in figure 2.4. This device is intended for intensive care units
5http://www.biotexmedical.com
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Figure 2.4: A) Schematic representation of the hybrid sensor. Both the
oxygen and the glucose concentration are measured through optic-fibers.
B) The sensor is implanted subcutaneously for a duration of 24 h.
since, compared to other GO-based systems, the sensitivity loss due to oxy-
gen is compensated.
Another interesting concept has been developed by GluMetrics LLC.
Their device, the GluCathTM, contains a glucose-sensitive boronic acid-
based polymer that fluoresces in the presence of glucose6. The polymer
is embodied in a catheter inserted into the venous periphery, and the sys-
tem allows a direct monitoring of blood glucose for up to 48 h. The tar-
geted market is critically ill patients in intensive care units. They pretend
to avoid stability issues due to oxygen interference by working without an
enzyme-based reaction. This device is still under development, and no in
vivo results are available.
No needle glucose sensor based on optical method currently holds a
FDA or CE approval. Nonetheless, several serious candidates are present
in the semi-invasive glucose monitoring area.
2.4.3 Mechanical needle glucose sensors
A needle glucose sensor based on a chemico-mechanical principle has been
developed by the swiss company Disetronic7 under the trade name Gluc-
6http://www.Glumetrics.com
7http://www.disetronic.com
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Figure 2.5: A) GlucOnline device prototype from Disetronic. B) Schema-
tic view of measuring principle. 1) Reservoir and pump. 2) Microdialysis
through semi-permeable membrane. 3) Subcutaneous tissue. 4) Collecting
vessel. The viscosity is measured via the two pressure sensors η1 and η2,
and gives the glucose concentration.
Source: www.disetronic.com.
Online. This company was acquired by Roche in 2003 and the project was
sold to Sensile Medical AG. The semi-invasive needle sensor measures the
viscosity variations of a glucose-sensitive fluid. The fluid is based on the
competitive binding affinity of the ConA lectin with glucose and dextran.
The needle encloses a dialysis hollow fiber in which the sensitive fluid
flows. A pump initiates the flow and the viscosity is determined by mea-
suring the pressure difference at both ends of the fiber via two pressure
sensors. The device is shown in figure 2.5. For every measurement, a new
dose of the sensitive fluid is used. The GlucOnline is dedicated to intensive
car units and can monitor glucose levels subcutaneously over 5 days.
The GlucOnline sensor has served as an inspiration to design our im-
plantable glucose sensor, the IGLUS. The IGLUS is based on a similar glu-
cose-sensitive fluid but uses a different method to measure the viscosity. As
detailed in section 3.3, the IGLUS uses a rotational microviscometer and the
sensitive fluid is kept during the sensor life time. The device is implantable
and therefore is suitable for a long-term activity.
2.5 Implantable sensors
Among existing implantable sensors, one can distinguish two groups: the
minimally invasive and the invasive sensors. The invasive category re-
quires surgery in order to be implanted. As for the minimally invasive
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ones, they can be implanted subcutaneously with a syringe-trocar upon a
local anesthesia. The IGLUS belongs to the minimally invasive implantable
sensors.
Since 1997, Animas corp.8 (acquired by Johnson & Johnson in 2005)
has been working on a long-term implantable continuous glucose sensor
which can be classified in the invasive category. They decided not to base
their sensor on the enzymatic method to avoid the known stability and
drift issues. The Animas sensor measures the near-infrared absorption of
blood and they target a sensor life time of over 5 years. The rather large
device (twice the size of a pacemaker) is surgically implanted under the
skin, and a probe, connected to the main device through an optical fiber,
is inserted in a blood vessel. The system has the advantage of indicating
directly the blood glycemia. However, the information about the sensor
has disappeared from Animas web site, which is not a sign of success.
The methods used for minimally invasive implantable sensors are elec-
trochemical, spectroscopic or mechanical, and are similar to the ones used
for non-invasive and semi-invasive sensors. A substantial number of de-
vices has been recently reviewed [61], and the Diabetes Monitor web site9
lists the many companies working on such systems. However, as of today
no device has been approved by the FDA or CE mark.
An interesting technology, based on fluorescence measurement, is de-
veloped in competition by two companies, Dexcom10 and Sensors for Medi-
cine and Science (SMSI)11. The devices embed the excitation source (LED)
in the sensing element which is a matrix containing fluorescent indicator
molecules (fluorophore). SMSI has a FDA pre-market approval applica-
tion process underway. Surprisingly, Dexcom has recently abandoned its
long-term implantable glucose sensor and now focuses its efforts on the
short-term needle sensor (see section 2.4.1).
Finally, three devices are classified in the mechanical implantable sen-
sors. The IGLUS (our sensor), which uses a rotatory microviscometric mea-
surement of viscosity-variable fluid containing dextran and ConA. The sen-
sor of Zhao et al. [62] uses a similar glucose-sensitive fluid, but measures
the viscosity with a vibrating cantilever. The latter uses a regenerated cel-
lulose membrane as a selective interface, but no data showing a continuous
monitoring have been published yet.
The third device is from Lei et al. [63]. The basic device structure is a
passive (inductor/capacitor (LC)) micromachined resonator coupled to a
stimuli-sensitive hydrogel, which is confined between a stiff nanoporous
membrane and a thin glass diaphragm. As glucose molecules pass through
the nanoporous membrane, the hydrogel swells and deflects the flexible
8http://www.animascorp.com
9http://www.diabetesmonitor.com/meters.htm
10http://www.dexcom.com
11http://www.s4ms.com
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glass diaphragm, which is the movable plate of the variable capacitor in the
totally integrated passive LC resonator. The corresponding change in reso-
nant frequency can be remotely detected. The nanoporous membrane used
to cap the hydrogel is an anodic alumina membrane with 200 nm pores
and a thickness of 60 µm (from Whatman International), and the glucose-
sensitive hydrogel is based on phenylboronic acid. We believe this sensor to
be a very promising technology, since it eliminates the necessity of a molec-
ular selective interface to retain the sensing molecule (boronic acid), since
it is covalently linked to a gel. The technology is at the proof-of-concept
stage.
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Chapter 3
The IGLUS viscosity based
glucose sensor
3.1 Introduction
Over the last thirty years, in the race for continuous glucose monitoring
(CGM), all spectroscopic and electromagnetic glucose detection methods
have failed providing a long-term device. The electrochemical methods,
based on enzyme-catalyzed reactions, are nowadays used for discrete mea-
surements and short-term CGM devices, but have some significant draw-
backs which make them not suitable for long-term CGM. First, glucose is ir-
reversibly consumed by enzymatic reaction during detection, which might
change the equilibrium glucose concentration in tissue and influence the
actual measured glucose level. Furthermore, the rate of glucose consump-
tion is diffusion limited. Any changes in diffusion layers (e.g. by cell depo-
sition, capsule formation) on the sensor surface affect the diffusion rate, i.e.
the device sensitivity [64]. In order to overcome such drawbacks, our labo-
ratory proposed a viscosity-based glucose sensor, the IGLUS (Implantable
GLUcose Sensor), which was invented by Dr. Sigi Straessler, Dr. med.
Klaus Ganz and Prof. Dr. Peter Ryser [65].
Our glucose sensing technology is based on the rheological property
of an aqueous solution which changes its viscosity with the glucose con-
centration [66]. The sensitive fluid (SF) is enclosed in a small cylindrical
capsule with a small cylindrical rotor, making the entity a small rotating
viscometer. The capsule is partially surrounded with a semipermeable
nanoporous membrane which allows the glucose concentration equilib-
rium with the surroundings. In order to measure the viscosity of the SF,
the sensing capsule is magnetically coupled to another capsule, the drive,
which is driven by coils and electronics as an electrical motor. Ultimately,
the measured viscosity values could be sent via RF communication to an
integrated PC-based base station. A fully integrated implanted sensor is
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Figure 3.1: Concept of implantable autonomous glucose sensor.
now under development and the concept is shown in figure 3.1.
The system is designed to be able to track the variation rate of glucose
levels and warn the user to impede hypo- or hyperglycaemia. The targeted
operational life of the sensor implant is 6-12 months, after which it would
need to be replaced. The concept shown in figure 3.1 foresees the implan-
tation site in the abdomen because medical studies have shown that the lag
time is reduced in the abdomen and is of the order of 4-10 min [67]. The
response time in this case is mainly determined by the time lag with which
the interstitial fluid glucose level follows the blood glucose level.
This measuring technique presents two important advantages. First,
the SF is very selective to glucose due to the properties of the concanavalin
A (ConA). Second, the method is very sensitive at low glucose concentra-
tion, which is crucial to prevent hypoglycemia. We believe that the method
has a better long-term stability than electrochemical methods. Further-
more, there are no weak signals to measure as in spectroscopic glucose
measuring methods.
Since the sensor fully integrated with its electronic is still at the con-
cept stage and under development, we worked with a simplified system
where only the sensing capsule is implanted and the acquisition system is
in an external hand-held reader which allows the viscosity measurements
through the skin. The reader communicates with a computer allowing the
user to monitor glucose levels continuously or on demand. The system is
detailed further in section 7.2.2.
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3.2 IGLUS project organization
The IGLUS is a multidisciplinary research project and therefore requires
to associate scientists of different fields. The organization of the different
groups is shown in figure 3.2.
The project is centered on the micro-engineering team since it is the ini-
tiator of the project and does the integration of the different technologies
to get a fully working system. As illustrated in figure 3.2, this interdisci-
plinary project consists of four major research subjects:
a) The micro-engineering is done at the Laboratoire de Production Mi-
crotechnique (LPM) at the EPFL by Julien Chassot, Olivier Haldimann,
Sadasing Kowlessur, Dr. Simon Kuenzi, Eric Meurville, Jean-Pierre Rou-
gnon, and myself (Antoine Barraud), supervised by Prof. Peter Ryser and
Eric Meurville. The micro-electronics for the future autonomous implant is
being investigated by Léandre Bolomey at the LPM under the supervision
of Eric Meurville.
b) The SF has been developed in a collaboration between the LPM, the
Laboratory of Regenerative Medicine and Pharmacobiology (Dr. Nela An-
gelova and Dr. Christine Wandrey) and Sensile Medical AG (Dr. Uwe Beyer
and Dr. Richard Meier). The developed SF has been further adapted for the
IGLUS requirements by Dr. Simon Kuenzi and Dr. Nao Takano.
c) The characterization of the selective interface (SI) is being investigated
by Dr. Nao Takano and myself (Antoine Barraud) at the LPM. Since the SI
is designed to be in contact with the subcutaneous tissue, this part has been
done in close collaboration with Dr. Laurent Lavanant at the Laboratoire
des Polymères at EPFL who investigates the surface modification of mem-
branes.
d) The in vivo tests are performed in a close collaboration with the Centre
d’application du vivant and ISREC institute of the EPFL. There are mainly
two fields investigated within the in vivo tests:
- the biocompatibility test of the sensor components and histological analy-
sis are performed by Dr. Jessica Dessimoz from the Histology Core Facility
of the EPFL.
- the in vivo studies of our sensor are performed by Christophe Boss, Véro-
nique Garea, Marcel Gyger, Pierre Latin, Dr. Nao Takano and myself (An-
toine Barraud) under the supervision of Dr. Gisèle Ferrand, veterinary of
the ISREC institute at EPFL.
The micro-viscometer and the acquisition system have been developed
by Dr. Simon Kuenzi in his PhD thesis [22].
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Figure 3.2: Structure of the IGLUS project.
3.3 Mechanical measuring principle
The mechanical measuring principle is a rotating microviscometer. A cylin-
drical rotor is enclosed in a cylindrical capsule, whose inner free space is
filled by the fluid where viscosity must be determined. The cylindrical ro-
tor is a diametrically magnetized magnet which can be actuated by electric
coils. The coils create a rotating magnetic field which leads to the rotor
rotation. A shear stress is thus applied to the fluid and is directly propor-
tional to its dynamic viscosity. For Newtonian liquids, the shear stress is
described as
τ = η
∂u
∂x
(3.1)
where τ is the shear stress, η the dynamic viscosity and ∂u∂x the velocity
gradient.
As illustrated in figure 3.3, the rotor is accelerated by the applied mag-
netic field up to a desired rotating velocity, at which the magnetic field
is switched off. The rotor then decelerates due to the shear stress applied
onto the fluid. The rotor velocity is measured by hall sensors and the decel-
eration curve is memorized for mathematical treatment. The deceleration
curve is fitted with a decreasing exponential function f (x) ∼ e−λt in order
to extract the damping factor λ. Calibration curves on calibrated oils and
SF define the dynamic viscosity η and the glucose concentration.
In order to have a small volume of SF in the microviscometer, a system
composed of two magnetically coupled microviscometer is employed. The
system is composed of the drive capsule, with a bigger size and greater
inertia, and the sensing capsule, whose size is minimized and hence has a
low moment of inertia. It is important to minimize the volume of liquid in
the sensing capsule because it minimizes the response time of the sensor to
glucose variations. In addition, it is also preferable to keep the SF quantity
small enough in order to avoid any risk that could be caused by leakage of
the SF which has a certain toxicity. The last point is important for a future
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Figure 3.3: Measurement principle of the implantable glucose sensor.
authorization of a product (FDA and CE approvals). Considering these
requirements, the drive capsule has been designed to provide a sufficient
moment of inertia to the two coupled rotors system. The two rotors are
strongly coupled and thus the measured damping factor λt results from
these two rotors. A previous work [22] has shown that λt = λd + λs, where
λd and λs are the damping factors of the drive and the sensing capsule
respectively.
The viscosity of the SF being highly dependent on the temperature, the
temperature has to be measured accurately. The temperature dependency
of the SF is presented in section 3.4. During the period of this work, we
chose to measure the temperature with a separated sensor. The measure-
ment system is detailed in section 6.4.
3.4 Sensitive Fluid
3.4.1 Chemical mechanism
The sensitive fluid (SF) used within the sensor is the key for glucose recog-
nition. It is based on the competing affinity of two saccharide species, glu-
cose and dextran, to a specific saccharide-binding protein, concanavalin A
(ConA). Dextran is a branched polysaccharide issued from bacteria [3] and
ConA is a lectin protein extracted from the jack bean (Canavalia ensiformis)
which affinity to glucose and mannose and their polysaccharides has been
described by Goldstein et al [68]. The interaction of ConA with polysaccha-
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Concanavalin A  Glucose Dextran
a) b)
Figure 3.4: Chemical mechanism of glucose recognition in the SF. a) at low
glucose concentration, b) at high glucose concentration.
rides involves the chain ends of the polymer, i.e. the ending glycosyl group
of a branch (see binding site on dextran in section 3.4.2.B).
In 1979, Schultz and Sims [69] proposed to sense glucose using the prop-
erties of ConA as an alternative system to electrochemical methods and
developed the first affinity sensor [70]. They used a fluorescence-labeled
dextran to measure the glucose concentration by optical means. Another
method, described by Ehwald and Ballerstadt in 1993 [66], measures the
viscosity changes of a suitable aqueous dispersion of dextran and ConA.
The method offers a sensitive, rapid and stable viscosity dependence on
the glucose concentration.
The viscosity variation of the aqueous dextran-ConA dispersion hap-
pens as follows:
- In the absence of glucose, a ConA + dextran dispersion (ca. 0.7% ConA
and 7% dextran [71]) is cross-linked by the dextran-ConA bonds and there-
fore highly viscous.
- Increasing the glucose concentration progressively removes the cross-links
by replacing dextran-ConA bonds with glucose-ConA ones. A single glu-
cose molecule being able to link to one ConA at a time, whereas dextran
can link to several, the cross-linked structure is disintegrated and the dis-
persion viscosity decreases.
Figure 3.4 depicts the mechanism. The reversibility of the chemical pro-
cess has been demonstrated [66]. This competing affinity principle may be
also exploited for other measurement techniques such as infrared or fluo-
rescence spectroscopy, by appropriate labeling of ConA and dextran.
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a) b)
Figure 3.5: Illustration of two forms of D-glucose. a) α-D-glucose (or α-D-
glucopyranose), b) open chain form of D-Glucose
3.4.2 Important components of the SF
In this work we employed the viscosimetric means with the SF. The major
ingredients which have important roles in the SF are described in details in
the following sections.
3.4.2.A Glucose
Glucose, also known as dextrose, D-glucose or D-glucopyranose, is a sim-
ple sugar (monosaccharide sugar, C6H12O6), occurring widely in most plant
and animal tissue [72]. We use the name D-glucose and is a short name for
dextrorotatory glucose. It is one of the two stereoisomers of aldohexose
and only D-glucose is biologically active. Aldohexose sugars have 4 chiral
centers giving 24 = 16 stereoisomers. These are split into two groups, L and
D, with 8 sugars in each. Glucose is one of these sugars, and L-glucose and
D-glucose are two of the stereoisomers. Only 7 of these are found in living
organisms, of which D-glucose (Glu), D-galactose (Gal), and D-mannose
(Man) are the most important.
D-glucose contains six carbon atoms, one of which is part of an alde-
hyde group, and is therefore referred to as an aldohexose. In solution,
the glucose molecule can exist in an open-chain (acyclic) form and a ring
(cyclic) form (in equilibrium), see figure 3.5. The cyclic form is the result of
a covalent bond between the aldehyde C atom and the C-5 hydroxyl group
to form a six-membered cyclic hemiacetal. At pH 7 the cyclic form is pre-
dominant. In the solid phase, D-glucose assumes the cyclic form. Because
the ring contains five carbon atoms and one oxygen atom, which resem-
bles the structure of pyran, the cyclic form of glucose is also referred to as
glucopyranose. In this ring, each carbon is linked to a hydroxyl side group
with the exception of the fifth atom, which links to a sixth carbon atom
outside the ring, forming a CH2OH group.
31
Chapter 3. The IGLUS viscosity based glucose sensor
α-1,6 linkage
α-1,3 linkage
OH
Figure 3.6: High molar mass branched dextran. Blue circle shows the ter-
minal glucose residue recognized by ConA.
3.4.2.B Dextran
Dextran (C6H10O5)n is an α-D-1,6-glucose-linked polysaccharide with side-
chains mainly α-D-1,3-linked to the backbone units of the Dextran polymer.
Other conformation exists and are discussed by Dimler et al. [73]. In com-
mon dextrans, the degree of branching is approximately 5% (i.e. 95% of
α-D-1,6 links). The branches are mostly 1-2 glucose units long1.
Dextran is obtained from fermentation of sucrose-containing media by
the Leuconostoc mesenteroides bacteria and its molecular weight can vary
from 12 to 600 million g/mol [74]. Optimization of this synthesis has shown
the possibility of varying the branching links (α-D-1,3, α-D-1,2 or α-D-1,4)
and increasing the degree of branching up to 14.7% as done by Kim et al.
[75]. The production of dextran being possible by various bacterial species
from two genera, Leuconostoc and Streptococcus, and by various conditions,
the dextran properties varies for every manufacturers and production lots.
The role of the dextran in the SF is to create the viscosity when cross-
linked by ConA. ConA has a specific affinity binding site to the end glu-
cose residues of the dextran branches, as depicted in figure 3.6, and thus
the degree of branching has an impact on the polymerization and the SF
viscosity. The dextran molecules have to be retained inside the sensor and
this is achieved by the membrane which has size exclusion properties for
diffusion. It is therefore important to characterize the size distribution of
the dextran molecules. Ioan et al. [3] have measured the radii of different
dextrans and their results in pure water are shown in figure 3.7. The com-
1http://www.dextran.net
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monly used radius is the hydrodynamic radius Rh or the Stokes radius, and
is the radius of a hard sphere that diffuses at the same rate as the molecule.
The behavior of this sphere includes hydration and shape effects. It is not
restricted to the effective radius of the hydrated molecule in solution. An-
other less common measure is the radius of gyration Rg, which is the root
mean square distance of the monomers from the center of gravity. The ra-
dius of gyration has the advantage to be easily determined experimentally
with static light scattering as well as with small angle neutron- and x-ray
scattering. Rh and Rg are similar as shown in figure 3.7.
As discussed previously in this section, dextran size distribution and
degree of branching vary a lot from batch to batch and therefore we have
decided to use only two specific types of dextrans: the dextran 2000 from
Fluka and the dextran DXTB3M from Polymer Standard Service GmbH
(PSS). These dextrans are expected to have a sufficiently large molecular
weight to be retained by a selective membrane. Then, in order to assess
the quality of the dextran 2000 kDa from Fluka which is sold without char-
acteristics on the molecular weight (MW) distribution, we characterized
it by Size-exclusion Chromatography (SEC) and we discovered a broad
molecular weight distribution and peak at 200 kDa. The average MW is
much lower than expected and the smaller molecules are suspected to leak
through the membrane. Therefore we used a purified dextran from PSS, the
dextran DXTB3M, which has a narrow MW distribution and a peak at 3200
kDa (see data sheet in appendix A). Unfortunately the degree of branching
of these polymers are unknown from the manufacturers.
3.4.2.C Concanavalin A
Concanavalin A (ConA), illustrated in figure 3.8, is the most studied mem-
ber of the legume lectin family. It was isolated from the jack bean (Canavalia
ensiformis) and crystallized for the first time in 1919 by Sumner [76]. One of
the most noteworthy properties of ConA is its affinity to α-D-glucopyrano-
syl and α-D-mannopyranosyl residues (α-D-glucose and α-D-mannose) and
their derived polymers. It was described by Goldstein et al. [68] and,
since then, numbers of publications on ConA characterization have been
made. The sugar binding site is depicted in figure 3.9. The primary and
tertiary structures are elucidated [77, 78], and the interactions between the
subunits that form the crystalline quaternary structure have been well de-
scribed [79]. Moreover, the topography of the binding site is described
[80, 4], as depicted in figure 3.8. ConA crystallizes as a tetramer of identical
25’500 g/mol molecular weight protomers [81], some of which are frag-
mented [82, 83]. The quaternary structure in solution is pH and temper-
ature dependent as it appears in dimer and tetramer configurations. The
size of the ConA monomer has been studied at 2-Å resolution [84] and is
reported to be a globular protein of overall dimensions 42× 40× 39 Å. The
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Figure 3.7: (A) Molar mass dependencies of the radius of gyration Rg
(circular symbols) and the hydrodynamic radius Rh (triangular symbols)
for different dextran samples in water: (N), (•) dextrans-Sigma; (gray
triangle), (gray circle) dextrans-degraded; (M), (◦) dextrans-Nordmeier.
B) The ratio ρ = Rg/Rh of the two radii as a function of the molar
mass Mw: () dextrans-Sigma; (gray tilted square) dextrans-degraded; (♦)
dextrans-Nordmeier; (O) pullulan-Nordmeier (dashed line: fit); () de-
graded starches. Source:[3]
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a) b)
Figure 3.8: Concanavalin A 3D structures; a) the globular tertiary structure
of the ConA monomer, b) the quaternary structure of the ConA tetramer
where the S1 and S2 sites are represented by the blue spheres and the glu-
cose molecules by the black and red spheres.
crystallographic size of the dimers is approximately 84× 40× 39 Å and in
water the hydrodynamic radius is Rh = 3.3 nm [84]. Finally the tetramer
conformation has been studied [79] and is the result of the association of
dimers. The crystallographic dimensions are 6× 7× 7 nm [62] and the hy-
drodynamic radius is Rh = 4.4 nm. The dimensions of molecules are listed
in table 3.1.
ConA exists as a dimer in solution at pH values below 5.5. Above pH
7 it exists mainly as a tetramer of identical subunits. In intermediate range
both dimer and tetramer exist [85, 86, 87, 88] and some ConA seems to
remain as dimer even above pH 7 [79, 89]. Each subunit of ConA has one
specific carbohydrate-binding site [4]. The isoelectric point is in the pH
range of 4.5-5.5. In literature, different pI values can be found for ConA
because it exists in slightly different forms [90].
For the SF to work properly in an implantable glucose sensor, the saccha-
ride-binding properties of ConA must stay constant. It has been known
for quite a long time that the saccharide affinity of ConA depends on the
presence of divalent metals within the protein [91]. These divalent metallic
cations must remain in the protein and not be substituted by others, as we
could expect the saccharide affinity to change. It is therefore important to
describe the ConA activity as a function of different metal cations.
In its natural form, ConA contains two divalent cationic sites S1 and
S2, occupied by Mn2+ and Ca2+ respectively, quite near the saccharide-
binding site [92]. This fully metallised protein is in an active "locked" form
(LMnCa). Upon leaching away of these cations (done by leaching e.g. with
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glucoside
ConA binding site
Figure 3.9: Hydrogen bonding interactions of glucoside in the binding site
of concanavalin A. The hatched lines depict hydrogen bonds between the
sugar and protein, and the doted line separates the two molecules. Source:
[4]
EDTA2 in acidic solutions) to give the metal-free "apportion", locked apo-
ConA (L) progressively undergoes a structural transformation (conforma-
tion change) to an "unlocked" form (U), whose saccharide affinity is very
low [93]. Subsequent exposure to free Mn2+ and Ca2+ leads to a reversal
of these transformations, e.g. metal uptake followed by a conformation
change back to the active locked form (LMnCa). The site occupation is es-
sentially sequential, in that S1 must be occupied (normally Mn2+) before
the 2nd metal ion (normally Ca2+) can go to S2 [93, 94]. The conformation
of ConA is the most important factor, before the cation content, determin-
ing saccharide affinity [95]. Reaching the locked state is not an issue as
long as ConA is fully metallised, because essentially all such ConA is in
the locked state (LM1M2), due to a strong thermodynamic stabilization in-
duced by locking. The protein must absolutely remain metallised, because
the apoprotein (U) is reported to unfold irreversibly at low temperatures
and high pH values: the onset of transformation is ca. 35˚C at pH 6.9.
The natural form of ConA (LMnCa), is quite stable: under normal phys-
iological pH, the equilibrium concentrations of Ca2+ and Mn2+ required to
keep ConA in this state are very low [93, 95, 96]. Moreover, the presence of
saccharide (glucose or dextran), at normoglycemia (5 mM), strongly stabi-
lizes metal bonding to ConA by a mass action effect, as evidenced from the
2EthyleneDiamineTetraAcetic acid
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Table 3.1: Molecular size of the main constituents in the sensitive solution.
RW is the van der Waals radius and Rh the hydrodynamic or Stokes radius.
The dimensions have been determined in the crystallin form.
Description Molecular weight Stokes radius or dimensions
Glucose 180.16 Da RW = 0.76− 0.85nm[106]
Dextran 2000 2’000 kDa Rh = 27nm [3]
Dextran 200 200 kDa Rh = 15nm [3]
ConA monomer 25,5 kDa 42× 40× 39 Å[78]
ConA dimer 52 kDa 84× 40× 39 Å[84]
Rh = 3.3nm
ConA tetramer 104 kDa 6× 7× 7nm [64]
Rh = 4.4nm
equilibrium constants [96], a stabilization which occurs to various degrees
for all metallised forms of ConA (see below).
In the case of a large concentration of Ca2+ and quasi absence of Mn2+,
both metal binding sites may be filled with Ca2+, or, vice versa with Mn2+
[97, 96]. However, the corresponding equilibrium concentrations to main-
tain these LCaCa or LMnMn forms are much higher, and the thermal sta-
bility of such modified ConA is lower [98]. In other words, there is a strong
thermodynamical advantage for the natural form vs. Mn2+ in S2 and es-
pecially Ca2+ in S1. However, this is not necessarily true for substitution
of Mn2+ in S1 by another divalent transition metal ion such as Ni2+, Co2+,
Zn2+, Cu2+, Cd2+, or even Mg2+ [99]. Substitution by Zn2+ or Cu2+ is quite
likely in the body, and also by Ca2+ and Mg2+, although much less favor-
able for ConA [100, 95], because of their much higher concentration. Sub-
stitution of Mn2+ by Mg2+ is also observed, and it is reported that Mg2+ is
actually more abundant in S1 of most natural lectins, including ConA [101].
Mg2+ is specific to S1 and has no significant affinity for S2.
The saccharide affinity of metallised, locked ConA (LM1M2) is almost
independent of the metal ions M1 and M2 present in S1 and S2 [102, 95,
103]. This possibility of double metal binding (LM1M1) has been chal-
lenged by Sophianopoulos and Sophianopoulos [104, 105] for Mn2+. How-
ever, double Mn2+ and Ca2+ binding [19] has been confirmed by a recent
detailed study [20], who successfully isolated and crystallised both the LM-
nMn and LCaCa forms.
Respective affinities of ConA having different transition metals in S1
are not known. The only comparative equilibrium values found are for
metallization of S1 of the apo-ConA with no Ca2+ or saccharide in solution
[99], which is not really pertinent to our conditions.
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Table 3.2: Product description and references for the SF. For a preparation,
only one type of dextran is used at a time and also one antiseptic, either
sodium azide or phenol.
Description Product details Ref.Num. and Brand
C6H12O6 D-(+)-Glucose anhydrous 49138 Fluka
(C6H10O5)n Dextran 2000 (Leuconostoc spp.) 95771 Fluka Sigma
(C6H10O5)n Dextran broad/branched dxtb3m PSS
ConA Concanavalin A, type IV C2010 Sigma
Tris buffer Trizma pre-Set crystals, pH 7.4 T-7693 Sigma
NaN3 Sodium azide 13412 Riedel-de Haen
C6H6O Phenol 77610 Fluka
MnCl2 Manganese(II) chloride tetrahydrate 31422 Riedel-de Haen
CaCl2 Calcium chloride dehydrate puriss. 21101 Fluka
NaCl Sodium chloride puriss. 71379 Fluka
NaOH Sodium hydroxide purum p.a. 71691 Fluka
Water Millipore water -
3.4.3 Preparation and viscosity measurements
3.4.3.A Preparation of the sensitive fluid
The different constituents used for the SF preparation are listed in Table 3.2.
In the sensitive solution, the most important substances are dextran,
ConA and glucose. These three substances create the special chemistry that
allows the detection of the glucose concentration variation via the viscosity
changes. Tris Buffer is used to stabilize the pH of the sensitive solution.
Sodium azide or phenol is used as an antiseptic. Sodium azide is preferred
for in vitro studies because it allows the use of UV spectrometry since phe-
nol has an absorption peek at 280 nm which interferes with protein detec-
tion. Phenol is preferred for in vivo studies because it is less toxic and is
accepted by the body in small quantities. Manganese chloride and calcium
chloride are necessary to activate the ConA in order for the protein to link to
saccharides (c.f. section 3.4.2.C). The sodium chloride is useful to enhance
the solubility of ConA and corresponds to physiological conditions.
To prepare the sensitive solution we first prepare three different stock
solutions (c.f. Table 3.3), which are then used for all preparations. Stock
solutions 1 and 3 are known to be very stable, but there is a doubt for solu-
tion 2, thus if the solution 2 is older than two weeks, it is replaced. Depend-
ing on the choice of the antiseptic (in vitro or in vivo use), stock solution 1a
or 1b is used.
The whole recipe consists of preparing two solutions, the dextran so-
lution and the ConA solution, which are mixed at the end. The following
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Table 3.3: Stock Solutions.
Solution Description Concentration
Stock solution 1a Tris buffer pH 7.4 20 mM
NaN3 0.1%(w/w)
Glucose 4 mM
H2O -
Stock solution 1b Tris buffer pH 7.4 20 mM
Phenol 0.4%(w/w)
Glucose 4 mM
H2O -
Stock solution 2 MnCl2 2 mM
CaCl2 2 mM
NaCl 300 mM
H2O -
Stock solution 3 NaOH 50 mM
H2O -
is an example procedure for a SF containing 3% dextran 2000, 0.6% ConA,
2 mM glucose and 0.1% (w/w) sodium azide. The preparation is for 10 ml
of final product.
STEP 1) Solution A (dextran 2000 solution, total 6 g, density 1 g/ml.):
1. Solubilize 360 mg dextran 2000 in 5.64 g stock solution 1a.
2. Mix for at least 8h.
3. Control that the final weight is 6 g.
STEP 2) Solution B (ConA solution, total 6 g, density 1 g/ml.):
1. Solubilize 72 mg ConA in 5 g stock solution 2. (72mg corresponds to
1.2% in the Solution B).
2. Slowly adjust the pH of the solution to 7.4 by adding the stock solu-
tion 3. This is a critical process and it should be done carefully. We
use a Tecan pump to add the stock solution 3 at a rate of 10 µl/min.
The initial pH is usually between 4 and 5. If the transition is made too
fast the ConA tends to be denaturated and precipitates. However this
process should not take too long either, because ConA has a tendency
to precipitate in the absence of dextran.
3. Correct the weight of the preparation to 6 g with stock solution 2.
4. Make sure the pH is 7.4.
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5. Centrifuge the solution at 4600 min−1 for 10 min.
STEP 3) Mixing solutions A and B
1. Put 5 g of Solution A in a clean glass container.
2. Add 5 g of solution B filtered through a Millex HV 0.45 µm syringe
filter.
3. Quickly mix both solutions. The solution may turn a bit milky during
the first seconds.
4. After mixing, the solution should be clearer, and the viscosity should
be much higher.
5. Check that the total weight is 10 g.
6. Gently mix the solution for 24 h before any viscosity measurement.
7. The sensitive solution is stored at room temperature.
3.4.3.B Viscosity properties of the prepared SFs
Measurement method
As a reference, we measured the viscosity of the prepared solution with
a capillary viscometer. The choice of this method relies on the following
requirements:
1. It has to be standard and commercially available
2. Accuracy has to be better than 1%
3. Small volume of necessary liquid due to high cost of constituents
4. Evaporation has to be minimized for viscosity stability over the mea-
surement time
5. Stabilized temperature
In order to fulfill the last point, the capillary viscometer is placed in a tem-
perature controlled vessel described in section 6.4. We used different capil-
laries with different diameters for different viscosity ranges acquired from
Schott Instruments GmbH3 and Cannon Instruments Company Inc.4.
The viscosity properties of the SF as a function of dextran from Fluka
and ConA concentrations have been studied systematically in a previous
work [22]. The concentrations of these constituents have thus been chosen
3http://www.schottinstruments.com
4http://www.cannoninstrument.com
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in order to suit the viscosity range for the sensor demonstrator, see chapter
6. As discussed in section 3.4.2.B, the Fluka dextran is polydisperse and
contains smaller molecules than specified by the manufacturer. In order to
ensure the dextran retention by the SI, we also used the dextran from PSS
which is sold purified with a narrow peak at 3200 kDa. In the forthcoming
experiments, we used different variants of SF and their reference viscosities
have been measured and are presented in the followings.
The SFs are named after the concentrations of dextran and ConA as well
as type of dextran. For example, the name SF36F stands for a SF prepared
with 3% of Fluka dextran and 0.6% of ConA, and the name SF24P with 2%
of PSS dextran and 0.4% of ConA.
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SF36F - 3% dextran 2000 Fluka, 0.6% ConA
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Figure 3.10: Viscosity characteristics of SF36F.
Table 3.4: Viscosity of sensitive fluid SF36F in mPa · s.
20◦C 25◦C 30◦C 35◦C 37◦C 40◦C
2mM 47.7 35.3 25.9 19.2 17.1 14.5
4mM 34.3 26.6 20.4 15.7 14.2 12.2
7mM 23.1 18.7 15.0 12.1 11.0 9.6
11mM 16.2 13.5 11.2 9.3 8.7 7.8
16mM 12.3 10.6 8.9 7.6 7.2 6.6
22mM 10.2 8.9 7.6 6.6 6.2 5.7
30mM 8.9 7.8 6.7 5.9 5.6 5.3
42
3.4. Sensitive Fluid
SF23P - 2% dextran 3200 PSS, 0.3% ConA
0 5 1 0 1 5 2 0 2 5 3 03
4
5
6
7
8
9
1 0
1 1
1 2
0 . 8
0 . 9
1 . 0
1 . 1
1 . 2
1 . 3
1 . 4
1 . 5
1 . 6

Vis
cos
ity [
mP
as]
	


  Re
lativ
e flu
idity
, re
f 4m
M
2 %  D e x t r a n  3 2 0 0  P S S0 . 3 %  C o n c a n a v a l i n  A
Figure 3.11: Viscosity characteristics of SF23P.
Table 3.5: Viscosity of sensitive fluid SF23P in mPa · s.
20◦C 25◦C 30◦C 35◦C 37◦C 40◦C
2 mM 11.7 9.8 8.2 6.8 6.3 5.7
4 mM 10.2 8.5 7.2 6.0 5.6 5.1
7 mM 9.0 7.6 6.5 5.5 5.2 4.7
11 mM 8.0 6.8 5.8 5.0 4.7 4.3
16 mM 7.0 6.1 5.2 4.5 4.3 4.0
22 mM 6.4 5.5 4.7 4.2 4.0 3.7
30 mM 5.9 5.1 4.4 3.9 3.7 3.5
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Figure 3.12: Viscosity characteristics of SF24P.
Table 3.6: Viscosity of sensitive fluid SF24P in mPa · s.
20◦C 25◦C 30◦C 35◦C 37◦C 40◦C
2 mM 21.6 16.7 13.1 10.3 9.4 8.1
4 mM 16.9 13.6 10.9 8.8 8.1 7.2
7 mM 12.9 10.7 8.9 7.3 6.8 6.2
11 mM 10.4 8.7 7.3 6.2 5.8 5.3
16 mM 8.8 7.4 6.3 5.4 5.1 4.7
22 mM 7.7 6.6 5.7 4.9 4.6 4.3
30 mM 6.8 5.9 5.1 4.5 4.2 4.0
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Figure 3.13: Viscosity characteristics of SF36P.
Table 3.7: Viscosity of sensitive fluid SF36P in mPa · s.
20◦C 25◦C 30◦C 35◦C 37◦C 40◦C
2 mM 141.4 115.6 85.3
4 mM 158.8 97.8 81.0 61.3
7 mM 167.6 104.4 66.6 56.0 43.0
11 mM 105.3 70.1 48.0 33.9 29.6 24.4
16 mM 60.7 43.6 32.1 24.0 21.4 18.2
22 mM 28.8 22.9 18.5 14.9 13.8 12.3
30 mM 19.7 16.4 13.6 11.5 10.8 9.7
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Table 3.8: Effects of wound healing on sensor detection of small molecular
weight blood borne analytes. [19]
Hemostasis Inflammation
Minutes to hours Days
Cause Blood borne proteins and Proteins and cells of
platelets adhere to sensor immune system adhere to
surface sensor surface
Effect Membrane biofouling Membrane biofouling
restricts analyte diffusion to restricts analyte diffusion to
sensing layer sensing layer
Repair Encapsulation
Days to weeks Weeks to months
Cause Vascularized and gelatinous Increasing avascularity and
granulation tissue fibrocity of surrounding
formation tissue
Effect Increased analyte perfusion Decreased analyte
and diffusion to the sensor perfusion and diffusion to
surface the sensor surface
3.5 Body-sensor interface
The IGLUS is designed to be implanted subcutaneously, therefore the out-
side walls of the sensor are directly in contact with the living tissues. The
surgical procedure is followed by a healing process of the living tissues
and can be summarized in four stages: hemostatis, inflammation, repair
and encapsulation. The details are presented in table 3.8 and an illustration
is shown in figure 3.14. Unfortunately theses processes lead to an alteration
of the sensor operation and therefore have to be minimized. It is commonly
known as biocompatibility. The first gesture adopted in surgery is to set the
implant away from the wound with a trocar, but this only minimizes the is-
sues caused by hemostasis and tissue repair. For an implanted sensor, the
situation is more complicated than for passive implants, such a hip or knee
implant, since the access to chemical solutes such as glucose must remain
over time. The reasons for almost all actual sensors to fail after a few days
of implantation are the biofouling and encapsulation [107, 5]. It is thus
essential to apply chemical surface modification on our sensor in order to
enable its long-term efficiency. The situation is illustrated in figure 3.15. In
the frame of this work, we limited our research on the SI because it is the
most crucial and difficult external area to develop.
In literature, with key words "membrane biofouling" or "membrane
fouling", different methods to prevent the membrane fouling of a biosen-
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Figure 3.14: The foreign body reaction is the normal reaction of a higher
organism to an implanted synthetic material and is schematically illus-
trated here. (1) A surgeon implants a biomaterial in a surgical site (an
injury). (2) Quickly, the implant adsorbs a layer of proteins, the normal
process for a solid surface in biological fluids. (3) Cells (neutrophils and
then macrophages) interrogate and attack the "invader", i.e. the biomate-
rial. (4) When the macrophages find they cannot digest the implant, they
fuse into giant cells to engulf the object. However, it is too large to com-
pletely ingest. The giant cells send out chemical messengers (cytokines) to
call in other cells. (5) Fibroblast cells arrive and begin synthesizing colla-
gen. (6) The end stage of the reaction has the implant completely encased
in an acellular, avascular collagen bag. There are macrophages between the
collagen sac and the implant [5].
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Biosensor Interphase
Endothelial cell
Red blood cell
Capillary
Fibrin
Collagen
Proteins
Biocompatible coating
Figure 3.15: Illustration of the interface between body tissue and a glucose
sensor.
sor have been recently reviewed [19]. The prevention of encapsulation is
partially enclosed in the topic since it is believed that the adhering proteins
are one of the main factors that modulates the longer term cellular and/or
encapsulation response [107].
The choice of the best strategy for a SI with limit biofouling capabilities
was first based on the requirements of the IGLUS sensor:
1. Allow selective transport of glucose in and out of the sensor and si-
multaneously prevent leakage of dextran and ConA out of the sensor.
It must also prevent other proteins to penetrate the device.
2. Prevent fibrous encapsulation in the vicinity of the membrane to fa-
cilitate diffusion of glucose to the sensor device.
The possibilities of surface modifications found in literature are numer-
ous but only two solutions remain potential as they have been highlighted
by Lei et al. [63]. The two possibilities are the grafting of polyethylene
glycol (PEG) [108] or a biomimetic coating such as hyaluronic acid (HA)
[109]. Both techniques have the ability to create a super-hydrophilic sur-
face that repels proteins culpable for biofouling. Though these techniques
show potentials for biofouling, their effectiveness in vivo has not been fully
explored.
Prior to selecting the surface modification method, the support, i.e. the
selective membrane, was chosen. We chose a nanoporous anodic aluminium
oxide (AAO) membrane (detailed in section 4.5), also called alumina mem-
brane in literature. Since the membrane selection is an important topic of
this thesis, it is presented in details in chapter 4.
The choice of the surface modification had to suit the nanoporous alu-
mina membrane and has been made in a close collaboration with another
group (see section 3.2). We chose a poly(poly(ethyleneglycol methacrylate)
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(PPEGMA) coating as the best candidate because it is compatible with alu-
mina and was available at EPFL. Our partner developed this coating and
therefore the details of its chemistry are not presented here. In addition to
its biofouling capabilities, the coating was also used to tune the membrane
selectivity by pore filling.
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Chapter 4
Understanding the selective
interface
4.1 Introduction
The IGLUS implantable glucose sensor consists of three core technologies:
the sensitive fluid (SF), the micro-viscometer and the selective interface (SI)
between the inside and outside of the sensor. This chapter describes the
investigations conducted to create a dedicated SI for the IGLUS.
The SI is a semi-permeable membrane whose role is to retain the essen-
tial molecules of the SF (ConA and dextran) inside the sensor whilst allow-
ing glucose to diffuse freely in and out. In addition, the interface material
has to be biocompatible and to minimize biofouling by preventing the non-
specific adhesion of proteins. As presented in section 3.5, the membrane
has to act as an interface between the SF and the surrounding living tissues
which are composed of cells and the extracellular matrix, see figure 3.15.
This chapter aims to gather the necessary information to understand
the physical and chemical processes in and around the SI. The first section
details the requirements of the IGLUS for the interface. Subsequently a re-
view of potential nanoporous supports for the interface is presented and
the selected candidates are described. As a potential alternative, polyethy-
lene (PE) films which have different mechanical properties are presented.
Finally, a theoretical model for the diffusion of solutes through the interface
is introduced.
4.2 Requirements for IGLUS
The IGLUS measures the viscosity of a fluid which varies with the glucose
concentration. The sensor being implanted subcutaneously (see figure 4.1),
it bathes in the interstitial fluid (IF). The SI has to fulfil three functions:
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Figure 4.1: Cross-section of the human skin.
1. Maintain the rheological and glucose sensitive properties of the inner
SF
2. Allow the glucose concentration equilibrium between the IF and the
inner SF
3. Prevent biofouling of the membrane and nonspecific adhesion of pro-
teins
The two first functions are necessary for the basic functioning of the sensor
while the third function is required for a long term sensing functionality of
the implanted sensor.
Maintaining the rheological and glucose sensitive properties of the SF
means that the SF constituent molecules have to be retained inside the
sensor whilst preventing some of the IF constituents to penetrate into the
sensor. The main constituent molecules of both fluids are sketched in fig-
ure 4.2. On this figure, the relative sizes of the important molecules are
shown. The main constituents of the SF are the dextran and the ConA, and
for their activity to remain constant, their chemical environment needs to
remain the same over time. Since the viscosity is the key of the sensing
system, the only parameter that should induce viscosity changes must be
glucose. In order to satisfy this last statement, the concentration of each
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Sensitive Fluid Extracellular Matrix
(Inside of  sensor)
Dextran 2000 Cells ca. 10 m diameter
MW ca. 2 000 000 Da
Stokes radius ca. 27 nm
ConA
Plasma protein
Phenol
Glucose
Salts
MW = 104 000 Da (tetramer)
Stokes radius 4.4 nm (tetramer)
MW = 94
MW = 180 Da
MW = 18 Da
Glucose in the body
Physiologic ionic medium
Water
NaCl, MnCl , CaCl2 2
Extracellular water
Stokes radii
4 - 10 nm
3.3 nm (dimer)
Da
Figure 4.2: Illustration of the relative sizes of the molecules that the mem-
branes has to select. MW is the molecular weight in Dalton.
molecule (except for glucose) must remain constant. In other words, the
dextran and ConA molecules may not leak through the membrane and IF
macromolecules (peptides and proteins) may not pass through the mem-
brane either. As detailed in section 3.4, the SF activity depends on the pH
and the ionic composition, therefore they also must remain constant.
As the first goal is to make the sensor operating in vitro, we focused
on the two first functions because they are sufficient for a simplified in
vitro environment model. In this work, the simplified in vitro environment
model (SITEM) is a chemical environment where the IF is mimicked by a
reference solution (RS) which is an isotonic solution of the SF for all of its
constituents. In other words, the RS contains equal concentrations of ions
and has the same pH and buffer as the SF. During in vitro experiments, the
only component whose concentration is varied is D-glucose. The SITEM
has been chosen to test the two first functions of the membrane mentioned
above. It realizes a situation where the only chemical constituents which
differ on both sides of the membrane are dextran and ConA.
The three functions of the membrane listed earlier cannot be studied
simultaneously. Therefore we studied and characterized different mem-
branes by testing separately their glucose permeability, dextran retention
ability, protein retention ability. Finally, their retention capability of dex-
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tran and ConA simultaneously was investigated.
The function of maintaining large molecules inside the sensor implies
more than only selecting the chemical constituents. It also implies to strive
against overpressures and mechanical stresses that can arise from the use
and manipulations of the sensor. Moreover, the membrane has to resist the
osmotic pressure which arises from the difference of chemical constituents
on both sides of the membrane. Since some chemical constituents cannot
diffuse through the membrane, an osmotic pressure remains and has to be
sustained by the membrane. A swelling of the membrane would induce
a dilution of the SF and modify the distance between the rotor and the
membrane which has to remain constant in order to guarantee a constant
shear stress for every measurement. Therefore the membrane has to be
rigid.
4.3 Basic chemistry and physics of membranes
This section is intended to give the reader the necessary knowledge for un-
derstanding the basic chemical and physical phenomena relating to mem-
branes.
4.3.1 Membrane surface chemistry
The membrane chemistry indicates the chemical nature and composition
of the membrane surface, which is important because the chemical compo-
nents of the medium are directly in contact with the surface of the mem-
brane. The chemical makeup of the surface may often be different from the
chemistry of the membrane bulk. The membrane chemistry determines im-
portant properties such as hydrophilicity (or hydrophobicity), surface elec-
tric charges, chemical and thermal resistance, binding affinity of solutes,
biocompatibility, etc.
Because of the importance of the surface chemical properties, the mem-
brane chemistry can be modified to improve the performances for specific
applications. The modifications can be applied to the bulk (e.g. annealing
of porous alumina membranes makes it resistant to water, see section 4.6),
to the surfaces either by chemical treatment and/or grafting of a modifier
(e.g. grafting of polymer brushes on anodic alumina membranes, see sec-
tion 4.5). The surface modifications are applied through numerous meth-
ods [9] depending on the desired affinity with specific solutes.
The hydrophilicity (or hydrophobicity) of a surface is expressed by
means of water contact angle. It is important because it determines the
wetting properties of the solvent (in our case water). In the case of an hy-
drophilic surface, the membrane pores are spontaneously filled, whereas,
when hydrophobic, the pores must be wetted by applying pressure or by
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Table 4.1: Isoelectric points of selected membranes. [9].
Membrane material Manufacturer pI
Aluminium oxide Whatman 4.4
Polysulfone DDS 3.6
Polycarbonate Whatman 2.5
Sulfonated polyslufone DDS <2.5
Cellulose acetate/nitrate Millipore 2.2
using another solvent at start. For example, porous polyethylene is hy-
drophobic (high contact angle of water) but is easily wetted by ethanol (low
contact angle of ethanol) and so, one can wet it by soaking in ethanol prior
to water. Once wetted by ethanol, the membrane can be rinsed with water
and since the two solvents are miscible, water replaces ethanol in the pores.
The surface charges of a membrane is another important aspect of the
surface chemistry. The presence of net electrical negative or positive charges
changes the character of the membrane-liquid interface. The nature of the
charged groups is also important as the liquid-phase properties, such as
pH and ionic strength, can vary these charges. When the charge of a sur-
face or molecule is dependent from the pH, the isoelectric point is used to
describe the charge state. By definition, the isoelectric point (pI) is the pH
at which a particular molecule or surface carries no net electrical charge.
The net charge can become more positive or negative when varying the pH
of surrounding environment. The pI’s of different commercial membranes
are given in table 4.1. In particular the affinity of a biomolecule to be ad-
sorbed or repelled by the surface is partially defined by the charge status
of both surface and molecule. As discussed by Zeman and Zydney [9], this
influences the molecular selectivity and fouling properties of a membrane.
4.3.2 Porous structure and pore sizes
In addition to the different materials for membranes, manufacturers have
the ability to cast a number of different membrane structures. Various pro-
duction methods are employed depending on both the material and the
desired structure, especially for polymers [9]. For polymers, methods in-
clude air casting, immersion casting, melt casting, track-etching, stretching,
radiation-induced polymerization and others. Casting may also be per-
formed using another membrane as a substrate, often referred to as com-
posite membranes. The structural characteristics of the membrane play a
major role in determining permeability, retention capability and flux for fil-
tration processes. More recent methods are able to produce composite and
multi-layer membranes which provide dramatic increases in membrane ca-
pabilities compared to the isotropic membranes. Figure 4.3 shows the dif-
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50µm 1µm30µm8µm
a) b) c) d)
Figure 4.3: Cross-sectional view of different porous structures of mem-
branes; a) isotropic and b) anisotropic membranes. More complex mem-
branes co-cast structures c) of anisotropic or d) isotropic layers. a) to c) [6]
t = 1.0 t = 1.5 t ~ 1.5 − 2.5
Membrane
thickness
Figure 4.4: Cross-sections of porous membranes of different tortuosity t
[7].
ferent membrane structures. Besides the polymer membranes, the anodic
membranes, and in particular the anodic aluminium oxide membranes, can
be structured as being asymmetrical. They are isotropic membranes and,
when produced as bi-layer, are asymmetrical, each layer being isotropic,
see figure 4.3.d. The anodic alumina membranes are presented in details in
section 4.6.
The pore structure itself is also determinant for the membrane proper-
ties. Most of the membranes are made of polymers and their porous struc-
ture is the result of randomly situated and interconnected cavities. Some
membranes, such as the anodic and track-etched have straight pores and
this has an impact on the diffusions of solutes through the membrane. The
form factor of pores is characterized by its tortuosity. The membrane tortu-
osity t reflects the average length of the pores compared to the membrane
thickness. Simple cylindrical pores at right angles to the membrane surface
have a tortuosity of one, that is, the average length of the pores is the mem-
brane thickness, see figure 4.4. The more meandering the path through the
membrane, the higher the tortuosity. Typical tortuosities are in the range of
1.5-2.5.
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4.3.3 Membrane selectivity mechanisms
The intrinsic selectivity of the membrane is determined by the underlying
pore size distribution and the membrane surface properties. For example,
highly selective ultrafiltration membranes can be developed using electri-
cally charged membranes that exhibit very high retention of proteins with
the same polarity [110, 111]. Similarly, adsorptive membranes can provide
highly selective separations based on the specific binding of various com-
ponents. In details, the rejection of organic compounds represents a com-
plex interaction of steric hindrance, electrostatic repulsion, solution effects
on the membrane, and solute/membrane properties. Some interactions are
fairly well understood. For example, the major mechanism of solute rejec-
tion by nanofiltration is physical sieving of solutes larger than the mem-
brane molecular weight cut-off (MWCO). Other mechanisms of rejection
such as electrostatic exclusion and hydrophobic-hydrophobic interactions
between membrane and solute are considered important but are not as well
understood [112]. For the ultrafiltration (larger molecules) range, physical
sieving is not as predominant and the selectivity is a complex mechanism
involving all the cited interactions. The major difference between nano-
and ultrafiltration solutes is that when a molecule increases in size, such
as polymers and polypeptides, the molecule dimensions depend on the
tertiary structure which itself depends on the chemical environment. The
molecule dimensions thus depends on the environment.
For the sieving mechanism to act correctly one could simply choose a
membrane with pore much smaller than the dimensions of the molecules
one wants to retain. In the case of a membrane for the IGLUS, we have to
find a situation where glucose diffuses freely and other larger molecules
such as the ConA dimer are completely retained. The difference of sizes
between glucose and ConA dimer (see table 3.1) is only a factor 4-5 and
thus we have to face the case where the molecule size and pore size are
comparable. This situation is known as hindered molecular transport [113].
In this case we can define the ratio λ between molecular diameter dsolute and
pore diameter dpore:
λ =
dsolute
dpore
(4.1)
The results of the hindered diffusion observations are that the apparent
diffusion coefficient D of the molecule in the pore is much lower than the
bulk solution diffusion coefficient D∞. The main results found in literature
have been reviewed by Deen et al. [8] and a selection of plots is given in
figure 4.5.
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Figure 4.5: Experimental results of hindered diffusion in cylindrical track-
etched pores. [8]
4.3.4 Size selectivity (dextrans, proteins)
As described in the last section, the pore size of a membrane is the ma-
jor property for the size selectivity of a solute. Among the commercially
available membranes, there are two ways of describing their size selectiv-
ity, either by their pore size or nominal MWCO which is typically defined
as the molecular weight of a solute that has a retention coefficient of 90%
(although this definition is not explicit and it can vary between 60% and
90% depending upon protocols used by various manufacturers [112]).
As shown in figure 4.6, there is a wide variety of membrane pore sizes
and biomolecule sizes. The need of the IGLUS is among the dialysis and
ultrafiltration membranes. The latter membranes are characterized by their
manufacturer using either two proteins of different molecular weight (one
retained and one passing solute) or a mixture of dextrans covering a large
molecular weight range. When using proteins it is important to note the
pH and surface charges as these have a significant impact on the hydro-
dynamic volume and hence sieving capability by membranes [114]. The
common mixed dextran test [6] uses a mixture of dextrans with various
molecular weights typically spanning a range of 1-2000 kDa. Samples of
feed and filtrate taken under steady-state conditions are run on size exclu-
sion chromatography and the resulting filtrate chromatogram is divided by
the feed chromatogram to provide sieving as a function of retention time.
Retention time is converted to dextran molecular weight with a calibration
curve generated by running individual dextran standards. With both meth-
ods it is also important to note the mass transfer conditions if the measure-
ments are done in filtration. Stirred cells will typically have much lower
mass transfer coefficients than tangential flow ultrafiltration membranes,
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which will impact the sieving performance [9].
The problem is that there is no general link between the pore size of
membrane and the molecular weight of a molecule to ensure the selectivity.
However correlations have been made between sieving of proteins, dex-
trans, and polyethylene glycols (PEG) based on their Stokes radius [9, 6]
rather than the molecular weight (MW). An example in figure 4.7 shows
the rejection differences as a function of the MW and the Stokes radius.
Further details on the Stokes radius of dextrans and proteins are given in
section 4.4.
4.3.5 Membrane functions: dialysis & filtration
A distinction must be done between the two different uses of a membrane:
filtration and dialysis. For filtration one apply a pressure difference be-
tween both faces of the membranes which creates a flux of the solvent. For
dialysis, no such pressure is applied. Dialysis can be thus defined as the
diffusion of dissolved solutes across a semi-permeable membrane against
a concentration gradient in an effort to achieve equilibrium. The results
is that small solutes pass through the membrane while larger solutes are
trapped on one side of the membrane. Having a flux of the solvent through
the membranes impacts the molecular transport [115]. The IGLUS uses the
membrane in the dialysis mode.
4.4 Properties of biomolecules
The biomolecules of interest for the IGLUS are dextran and the different
proteins present inside and outside the sensor such as ConA (dimer and
tetramer), albumin and fibrinogen. The properties of dextran are simple
with respect to its environment since it is a neutral molecule. Its structure
and Stokes radius have been presented in section 3.4.2.B. The properties of
proteins are more complex and therefore an introduction is required.
The biological activity of a protein is determined by its unique three-
dimensional structure and surface functionality. Proteins are biopolymers
formed by a linear sequence of the 20 natural-occurring amino acids. The
native state (or conformation) is stabilized primarily by hydrophobic in-
teractions due to the unfavorable free energy associated with solvation of
nonpolar groups by water. The net result is that the non-polar side chains
tend to collapse together to form the protein hydrophobic core. Hydrogen
bonds between weak acid donor groups (e.g. N−H and O−H) and accep-
tor groups with one pair electrons stabilize the protein secondary structure
including both α-helices and β-sheets. Positively-charged amino groups
and negatively charged carboxylic acid groups are typically located along
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Figure 4.6: Relative size chart of membrane pore sizes and molecule sizes.
Source: Spectrum Laboratories Inc.
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Figure 4.7: Measured values of rejection coefficients for dextrans and
proteins plotted as a function of (a) molecular weight and (b) Stokes ra-
dius. The used membrane has an approximate 100 kDa MWCO and a low
protein-binding surface. [9]
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the protein exterior [116]. The net protein charge is determined by the num-
ber and pKa1 of these acidic and basic amino acids. The isoelectric point
(pI) is the pH at which the protein has no net electrical charge, typically
determined by the equilibrium position in an isoelectric focusing gel or the
lack of motion in an applied electric field. Since the three-dimensional ge-
ometry of a given protein can be quite complex, the hard sphere radius is
usually estimated from the measured diffusion coefficient using the Stokes-
Einstein equation:
Rh =
kT
6piηD
(4.2)
where Rh is the Stokes or hydrodynamic radius, k the Boltzmann constant,
T the temperature, η the dynamic viscosity of the medium and D the diffu-
sion coefficient.
The effective radius of a protein in the context of membrane separation
can be considerably larger than the hard sphere radius due to the pres-
ence of the diffuse ion cloud (the electrical double layer) that surrounds
the charged protein in aqueous solution [117]. This effect can be quite dra-
matic, with the effective molecular weight of a protein (as determined by
size exclusion chromatography) increasing by more than a factor of 20 as
the solution ionic strength is reduced from 150 to 5mM [114].
The electric charges along the protein skeleton are the source of impor-
tant differences in the tertiary structure with the dextran. Among them is
the difference of Stokes radius as a function of the MW. The Stokes radius
being related to the diffusion coefficient, it can be determined. This work
has been done by Tyn et al. [118] and the diffusion coefficients of various
proteins are plotted in figure 4.8. Young et al. [119] developed an equation
for the proteins
D = 8.34 · 10−8
(
T
ηM
1
3
)
(4.3)
Where D is in m
2
s , T in Kelvin, η in mPa · s and M the molecular weight in
Da.
When associating equation (4.2) and (4.3), we get the relation
Rh = 0.88 ·M 13 (4.4)
for proteins.
A similar relation as equation (4.3) has been experimentally established
for dextrans [120]
D = 7.667 · 10−9M−0.47752 (4.5)
where D is in m
2
s and M in Da.
1Acid dissociation constant
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Figure 4.8: Diffusion coefficients of different proteins. The dashed line is
the model of equation (4.3) and the solid line of equation (4.5). [9]
The difference of MW-Stokes radius relation is in accordance with the
results of figure 4.7 and emphasizes the fact that the selectivity of a mem-
brane is more likely to be compared by the Stokes radius of the molecule
when dealing with proteins and/or dextrans.
4.5 Selection of nanoporous membranes
The choice of the suitable membrane for the IGLUS is based on its require-
ments (section 4.2), the basic chemistry and physics of membranes (section
4.3) and the properties of the involved macromolecules (section 4.4). The
membrane requirements for the IGLUS can be summarized as follows:
1. Selective to ConA and dextran
2. Rigid (to sustain osmotic pressure)
3. Asymmetric (to optimize glucose diffusion)
4. High porosity (to optimize glucose diffusion)
5. Low tortuosity (to optimize glucose diffusion)
6. Chemically inert (for long term chemical stability of membrane and
SF)
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7. Low protein adsorption (for chemical stability of SF and fouling pre-
vention)
8. Coating possibilities (to improve selectivity and prevent biofouling)
Considering these requirements, we reviewed the existing membranes and
made a selection.
There are several kinds of membranes with nano-sized pores. In fact,
there are thousands of commercially available membranes in the ultrafiltra-
tion range [121]. Each manufacturer has his own recipe for membrane fab-
rication, modification and also characterization. As discussed previously in
section 4.3.4, there is no standardization for determination of the MWCO
or pore size of a membrane. The end-users of ultrafiltration membranes
have to face an enormous difficulty in comparing membrane products pro-
vided by different manufacturers and made of different polymeric or ce-
ramic materials. In the industry, the ultrafiltration membranes are mainly
employed for filtration in production processes. And since polymer and ce-
ramic membranes are adapted for this use, they are the most present mem-
branes on the market. Nevertheless many other types of membranes exist
and need to be considered. We grouped the reviewed membranes in classes
as follows:
• Porous polymer membranes
• Track-etched polymer membranes
• Sol-gel ceramic membranes
• Anodic alumina membranes
• Structures obtained by nano-imprint lithography (NIL) of various ma-
terials
• Silicon-based membranes
4.5.1 Porous polymer membranes
Porous polymer flat sheet ultrafiltration membranes exist out of various
materials such as polysulfone (PS), polyethersulfone (PES), polyethylene
(PE), polyvinylidene fluoride (PVDF), polytetrafluoroethylene (PTFE), re-
generated cellulose (RC) (see figure 4.9 a), cellulose acetate (CA) or cellu-
lose ester (CE). These membranes have an asymmetric (skinned) structure,
with a thin skin providing the desired selectivity while the substructure
with larger pores provides the necessary mechanical support. Some of
these synthetic polymers have high thermal stability and chemical resis-
tance, allowing the use of fairly harsh cleaning chemicals. However only
the cellulose membranes allow relatively low cut-offs [122] as required by
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the IGLUS and recent RC and CE membranes are more hydrophilic, reduc-
ing both protein adsorption and fouling. But their chemical resistance is
not suitable for a long term implant. We have to point out that suppliers
such as Millipore2 rarely quote rejections above 99%, leaving the poten-
tial issue of some pores being much larger than the nominal cut-off. Other
drawbacks of the polymer membranes are their non-rigidity and their high
tortuosity.
Hollow fibres made of the same polymers exist and are for example
used in artificial kidneys for blood dialysis, but their shape is not applicable
for the IGLUS.
Recently (2006), nanoporous PE films have been reported by Uehara et
al. [17] and exhibit promising structural and chemical properties for our
application. PE is mechanically and chemically very robust and films can
be prepared thinner than 10 µm. These films are flexible and therefore can-
not be used on the IGLUS demonstrator presented in this work. However,
the flexibility of the PE films is an advantage when considering a non-flat
SI for a future version of the IGLUS having a cylindrical shape, nonethe-
less a rigid supporting structure is required. Taking into account the future
of the IGLUS and promising properties of the PE films, we selected this
technology as a potential component for the SI.
4.5.2 Track-etched polymer Membranes
Track etching was the first technique to enable fabrication of membranes
with straight nanopores of well-defined size [10]. Fabrication procedure
consists of a sequence of two operations: irradiation of a thin polymer foil
with suitable high-energy particles, followed by a chemical etching of the
tracks the particles left in the foil.
From figure 4.9.b), one can see the pores are straight, have a narrow
size distribution and a filling factor which could be acceptable, although
still relatively low. Common track etched materials include polyethylene
terephtalate (PET), which is hydrophilic and biologically inert, and poly-
carbonate [10].
Commercially, track-etched membranes are available down to 10 nm 3
or 15 nm 4 nominal pore size, which would fit our requirements. However,
combining small pore size and high pore filling factor is not possible, be-
cause there is an increasing probability of overlapping pores when increas-
ing the pore density. For instance, the aforementioned commercial mem-
branes are limited at 6 · 108 pores/cm2, which corresponds to 6 pores/µm2
and therefore yields very low filling factors of 0.4% for 30 nm, 0.1% for
2http://www.millipore.com
3http://www.spi.com
4http://www.whatman.com
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a) b)
c) d)
e)
50nm
f)
Figure 4.9: SEM images of the different types of membranes; a) regener-
ated cellulose (RC) polymer membrane [6], b) polycarbonate track-etched
membrane [10], c) TiO2 ceramic membrane [11], d) anodic aluminium oxide
membrane, e) nano-imprinted membrane [12], f) silicon dioxide membrane
[13].
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15 nm, and 0.05% for 10 nm. Moreover, the membranes are relatively thick,
ca. 6 µm. Considering the very low porosity of such membranes, it is clear
that they don’t meet the IGLUS requirements. The response time of the
sensor would be much too long.
4.5.3 Sol-gel ceramic membranes
Sol-gel / colloïd techniques can be used to form in-situ membranes with a
very small pore size (down to < 1 nm). Usually, a liquid containing suit-
able precursor is applied onto a porous ceramic support by spin casting,
dipping or spraying, followed by a drying and a firing step, during which
calcination / pyrolysis and partial sintering occur, resulting in a very fine-
grained oxide film. By selecting the correct firing temperature, the film
may exhibit good cohesion whilst remaining porous. This process inher-
ently yields a large porosity (up to 30%), which however exhibits some tor-
tuosity. The porous ceramic support is easily obtained by classical powder
technology.
Many materials may be used, such as TiO2 (titania / anatase), ZrO2
(zirconia), SiO2 (silica), aluminosilicates, SiO2 − ZrO2, H f O2 (hafnia) and
γ− Al2O3 (alumina) [106, 123, 124, 11, 125, 126]. They may exhibit excellent
corrosion resistance [11], which means corrosion is not a critical issue at all
in animal body conditions.
Due to the very small achievable pore sizes, cut-off may be achieved
just above the size of glucose, for instance between glucose (0.86 nm) and
glucitol (0.97 nm) [106]. However, the loss incurred in terms of glucose
diffusivity is very high in this case: a factor of ca. 4’000. In comparison, the
same type of membranes with ca. 11 nm pores achieve a quite acceptable
decrease of diffusivity compared to free glucose diffusion: only a factor of
ca. 7, which is quite promising for the IGLUS system. Pore size distribution
lies within a factor of ca. 2 [123].
There are however three drawbacks to this technology: 1) the theoret-
ical possibility of cracks if the process is not well controlled; 2) the lack of
commercial availability of standard sheets of membrane material; 3) an im-
portant lower diffusivity due to the tortuous nature of the pores. These are
only relatively small difficulties, however, compared with the relative sim-
plicity of the fabrication process and the very fine structures (figure 4.9.c)
that can be achieved.
4.5.4 Anodic alumina membranes
Anodic aluminum oxide (AAO) or anodic alumina membranes is a pecu-
liar technology that shares common features with both the track-etched
membranes and the ceramic membranes. AAO membranes exhibit arrays
67
Chapter 4. Understanding the selective interface
of straight parallel pores of quasi-uniform shape and have the chemical
properties of a ceramic, i.e. alumina. Initially developed by Anotec Ltd.,
the technology was sold to Whatman Ltd.5 The pore size ranges from
> 200 nm down to < 10 nm and the thickness from 100 µm down to
15 µm. The smallest pore size has been reported by Zhang et al. [64] at
6.8 nm and the smallest pore size commercially available is 5-7 nm from
Synkera Technologies Inc.6 The pore size is regulated by the choice of the
acid electrolyte and the anodization voltage employed during preparation.
More details about the fabrication are given in section 4.6. The porosity of
such membranes can go up to 50% and they exhibit a low protein adhesion
[9]. Alumina is rigid and the straight pores (minimum tortuosity) allow an
optimum diffusion of small solutes such as glucose.
Anodic oxide films and membranes also can be made from sputtered
or evaporated aluminum thin films, which means they may be applied on
practically any substrate [127, 128, 129, 130]. The natural hexagonal order-
ing of the pores may be improved by nano-imprinting the aluminum with
spheres, provided that the pattern is close to the natural one [131]. Finally,
the surface of nanoporous alumina can be modified and various coatings
can be added especially for biomedical applications [20]. This makes the
AAO membranes a good candidate for the IGLUS.
4.5.5 Structures obtained by nano-imprint lithography of
various materials
Nano-imprint lithography (NIL) involves fabrication of a mould, which is
then repeatedly imprinted onto a soft material. This may then be followed
by various etching steps to obtain the desired structure. NIL is potentially
a relatively inexpensive fabrication technology [132]. While fabrication of
molds is usually a tedious and expensive process, the mold may then be
replicated a large number of times. Additionally, there are techniques to
produce "daughter-molds" from the original one at a fraction of the cost of
initial fabrication: wear is not a severe problem. There is a wide choice of
materials, as NIL may be used to pattern several photolithographic resins.
The resulting pattern can then be transferred to many materials using stan-
dard etch methods. For example, pores of anodic alumina membranes can
be patterned by NIL to create organized porous alumina membrane [131].
The method have the following drawbacks. A compromise must be
made between membrane thickness and pattern size. The mold features
should not have a too high aspect ratio as they would become fragile.
Therefore, if one wishes to have a large open cross section of very small
pores, for example 25 nm pores with 100 nm spacing, the nanoimprinted
5http://www.whatman.com
6http://www.synkera.com
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layer has to be as thin as 10 nm [12]. However, one should not forget that
the nano-imprinted layer can then be used as a mask for etch techniques
which allows a much larger aspect ratio, such as reactive ion etching. The
problem of pore density may be ameliorated if one chooses another pore
geometry such as slits instead of circular holes. However, at present stage
of development, NIL produces very low porosity membranes and the pore
size remains too large. The method is still young and future development
must be followed.
4.5.6 Silicon-based membranes
Membranes based on silicon structuring should a priori be available, given
the wide knowledge and industrial base of this technology. However, exist-
ing photolithographic techniques still do not allow the desired feature size,
especially if the cost factor is taken into account. However, we do not need
to confine ourselves to cylindrical pores, and slit-based geometries, where
the width of the slit is defined by the thickness of a thin film, may easily be
defined in the 10 nm range [133].
The open area fraction of silicon structured membranes is around 1% at
20 nm [13], which is roughly 1 order of magnitude higher than that achiev-
able by track etched membranes, and they are available commercially 7.
The low porosity is a major drawback for the IGLUS.
A newer technology (2007) has recently been described by Striemer et al.
[134, 135], where a nanoporous membrane of crystallin silicon is obtained
by self-organization. They presented a 5-17 nm pores membrane with a
thickness of 15 nm which bears a pressure of 1 bar. The achievement of
thinner membranes down to 5 nm with a surface of up to 2× 2 mm2 is also
described. The technology is promising but too recent to be investigated in
the present work.
4.5.7 Conclusion on membrane selection
Among the presented technologies summarized in table 4.2, two types of
membranes were selected to constitute a base for the SI: the anodic alumina
membranes and the polyethylene films. For the IGLUS demonstrator pre-
sented in this work, anodic alumina membranes are clearly the most ma-
ture nanoporous membrane technology, because of their good availability
and performance. However, their diffusion performance were not yet suf-
ficiently characterized. It remains to be seen whether they can achieve the
necessary molecular selectivity. In order to fully satisfy the requirements
for the IGLUS (see section 4.2), the PPEGMA coating was selected to im-
prove the performances of the anodic alumina membranes (see section 3.5).
7http://www.imeddinc.com
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Table 4.2: Summary and comparison of membrane technologies.
Membrane technology Advantages Disadvantages
Porous polymers small pore size, chemical resistance
availability excepted for PE,
high tortuosity,
support required
Track-etched polymers narrow pore size very low porosity,
distribution support required
Sol-gel ceramics high chemical resis-
tance, small pore size
high tortuosity, de-
fects
Anodic alumina High porosity, narrow
pore size distribution,
rigid, chemical resis-
tance
limited shape avail-
ability (flat), brittle
NIL structured narrow pore size distri-
bution
very low porosity,
pores too large
Silicon based thickness, small pore
size
availability
Selectivity results of a nanoporous alumina membrane coated by PPEGMA
are presented in chapter 5. The details of structure and fabrication of the
anodic alumina membranes and polyethylene films are presented in sec-
tions 4.6 and 4.7 respectively.
Other alternative technologies may be available in the future such as
nanograin oxide ceramics, NIL and silicon technologies since they also
have the potential for fabrication of nanosieving membranes with suffi-
cient open area. Alternatively, RC with a coating to prevent biodegradation
could be possible. Unfortunately, at their current stage of development,
they are not suitable for the IGLUS.
4.6 Anodic alumina membrane
4.6.1 Structure
Anodic aluminum oxide (AAO) membranes (or anodic alumina membra-
nes) have symmetrical morphology with high density cylindrical pores that
are aligned perpendicular to the membrane plane. The fabrication process,
described in section 4.6.2, is intrinsically selfhealing and yields defect-free
nanoporous membranes.
An electrochemical process involving anodic oxidation of high purity
aluminum sheets can be used to form porous oxide films. In certain acid
70
4.6. Anodic alumina membrane
Figure 4.10: Anodic aluminium oxide structure. [14, 15]
electrolytes, this oxidation process results in a film comprised of a uniform
columnar array of parallel-sided, closely packed, hexagonal alumina cells,
each containing a circular pore. This film is in intimate contact with a thin
nonporous alumina layer adjacent to the aluminum substrate, as shown in
figure 4.10. By appropriate selection of the process conditions, pore diam-
eter is controlled with great precision and reproducibility in a wide range,
from <10 to >200 nm. The corresponding pore density is from 1012 to
108 cm−2. The porosity varies from 8 to 50%, depending on other specifica-
tions. The standard deviation of pore diameters is typically <10% and as
low as 5% for optimized conditions. No other type of membrane can match
such pore uniformity.
4.6.2 Fabrication process
Anodic alumina membranes are formed by an electrochemical process in-
volving the oxidation of high purity aluminum sheets. In this process, an
electrical circuit is established between a carbon cathode and a thin film
of aluminum which serves as the anode, resulting in the oxidation of the
aluminum to form alumina.
In appropriate electrolyte solutions, the film that is formed has a uni-
form columnar array of hexagonally close packed alumina cells, each con-
taining a circular pore. This film is in intimate contact with a thin non-
porous alumina layer, called the barrier layer, which is adjacent to the alu-
minum anode. Pores form in the oxide film because of field assisted disso-
lution of the alumina from the base of each pore. As the alumina and the
pores penetrate the aluminum film, chemical dissolution of alumina from
the pore walls also occurs, yielding pores which are slightly larger at the
exterior film surface than at the base. With appropriate process conditions,
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Figure 4.11: Example of anodization equipment and corresponding mem-
brane fabrication steps. A) pre-anodisation step; B) removal of pre-
anodisation oxide; C) final anodisation; D) removal of Al; E) removal of
barrier oxide. [16]
Table 4.3: Detailed geometric parameters of Whatman Anopore 20 nm
alumina membranes [20].
Mean pore Pore density Pore area
Layer diameter [nm] [m−2] fraction
Active 26 6.5 ×1014 0.37
Support 207 1.0 ×1014 0.37
films can be formed with pore diameters between 10 and 300 nm, pore
densities between 108 to 1012 cm−2 and film thicknesses up to 200 µm [136].
Porous membranes can be prepared from these films by removing the bar-
rier layer and the unoxidized aluminum from the porous oxide layer. An
example of an anodization equipment and the corresponding membrane
fabrication steps are depicted in figure 4.11.
Anodic alumina membrane can also be prepared with a bilayer struc-
ture. These are called asymmetrical as each layer has a different pore size.
The most common commercial membranes having this structure are the
Anopore membranes from Whatman. In this work we used the product
with 20 nm pores. As described by the manufacturer, they have a thin ac-
tive layer of 1 µm thick with 20 nm pores and a support layer of 59 µm thick
with 200 nm pores. More precise values are given by Lee et al. [20] and
detailed in table 4.3. In order to assess the structure of the 20 nm asymmet-
ric membrane that we purchased from Whatman, we performed Scanning
Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM)
on a sample. The obtained images are shown in figure 4.12 and correspond
to the ones found in literature [20, 137]
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Asymmetric Whatman
Anopore 20 nm
Active
layer
Support
layer
20 nm pores
200 nm pores
a)
b)
c) d)
e) f)
500 nm 100 nm
200
Figure 4.12: Electronic micrographs of a Whatman Anopore 20 nm asym-
metric alumina membrane. a) illustration of the asymmetric structure, b)
SEM image in cross-sectional view, c) SEM image of the active layer, d) SEM
image of the support layer, e) and f) TEM micrographs of the active layer
in different magnification.
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4.6.3 Chemical properties
As-prepared amorphous AAO can be converted by annealing into poly-
crystalline γ- and α-alumina that retain nanoporous morphology. Such
membranes have excellent chemical resistance and long-term stability in
aqueous solution. Their upper operating temperature is up to 1000˚C for
γ-alumina and up to 1100˚C for α-alumina membranes. AAO membranes
are mechanically robust and exhibit good flexibility, hardness, and fracture
toughness. The Whatman Anopore membranes are out of γ-alumina and
their pI has been reported to be pI = 4.4 [9, 138] (see table 4.1).
4.6.4 The PPEGMA coating and antifouling mechanism
The polymer used to coat and pore-fill the alumina membrane is poly(poly-
(ethylene glycol) methacrylate) brushes (PPEGMA) grown on the surface
by surface-initiated polymerization. An illustration is shown in figure 4.13.
The PPEGMA brushes have also shown to have non-fouling properties
[139, 108, 140] which is essential for long-term permeability of the mem-
brane.
Membrane
Coating
Figure 4.13: PPEGMA brushes coat the surface of the alumina membrane
and partially fill the pores.
As discussed previously in section 3.5, it is the nonspecific adhesion of
proteins on the surface of the implant that creates an immune response,
followed by a tissue encapsulation. The mechanisms for prevention of
adhesion of proteins have been suggested [140]. It has been found that
poly(ethylene glycol) (PEG), a water soluble, nontoxic, and nonimmuno-
genic polymer, serves as an excellent coating material [139]. It is compatible
with biological systems and has been shown to reduce protein adsorption
and cell adhesion on synthetic surfaces [141]. The protein repulsive nature
of PEG is mainly attributed to its hydrophilicity, steric stabilization force,
and chain mobility effect. The two main contributions to this repulsive
force are the excluded volume component and the mixing interaction com-
ponent. When protein molecules approach the PEG-coupled surfaces, the
available volume for each polymer segment is reduced, and consequently
a repulsive force is developed due to loss of conformational entropy of the
PEG chains. Also, the number of available conformations of the PEG seg-
ments is reduced owing to their compression or interpenetration of the pro-
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tein chains generating an osmotic repulsive force. We made the choice of
a neutral polymer as a coating because a charged surface like alumina at
physiological pH can promote protein adsorption. Finally, we can summa-
rize the PPEGMA properties as follows:
- Neutral polymer to screen the charges of the substrate (alumina)
- Prevent non-specific adhesion of proteins
4.7 The polyethylene membrane
4.7.1 Structure
The polyethylene membranes have been kindly provided by Prof. Dr. Hi-
roki Uehara from Gumna University, Japan. In a publication [17], he de-
scribes the structure and fabrication procedure in detail. The provided PE
films are 15 or 30 µm thick and have pores of about 10-30 nm. The fabrica-
tion process is limited to ultrathin films and the pore size is linked to the
film thickness, i.e. the thinner the film, the smaller the pores. This property
is an advantage to create a selective and diffusion efficient interface. At the
end of the fabrication process, an etching step creates the pores and the pore
size can be somewhat tuned by the time length of etching. The nanoporous
structure of the PE film is depicted in figure 4.14. The films exhibit a con-
tinuous cylinders porous structure which comes from the structure of the
crystalline component (PE). The crystallinity of the PE component was es-
timated by density measurement as 45%.
The nanoporous PE films prepared by Uehara et al. are very flexible and
mechanically very resistant. Moreover PE is very stable over time, since it
is chemically inert. Such superior characteristics make the PE nanoporous
film an excellent candidate for a SI if coupled to a rigid support.
4.7.2 Fabrication process
The PE films are prepared from a polyethylene (PE)/polystyrene (PS) di-
block copolymer. The average MW of each component was 5.4× 104 for
PS and 6.7× 104 for PE, with a MW distribution of 1.04. The PE block is
semicrystalline, but the PS block is always amorphous. Thus, their crys-
talline/amorphous phase separations are controlled by processing condi-
tions, including isothermal crystallization temperature and time after the
melt. The amorphous component (PS) is selectively removed by wet etch-
ing with fuming nitric acid. With increased etching time, the pores gradu-
ally develop and interconnect with each other.
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e)d)
20 m
200 nm
1 m 1 m
1 m
Figure 4.14: (a-c) SEM images of the edge of the film etched for 30 min. The
film was freshly cleft in liquid nitrogen. (a) Whole image with a scale bar of
20 µm. The surface and internal regions that are marked by the dotted line
are enlarged in (b) and (c) with each scale bar of 1 µm. SEM image with a
scale bar of 1 µm. (d-e) surface view of PE film, (e) enlarged image of the
area marked by the dotted line in (d) [17].
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4.8 Diffusion theory in membranes
4.8.1 Situation
Different membranes have been characterized in diffusion cells and we pro-
pose a theoretical model to understand the experimental results presented
further in chapters 5 and 6. In the cases of a membrane in the diffusion cell
or on the IGLUS demonstrator in the in vitro setup, we face similar situ-
ations where a membrane is separating two volumes and the solute (glu-
cose) can go from one volume to the other by pure diffusion through the
membrane.
We present here a general model inspired from the work of Hooger-
vorst et al. [142] which will allow us to compare different situations. The
model describes the transient diffusion through a membrane separating
two unequal volumes of well-stirred solutions. The treatment is restricted
to one-dimensional flow, the volume flow being zero at every point in the
membrane. We consider the membrane to be homogeneous.
4.8.2 General solution
As shown in figure 4.15, the system is composed of three zones, the two
volumes Va and Vb, and the membrane. The latter is of cross sectional area
S and thickness l. Outside the membrane, the solute is present in concentra-
tion ca(t) and cb(t), whereas the solute concentration inside the membrane
at coordinate x and time t is defined as c(x, t).
Chamber A Chamber B
Membrane
Va
S
Vb
l
c (t)a c (t)b
a) b)
Figure 4.15: Schematic of the model situation; a) cross-sectional view,
b) top view.
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At the interfaces (x = 0 and x = l) a coefficient k describes the parti-
tioning of the solute
k =
c(0, t)
ca(t)
=
c(l, t)
cb(t)
(4.6)
This coefficient k can be developed as
k = Kφ
υ0
υ
(4.7)
where K is the partition coefficient, φ the porosity of the membrane and υ0
and υ are the molar volumes of the solute outside and inside the membrane
respectively. K is defined for two solvents at their interface at equilibrium
as
K =
[solute1]
[solute2]
(4.8)
k is thus a partitioning coefficient which takes into account the volume oc-
cupied by the membrane and the molar volumes changes at the interface.
The diffusion process is described by the diffusion equation
D
∂2c
∂x2
=
∂c
∂t
(4.9)
and by the boundary conditions
Al
∂c(0, t)
∂t
= D
(
∂c
∂x
)
x=0
Bl
∂c(l, t)
∂t
= −D
(
∂c
∂x
)
x=l
(4.10)
with the abbreviations
A =
Va
kSl
, B =
Vb
kSl
(4.11)
and by the initial conditions
ca(0) = a
cb(b) = b
c(x, 0) = k[(q− p x
l
)(a− b) + b] (4.12)
Where D is the diffusion coefficient and p and q represent adjustable pa-
rameters which can describe any linear solute concentration profile. The
boundary conditions (eq. (4.10)) relate the change in the solute concentra-
tion in the external volumes to the rate at which the solute penetrates or
leaves the interfaces. In fact they express the continuity of fluxes together
with the solute partition equilibrium at the interfaces.
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The system of equations 4.9-4.12 can be solved using the Laplace trans-
formation method (see [142]). The solution can be expressed as
c(x, t) = k
(
C∞ +
∞
∑
n=1
Cn(x) exp(− t
τn
)
)
(4.13)
where C∞, Cn(x) and τn represent
C∞ =
(A + q− 12 P)a + (B + 1− q + 12 p)b
A + B + 1
(4.14)
Cn(x) = [(a− b)(E + F)]/([12 (A + B)Q
2
n + ABQ
2
n]
sin Qn
Qn
−[1
2
(A + B) +
1
2
(1− ABQ2n)] cos Qn)
E =
{
(1− q)A + P
Q2n
}
[BQn sin
{
Qn(1− xl )
}
− cos
{
Qn(1− xl )
}
]
F =
{
(q− p)A + P
Q2n
}
[cos
{
(
Qnx
l
)
}
−AQn sin
{
(
Qnx
l
)
}
] (4.15)
τn =
l2
Q2nD
(4.16)
and where the Qn are the nonzero, positive roots of the transcendental
equation
(ABQ2 − 1) tan Q = Q(A + B) (4.17)
We notice that the local concentration c(x, t) changes with time un-
til a uniform limiting value k · C∞ has been reached. One can also note
that the coefficients Cn are dependent of the initial condition parameters
(eq. (4.12)) imposed on the membrane, while the characteristic times τn is
not but rather depends on the geometric parameters.
Equations for the measurable concentrations ca(t) and cb(t) can be de-
rived by substituting the expression for k (eq. (4.6)) into the general solution
(eq. (4.13)) of the diffusion equation. We have
ca(t) = C∞ +
∞
∑
n=1
Cn(0)exp(− t
τn
)
cb(t) = C∞ +
∞
∑
n=1
Cn(l) exp(− t
τn
) (4.18)
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4.8.3 Case p=0 and q=0
The initial conditions (eq. (4.12)) have been established as a function of co-
efficients p and q with the aim to be as general as possible. In the literature
[142], three cases are discussed: I. p = 0 and q = 0, II. p = 0 and q = 1,
and III. p = 1 and q = 1. Cases I and II represent the situation where the
membrane is first equilibrated by the solutions of volume b and a respec-
tively. The case III represents an initial linear concentration profile within
the membrane with equilibrium at the interfaces. These cases are acces-
sible experimentally and cases I and II are equivalent. Our experimental
situation corresponds to case I and therefore we now propose to detail the
solution for this specific case.
Considering p = 0 and q = 0, we substitute these values into eq. (4.18)
and rearrange with the use of eq. (4.17), and we find for the difference of
the solute concentrations in the bathing solutions
∆c(t) = ∆c(0) +
∞
∑
n=1
An exp(−Q
2
nDt
l2
) (4.19)
in which
An =
A{(1+ B2Q2n)± [(1+ A2Q2n)(1+ B2Q2n)] 12 }
1
2{(1+ A2Q2n)(1+ B2Q2n) + (A + B)(1+ ABQ2n)}
(4.20)
The plus sign in the equation for An applies if the Qn lie in the first and the
second quadrant, whereas the minus sign applies if the Qn lie in the third
and the fourth quadrants. A great simplification is obtained if the volumes
of the bathing solutions are equal (A = B). In that case eq. (4.17) and An in
eq. (4.19) reduce respectively to
AQ tan
1
2 Q = 1
An =
4A
1+ A2Q2n + 2A
(4.21)
4.8.4 The quasistationary case
Generally the sum in eq. (4.13) represents a rapidly converging series to
which all terms contribute in early stages of the diffusion process. How-
ever, after a certain period only the leading term (n = 1) is of importance
and the diffusion process is said to be quasistationary. Under this condition
eq. (4.13) and (4.19) reduce with eq. (4.16) to
c(x, t) = k
(
C∞ + C1 exp(− t
τ1
)
)
∆c(t) = ∆c(0) exp
(
− t− θ
τ1
)
(4.22)
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in which θ is
θ = τ1 ln A1 =
lnA1
Q21
l2
D
(4.23)
and represents the time lag with which a region of simple exponential de-
cay sets in.
Explicit expressions for Q1 and τ1 can be formulated in the case where
the quantities A and B are very large compared to unity. This corresponds
to the case where volumes Va and Vb are much larger than the volume of
the membrane given by Sl. And so the approximation tan Ql = Ql applied
to eq. (4.17) yields with eq. (4.11)
Q21 = kSl
Va +Vb
VaVb
(4.24)
Substitution of this equation into eq. (4.16) leads to
τ1 =
VaVbl
kS(Va +Vb)D
(4.25)
This expression for the relaxation time of the solute diffusion can be applied
to compare the measurements of glucose diffusion with the diffusion cell
and in the case of in vitro testing of the IGLUS demonstrator. The difference
between these two cases is the geometry since in both cases the volumes are
stirred.
4.8.5 Model extension
The present model can be extended to unstirred and/or semi-infinite vol-
umes [143, 144]. The complexity of the transport of the solute at the inter-
face solvent-membrane and inside the membrane can be increased by de-
veloping in more details the partition coefficient k [142]. The non-equilibri-
um thermodynamics in membranes is detailed by Staverman [145]. It is
also possible to integrate the dynamic of the chemical reaction inside the
sensor as done by Clark et al. [146].
4.9 Conclusion
In this chapter, we have presented the chemical and physical basis neces-
sary to understand the use of a membrane, and exposed the requirements
of the IGLUS for a SI. From this basis, we reviewed the different membrane
technologies and selected two potential candidates for the IGLUS, the an-
odic alumina membranes and the polyethylene films. The properties and
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structure of these two types of membranes were subsequently detailed. Fi-
nally, we presented a theoretical model for the transient diffusion of a so-
lute through a membrane, which will be validated through experiments in
the coming chapter (see section 5.3.2.A).
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5.1 Introduction
As discussed in the main introduction (section 1.5), the purpose of charac-
terizing membranes is to select the appropriate membrane for the IGLUS.
We aim to provide simple tools to measure the important parameters nec-
essary for the well functioning of the sensor. Following this thread, the
first experiment performed was to measure the diffusivity of glucose. Next
comes to measure the retention capabilities of each membrane for con-
canavalin A (ConA) and dextran. Dextran being much larger than ConA
(see table 3.1), the retention of ConA is a priority and a tool was built for
this purpose.
In order to measure the diffusivity of glucose through a membrane, we
fabricated a diffusion cell which consists of two chambers separated by
a membrane. The setup is detailed in section 5.3. The idea is to fill the
two chambers with water, set glucose in one of the chambers and monitor
the glucose concentration over time in the other one. The measurement of
glucose concentration is an issue when dealing in the range of body con-
centrations (2-30 mM). Among different techniques, such as infrared spec-
troscopy, polarimetry, viscosity, density and reagent assay, refractometry
turned out to be the most accurate (1.5 mM sensitivity, see section 5.2.1)
and accessible. Refractometry is limited to determine the concentration
variations of one species at a time, but on the other hand, the concentra-
tion variations of several species can be monitored. Therefore we also used
this technique to measure dextran leakage.
The concentration measurement of proteins requires a more sensitive
technique in order to detect small leakage through a membrane. We chose
the UV absorption spectrometry as it is a simple and accessible technique.
An enzymatic technique such as ELISA (Enzyme-Linked ImmunoSorbent
83
Chapter 5. Selective interface characterization
Assay) would be more sensitive but we have not found the specific proce-
dure for ConA. We found a possible antibody, the anti-canavalia ensiformis
lectin1, but the process still needs to be established by specialists. Moreover
the UV absorption spectroscopy is sufficient for a quick "yes or no" test for
leakage of a protein and therefore we used it for retention measurements
of ConA as well as bovine serum albumin.
ConA presents some solubility issues and the commercially available
ConA is not pure. Therefore we used a test protein, the bovine serum al-
bumin (BSA), because it is a standard for testing membrane selectivity in
literature. BSA also presents the advantage to be stable over days and is
commercially available with a high purity. The size of BSA is similar to the
ConA dimers and smaller than the ConA tetramers, therefore its retention
is representative of dimers and tetramers of ConA.
In the previous chapter, the reasons of the choice of an alumina mem-
brane with a poly((polyethylene glycol) methacrylate) (PPEGMA) coating
as a selective interface for the IGLUS (see section 4.5) have been revealed.
Anodic alumina membranes with 20 nm pores have been purchased from
Whatman and coated with PPEGMA. The selectivity (glucose diffusivity
vs. protein retention capability) of these membranes has been studied and
presented in this chapter. In order to compare this choice of interface with
another technology, we characterized the selectivity of polyethylene (PE)
membranes as they show the same coating ability and high chemical resis-
tance. The PE membranes are not suited for the IGLUS sensor presented
in this work but are envisioned for a future version with a tubular shape
membrane.
5.2 Experimental techniques
5.2.1 Refractometry
Refractometry is the method of measuring the refractive index (rI) of a sub-
stance. The rI measurement is commonly used for the measurements of
sugars concentrations in the food industry. The rI of a substance is strongly
influenced by temperature and the wavelength of light used for measure-
ment. Therefore rI measurements are reported at the reference temperature
of 20◦C and at the reference wavelength of 589.3 nm (the sodium D line).
To perform the rI measurements, we used the high precision refractometer
Bellingham+Stanley2 RFM 342. This apparatus is shown in figure 5.1 and
has a resolution of five digits and an accuracy of ±0.00004, which corre-
sponds to an accuracy of 1.5 mM of D-glucose. For high accuracy measure-
ments, a drop as small as 60 µl is sufficient and placed on the refractometer
1http://www.sigmaaldrich.com/catalog/search/ProductDetail/SIGMA/C7401
2http://www.bs-ltd.com
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Crystal
Figure 5.1: Refractometer with five digits precision.
crystal for acquisition. In figure 5.2, the calibration curve for D-glucose is
presented.
5.2.2 UV absorption spectrometry
Ultraviolet (UV) absorbance spectrometry is used to quantify the concen-
tration of a protein. The UV light absorbance of proteins come from 3
sources: peptide bonds (190-220 nm), aromatic amino acids (250-295 nm)
and prosthetic groups (Ca2+ and Mn2+ ions for ConA). Hence the nature
of the protein cannot be determined but for a single protein solution the
quantity can be determined. Our system allows measurements from 220
nm and above and therefore we detect the tyrosine (274 nm) and trypto-
phan (280 nm) aromatic amino acids because they are the most absorbing
component of proteins3.
We used an ultraviolet-visible (UV-Vis) light spectrometer and its con-
figuration is shown in figure 5.3. The light source is a DT-MINI-2-GS with a
deuterium bulb from Ocean Optics4 and the spectrometer is a USB4000-UV-
VIS from the same company. The UV light is transported via optical fibers
in order to minimize losses and is collimated by quartz lenses through a
UV micro-cuvette. We used the UV-Cuvette micro from Brand5 with a ca-
3http://www.sci.sdsu.edu/TFrey/Bio750/UV-VisSpectroscopy.html
4http://www.oceanoptics.com
5http://www.brand.de
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Figure 5.2: Calibration curve of the refractive index of D-glucose in deion-
ized water, measured at the standard reference of 20◦C and 589.3 nm wave-
length.
pacity of 70 µl and a path length la of 10 mm, and the cuvette holder is
home-made. The liquid to be measured is set in the cuvette and the spec-
trometer measures the intensity of the transmitted UV light. The technique
requires a reference in order to measure the relative absorption. For all
measurements, the reference has the same ionic and buffer solution as the
one containing the protein.
The absorbance is measured as a function of the wavelength and is de-
fined as
A(λ) = − log10
I(λ)
I0(λ)
(5.1)
where I is the transmitted intensity, I0 the reference transmitted intensity
and λ the wavelength.
The concentration of the protein or solute to be detected is calculated
using the Beer-Lambert law
A = eCla (5.2)
where e is the molar absorptivity or molar extinction coefficient of the so-
lute, C the concentration and la the path length. Another measure of the ex-
tinction coefficient is E1% which gives the mass extinction coefficient. E1%
is the absorbance of a 1% solution by mass and has the units lg·cm . The con-
version between e and E1% is e = E1% × MW, MW being the molecular
weight.
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UV Light
Source
Spectro-
meter
Colimanting
lenses
Optical
fiber
UV cuvette 70 l Protein solution
la
Figure 5.3: UV absorption spectrometry setup.
Figures 5.4 and 5.5 contain the calibration spectra and absorbance at 280
nm employed to determine the BSA and ConA concentrations respectively.
The BSA was purchased from Sigma-Aldrich and the product number is
A7906. The ConA was purchased from Sigma-Aldrich and the product
number is Type IV C2010.
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Figure 5.4: Calibration spectra of UV absorption and absorbance at 280 nm
of BSA in 150 mM NaCl pH=7.0 at 25◦C.
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Figure 5.5: Calibration spectra of UV absorption and absorbance at 280 nm
of ConA in 50 mM TrisHCl buffer pH=7.0 at 25◦C.
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Figure 5.6: Diffusion cell configuration.
5.2.3 Diffusion cell
For diffusion measurements of D-glucose and retention tests of dextran,
BSA and ConA, we used home-made diffusion cells. The setup configura-
tion is shown in figure 5.6. The test cell has two compartments which are
separated by the porous membrane to be characterized. A solution with
a given concentration of the solute is set in chamber A and pure solvent
in chamber B at the beginning of the experiment. Both chambers are well
stirred by standard PTFE magnetic stirrers, and solute diffusion is moni-
tored in the low concentration chamber by taking samples and measuring
the solute concentration by either refractometry or UV absorption spec-
trometry.
We designed and fabricated three different types of cells with two equal
volume chambers (Va = Vb) of 393 µl, 785 µl and 1178 µl. They have been
designed for 13 mm diameter disk membranes and all the chambers have
an inner diameter of 10 mm but different length lc of 5 mm, 10 mm and
15 mm respectively. Hereafter the cells are call by their chamber length,
e.g. "15 mm cell". All cells are made of poly(methyl methacrylate) (PMMA)
and the sealing between the chambers and the membrane is ensured by a
silicone rubber ring of 50 Shore A.
5.3 Glucose diffusion
5.3.1 Experimental conditions
The glucose diffusion measurements were conducted in the diffusion cells
described in section 5.2.3. A 100 mM D-glucose (in ultrapure water) so-
lution and ultrapure water are put in the chambers A and B, respectively,
at the beginning of each experiment. Both chambers are well stirred dur-
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Figure 5.7: Comparison of glucose diffusion kinetics in three different cell
sizes: lc = 5 mm, 10 mm and 15 mm. A Whatman alumina 20 nm pores
membrane was employed and the measurements were performed at 25◦C.
ing the whole experiment. The glucose concentration of the liquid in the
chamber B is measured by refractometry from time to time as described in
section 5.2.1. The rI values are converted to glucose concentration values
using the calibration curve of figure 5.2. We obtain a curve of the glucose
concentration variation in chamber B as a function of time. The glucose
diffusion measurements were performed at 25◦C because it is a standard
in literature and the diffusion coefficient can be easily extrapolated to the
desired temperature using the Stokes-Einstein relation (see eq. (4.2)).
5.3.2 Results
5.3.2.A Assessment of the glucose diffusion setup
As the IGLUS requires, the glucose needs to diffuse through the membrane
and this diffusivity has to be as fast as possible in order to minimize the
response time of the sensor. It is thus important to understand the glu-
cose diffusive properties of the selected membranes. We started by mea-
suring the diffusivity on a non-coated Whatman anodic alumina 20 nm
pores membrane and compared the results obtained in the three diffusion
cell sizes, as shown in figure 5.7. This experiment was a validation of our
method in relation with the diffusion theory exposed in section 4.8.
From the resulting curves of the diffusion measurements, we can extract
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Table 5.1: Effective diffusivities De of glucose in a Whatman alumina 20
nm non-coated membrane measured in 5 mm, 10 mm and 15 mm diffusion
cells at 25◦C.
Diffusion cell τ1 [min] De [mm
2
s ]
05 mm cell 16.9± 0.1 1.25± 0.04× 10−04
10 mm cell 35.7± 0.2 1.29± 0.08× 10−04
15 mm cell 59.0± 0.8 1.21± 0.17× 10−04
the relaxation time τ1 by fitting the data with the relation
∆c(t) = ∆c(0) exp
(
− t
τ1
)
(5.3)
which corresponds to eq. (4.22) without the transition term θ which is neg-
ligible. In the case of our diffusion cell, eq. (4.25) is adapted with the fol-
lowing simplifications
Va = Vb = V
V = Slc (5.4)
and becomes
τ1 =
Vl
2SDe
=
lcl
2De
(5.5)
where lc is the length of diffusion cell chambers, l the membrane thickness
and De is the parameter commonly used in the literature to express the
effective diffusivity of a solute in a membrane [109]. From eq. (5.5), we can
express De as a function of the geometric parameters
De =
lcl
2τ1
(5.6)
The effective diffusivity De is nothing more than the contraction of k · D
and therefore includes the interaction processes between the solute and the
membrane and the porosity of the membrane.
The results of processing the measurements from figure 5.7 are given in
table 5.1. We observe that the effective diffusivity of glucose is the same
when measured in the three different cell sizes. De being an intrinsic pa-
rameter of the membrane, it must be independent on the cell geometry.
This result demonstrate the validity of the experimental setup and the ac-
cordance of the results with the theory.
The obtained effective diffusivity De of glucose can be compared to its
diffusion coefficient in water D = 6.8 · 10−4 mm2s [147] knowing that the
porosity of the membrane is φ = 0.37 [20]. By combination of eq. (4.7) and
the definition of De, we get
De = Kφ
υ0
υ
D (5.7)
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Table 5.2: Effective diffusivities De of glucose through PPEGMA coated
Whatman alumina 20 nm with different thicknesses of coating expressed
in polymerization time. Measurements performed in a 15 mm diffusion
cell at 25◦C.
Membrane Coating τ1 [min] De [mm
2
s ]
WA20-NC non-coated 59.4± 1.8 1.20± 0.36× 10−04
WA20-10-1 coated 10 min 41.9± 1.4 1.70± 0.57× 10−04
WA20-20-1 coated 20 min 57.4± 1.8 1.24± 0.39× 10−04
WA20-30-1 coated 30 min 61.3± 2.3 1.16± 0.43× 10−04
WA20-40-1 coated 40 min 76.2± 2.2 0.93± 0.26× 10−04
WA20-60-1 coated 60 min 133.0± 3.1 0.54± 0.13× 10−04
We can extract the unknown factor coming from the chemical interactions
between the non-coated membrane (alumina), the solvent (water) and glu-
cose
K
υ0
υ
=
1
2
(5.8)
which expresses the reduction of the diffusion coefficient in the membrane
pores compared to bulk water. We can then calculate Dm the modified dif-
fusion coefficient of glucose in the non-coated membrane
Dm = K
υ0
υ
D =
De
φ
= 3.4× 10−04 mm
2
s
(5.9)
5.3.2.B Diffusivity through PPEGMA coated alumina membranes
We now present the results obtained for Whatman 20 nm alumina mem-
branes coated with different thicknesses of PPEGMA. The diffusion curves
are shown in figure 5.8 and the calculated effective diffusivities are given in
table 5.2. The different coated membranes are compared using the effective
diffusivity De because the porosity and chemical interactions are modified
by the PPEGMA coating and only De is important for the IGLUS response
time. The thickness of the coating is expressed with the polymerization
time as we have not been able to establish a direct link between thickness
and polymerization time. The current issues are the non reproducible coat-
ing process and the impossibility to measure the coating thickness by ellip-
sometry.
The nomenclature of the alumina coated membranes has the form WA20-
XX-Y, where WA20 stands for Whatman alumina 20 nm, XX for the coating
polymerization time in minutes and Y for the version number. Refer to
appendix B for alternative nomenclature.
We observe that the effective diffusivity is increased with a very thin
coating (10 min) and then decreases as the thickness increases. This was
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Figure 5.8: Diffusion curves of glucose through PPEGMA coated What-
man alumina 20 nm with different thicknesses of coating expressed in poly-
merization time. Measurements performed in a 15 mm cell at 25◦C.
expected since the coating fills the pores as it grows. The explanation for the
increase of diffusivity with a thin coating is the modification of the factor
K υ0υ as we can expect that the chemical interaction between the glucose and
the coating are different than between glucose and alumina.
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Figure 5.9: Diffusion curves of glucose through PPEGMA coated What-
man alumina 20 nm at pH = 4 and 7.4. The pH has no influence on the
diffusion speed. This measurement was performed using an automated
measurement of the rI.
5.3.2.C Neutrality of the PPEGMA coating
The PPEGMA coating is supposed to be neutral because PEG, which is
at the surface of PPEGMA, is known to be neutral [148, 149]. The non-
neutrality can have an effect on the swelling of the coating. In order to
check the neutrality of the coating and to verify that the effective diffusiv-
ity of glucose is not modified, we performed diffusion measurements at
pH=4 and 7.4, the first value being the pH of 100 mM D-glucose in ultra-
pure water, and the second value being the physiological pH. The curves
are shown in figure 5.9 and the result is that the glucose diffusivity is not in-
fluenced by the pH. We conclude that the coating is neutral and its swelling
by water absorption is not affected by the pH. Hence, the solutions used in
the diffusion cells for glucose diffusion measurements do not always need
to be buffered at pH=7.4, and a simple solution of D-glucose in ultrapure
water can be used.
5.3.2.D Diffusivity in PE membranes
As discussed in the beginning of the chapter (see section 5.1), we also char-
acterized polyethylene (PE) membranes as an alternative technology and
as a comparison to the alumina membranes. The nomenclature of the PE
films has the form PE-XX-YY, where PE stands for polyethylene, XX for the
thickness in µm and YY for the etching time. Refer to appendix B for alter-
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Figure 5.10: Comparison of Whatman alumina non-coated 20 nm pores
and PE 30 nm pores membranes. Glucose diffusion measurement were
performed in a 5 mm cell at 25◦C.
Table 5.3: Comparison of effective diffusivities De of glucose in Whatman
alumina non-coated 20 nm pores and PE 30 nm pores membranes. Mea-
surements performed in a 5 mm diffusion cell at 25◦C.
Membrane τ1 [min] De [mm
2
s ]
WA20-NC 18.3± 2.0 1.16± 0.13× 10−04
PE-30-30 52.0± 5.2 0.102± 0.010× 10−04
PE-15-30 34.1± 4.8 0.311± 0.044× 10−04
native nomenclature. The glucose diffusion curves are shown in figure 5.10
and the calculated effective diffusivities are given in table 5.3. The two PE
membranes exhibit low diffusivities of glucose and the reason comes from
their structure. The PE membranes are symmetrical (one layer) and have
30 nm pores through the whole thickness of 30 µm. The alumina mem-
brane has the advantage of being asymmetrical and the layer with 20 nm
pores is only 1 µm thick. Moreover the high tortuosity of the PE membrane
compared to the alumina membrane contributes to its low glucose effective
diffusivity.
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Figure 5.11: Leakage comparison of dextrans from Fluka and PSS through
a Whatman alumina non-coated 20 nm pores membrane. Diffusion mea-
surements were performed in a 5 mm cell at 25◦C and dextran concentra-
tions were monitored by refractometry.
5.4 Dextran retention
The hydrodynamic radius of 2000 kDa dextran (27 nm) is bigger than the
pore radius (10 nm) of the non-coated alumina membranes. Therefore it
is expected to be retained by the membrane. The dextran sold by Fluka is
however polydisperse in size and contains a lot of smaller fractions. The
leakage of the smaller molecules of dextran out of the membrane will re-
sult in an instability of the SF viscosity in the IGLUS. We measured the par-
tial leakage of the Fluka dextran through a non-coated Whatman alumina
membrane and compared with the purified dextran 3200 kDa obtained
from PSS (see section 3.4.2.B). The results shown in figure 5.11 demonstrate
a clear leakage of the Fluka dextran whilst the dextran from PSS exhibit a
limited leakage. The dextran from PSS is retained by the non-coated alu-
mina membrane and therefore is the appropriate candidate for the sensi-
tive fluid in order to obtain a long term stability of the sensor. In the next
chapter, we demonstrate the efficiency of the PSS dextran in the IGLUS
demonstrator.
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5.5 Albumin retention
5.5.1 Experimental description
The basic concept of the test cell is the same as the one for the glucose dif-
fusion test. A 1%-BSA solution with 150 mM NaCl (pH=7) and 150 mM
NaCl solution are put in the chambers A and B, respectively. The liquid in
the chamber B is measured with UV spectroscopy, as described in section
5.2.2, in order to quantify the leakage of BSA. Both chambers of the cell are
well stirred and the test is conducted over 48 hours. As a reminder, the
BSA has a MW of 66 kDa, a size of 4× 4× 14 nm3 and was purchased from
Sigma-Aldrich (product No. A7906). The measurements were performed
at 25◦C for convenience since the temperature only modifies the diffusion
coefficient of the protein but not the total retention capability of the selec-
tive interface.
5.5.2 Results
We measured the BSA retention ability of the PPEGMA coated alumina
membranes that were previously tested for glucose diffusivity. In figure
5.12 we show diffusion curves of BSA through a non-coated alumina mem-
brane and two PPEGMA coated membranes, one with a thin coating and
one with a thicker coating. The 60 min coated membrane exhibited a com-
plete retention of BSA over 48h. The BSA diffusivity in the membrane with
the thin coating is also higher than in the non-coated membrane as ob-
served for glucose, and this can be attributed to the same reason, i.e. a
modification of the factor K υ0υ .
We conducted BSA retention test on alumina membranes with different
PPEGMA coating thicknesses and compared with their effective glucose
diffusivity presented previously. The results of the BSA retention compared
to the glucose diffusivity are given in table 5.4 and we observed that there is
a relation between the effective diffusivity De of glucose and the retention
ability of BSA.
The link between the glucose diffusivity and the BSA retention for PPEG-
MA coated alumina membranes was further investigated by conducting
tests on other coated membranes with the aim to find the optimal coating
thickness. Knowing that the transition from non-retention to retention oc-
curs around 40 min of polymerization time, a series of membranes with
this polymerization time were prepared, the WA20-40-Y series. The first
observation was that, for this series of 13 membranes coated in the same
conditions and polymerization time, the measured glucose diffusivities are
very different from one membrane to the other. This clearly showed the
non-reproducibility of the coating process and therefore we decided to set
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Figure 5.12: Retention of BSA by increasing the PPEGMA coating thick-
ness on a Whatman alumina membrane with 20nm pores.
Table 5.4: Comparison of BSA retention and diffusivity of glucose through
Whatman 20 nm membranes coated with different PPEGMA thicknesses.
Polymerization time [min] Albumin retention De glucose [mm
2
s ]
0 leaks 1.20± 0.36× 10−04
10 leaks 1.70± 0.57× 10−04
20 leaks 1.24± 0.39× 10−04
30 leaks 1.16± 0.43× 10−04
40 retained 0.93± 0.26× 10−04
60 retained 0.54± 0.13× 10−04
180 retained retained
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Figure 5.13: Retention of BSA as a function of glucose effective diffusiv-
ity. The albumin retention of PPEGMA coated Whatman 20 nm alumina
membrane can thus be determined by glucose diffusion kinetics.
the glucose effective diffusivity value as the measure for the coating thick-
ness, and also the protein retention capability. The result obtained with the
WA20-40-Y series are presented in figure 5.13 and table 5.5. The first out-
come is the confirmation of the results obtained with the first coated mem-
brane series where a transition from non-retention to retention of BSA is
observed when the glucose effective diffusivity De decreases. More specif-
ically, the transition occurs for De values between 0.6 and 1 · 10−4 mm2s .
The PE films (membranes), described in section 4.7, have also been
tested for BSA retention and the results are presented in table 5.6. We ob-
served that BSA retention is obtained with 15 µm thick films, but at the
cost of very low effective diffusivity of glucose. The two films that retained
BSA, PE-15-05 and PE-15-10, have short etching time of 5 and 10 min re-
spectively, and therefore exhibit a low porosity. This is a promising result
knowing that thinner film with smaller pores and greater porosity can be
prepared. The last PE film in table 5.6, PE-15-60, has been etched for 60
min, and neither glucose nor BSA could diffuse through the film. In fact
the inner structure of the film collapsed because of the excess of etching.
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Table 5.5: Comparison of BSA retention and diffusivity of glucose throu-
gh Whatman 20 nm membranes PPEGMA coated, 40 min polymerization
time. The effective coating thickness varies for the same preparation con-
ditions.
Name De glucose ×10−4 [mm2s ] albumin test
WA20-40-2 1.70± 0.06 leaked
WA20-40-3 1.24± 0.04 leaked
WA20-40-4 1.16± 0.04 leaked
non-coated 1.16± 0.13 leaked
WA20-40-5 1.05± 0.05 leaked
WA20-40-1 0.934± 0.026 retained
WA20-40-7 0.898± 0.023 leaked
WA20-40-8 0.633± 0.029 leaked
WA20-40-9 0.621± 0.086 retained
WA20-40-10 0.535± 0.013 retained
WA20-40-11 0.337± 0.053 retained
WA20-40-12 0.334± 0.007 retained
WA20-40-13 0.323± 0.022 retained
WA20-40-14 0.143± 0.006 retained
Table 5.6: Comparison of BSA retention and glucose diffusivity through
PE membranes with different pore size and thickness.
Film name Pore size Thickness De glucose Albumin
[nm] [µm] ×10−4 [mm2s ] test
PE-30-20 <30 30 0.113± 0.021 leaked
PE-30-30 ca. 30 30 0.204± 0.020 leaked
PE-30-40 >30 30 0.357± 0.033 leaked
PE-15-05 <10 15 0.0263± 0.0013 retained
PE-15-10 ca. 10 15 0.0270± 0.0005 retained
PE-15-30 >10 15 0.311± 0.044 leaked
PE-15-60 collapsed 15 retained retained
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5.6 ConA retention
5.6.1 Experimental description
For ConA retention tests, we used the same test bench as for albumin reten-
tion, i.e. diffusion cells and UV absorption spectrometry. ConA presents
the disadvantage to be unstable without the presence of dextran. In fact
we observed its precipitation after a few hours at room temperature in a
solution with the same ionic composition as the SF. The presence of dex-
tran or PEG [150] increases the solubility of ConA. The purpose being to
evaluate the ability of a membrane to retain ConA in similar conditions
to the IGLUS, we conducted the ConA retention tests with the sensitive
fluid SF36F. Hence the diffusion cell was filled with SF36F in chamber A
and filled with reference solution (RS) in chamber B. A 15 mm cell was
employed and the operating temperature was 37◦C.
5.6.2 Results
Knowing that PPEGMA coated alumina membranes retain BSA for effec-
tive diffusivities of glucose below 0.6 · 10−4 mm2s , we conducted the ConA
retention tests on two membranes (WA20-80-1 and WA20-160-1) with De
values about 0.4 · 10−4 mm2s . At pH = 7.4, as it is the case for SF36F, the
ConA is mainly in tetramer form (104 kDa) and a small portion in dimer
form (52 kDa) as detailed in section 3.4. The MW of BSA being 67 kDa and
both proteins being globular, we expected the two selected membranes to
retain ConA. In figure 5.14 we show the diffusion comparison at 37◦C of
BSA and ConA through a non-coated membrane and the coated WA20-80-
1.
The reduced diffusivity of ConA compared to BSA through the non-
coated alumina membrane is caused by three reasons: the ConA tetramers
are bigger than BSA, the higher viscosity of SF36F reduces the diffusion
coefficient of ConA, and at low glucose concentration the ConA is bound
to dextran. In order to minimize the two last effects, we also conducted
ConA retention tests with SF36F containing 30 mM glucose where most of
ConA is unbound from dextran. The difference of ConA leakage through
non-coated alumina membranes with 2 mM and 30 mM glucose is clearly
seen in figure 5.14.
The coated membranes WA20-80-1 and WA20-160-1 both exhibit a small
leakage of ConA when tested with 30 mM glucose SF36F. The UV absorp-
tion spectra are shown in figure 5.15. The spectra are noisy because we
are at the limit of the sensitivity of the technique. Considering this small
leakage of ConA, we calculated the relaxation time τ1 of this leakage us-
ing eq. (4.22) and extrapolated the results for the geometry of the IGLUS
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Figure 5.14: Comparison of leakage behaviors of ConA and BSA through a
non-coated and a PPEGMA coated 20 nm alumina membrane. The solution
containing ConA is SF36F which contains either 2 mM or 30 mM of glucose.
The diffusion measurements were conducted in 15 mm diffusion cell at
37◦C.
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Figure 5.15: UV absorption spectra showing the ConA leakage through
PPEGMA coated Whatman 20 nm alumina membranes.
Table 5.7: Relaxation times of ConA leakage for two PPEGMA coated alu-
mina membranes. τcell is the relaxation time in the diffusion cell and τsensor
is the extrapolated relaxation time for the IGLUS demonstrator.
Name τcell [day] τsensor [day] De glucose ×10−4 [mm2s ]
WA20-80-1 192± 42 34± 7 0.439± 0.010
WA20-160-1 380± 93 67± 16 0.395± 0.007
demonstrator using eq. (4.25). The results are shown in table 5.7.
The coated alumina membranes showed a good retention over time.
The leakage of ConA might be dominated by the leakage of the fragments
and some of the fragments may not be detected by UV absorption spec-
troscopy. This is the case if they do not contain the Tyr amino acid. Tyr is
the only amino acid in ConA which absorbs at 280 nm because it is the only
amino acid in the ConA sequence to have an aromatic group.
5.7 Fouling
We tested the modification of glucose effective diffusivity through three
different PPEGMA coated alumina membranes because a decrease would
be the main issue that fouling can cause regarding the functioning of the
IGLUS sensor. The coated membrane has been dipped in SF24P for 1 week
and no detectable alteration of the effective diffusivity was observed. This
result is not further discussed because the study is underway and results
will be presented in a later work. Meanwhile no similar experiment using
the same hybrid membrane was found in literature. We estimate that the
fouling is minimal and that the membrane performance is adapted for a
use on the IGLUS demonstrator for at least one week.
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5.8 Discussion
5.8.1 PPEGMA coated alumina membranes
Compared to polymer membranes, which are the most widely used mem-
branes for protein separation, the anodic alumina membranes exhibit an
ideal structure for fast glucose diffusivity. The straight pores and impor-
tant porosity (37% for Whatman Anopore 20 nm) are the cause of these
performances. It was expected that pores of 20 nm were too big to retain
our test protein BSA of 67 kDa. However the strategy of pore-narrowing
with the PPEGMA coating, developed in the laboratory of Prof. Dr. Harm-
Anton Klok, revealed itself to be efficient, since we demonstrated the com-
pleted retention of BSA over 48h in a diffusion cell. We were also able to
make a link between the BSA retention ability and the effective diffusivity
of glucose. A measure of the PPEGMA coating thickness would be better
to control and tune the selectivity of the alumina coated membranes. For
this purpose, we would need to master the the polymerization process of
the PPEGMA brushes on an alumina membrane in order to prepare mem-
branes with a desired and precise coating thickness. As mentioned pre-
viously, a direct measurement of the hydrated thickness of the PPEGMA
coating, at least inside the pores, is not achieved at present. At present,
reasons for non-reproducibility of the coating thickness with respect to the
polymerization time are being investigated but are beyond the scope of
this thesis. However one possible reason is the heterogeneity of the surface
roughness and chemistry among the purchased alumina membranes, as re-
vealed by a study on anodic alumina [151]. Therefore the measurement of
the effective diffusivity of glucose remains the best alternative. Moreover it
gives a direct information on the response time of the IGLUS demonstrator
functioning with such membranes.
The BSA/glucose selective properties of PPEGMA coated alumina mem-
branes, combined to the low fouling property seem to be a novel result
which we have not found in literature. Although we found articles treating
either the membrane fouling reduction with a coating, or the tuned selec-
tivity with a coating, but no results were found gathering the both proper-
ties in a single membrane. Below, some results of four interesting papers
[152, 109, 20, 153] are reviewed, by chronological order, as a comparison to
our results.
The first paper is the work of Kapur et al. [152]. Their main result is the
reduction of protein diffusion (BSA) through a gel-filled pore membrane.
They achieved a shut-down of the BSA diffusion by increasing the den-
sity of a polyacrylamide (PA) gel in poly(vinylidine fluoride) membrane
with 0.22 µm pores. They also showed a diminution of the glucose diffu-
sivity by a factor of 2 when BSA retention is obtained, which is the same
ratio obtained in our case. Indeed we measured a glucose effective diffu-
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sivity of 0.6 · 10−4 mm2s for BSA retentive membranes whereas we have
1.2 · 10−4 mm2s for the non-coated membrane. The fouling of such mem-
branes has not been studied and the PA gel would not be an appropriate
choice for anti-biofouling.
The second comparison is with the study of Praveen et al. [109], which
showed that glucose can diffuse through a hyaluronic acid (HA) coating
with a loss of only 1/3 in diffusivity (i.e. 2/3 of original diffusivity in
polyvinyl alcohol (PVA) membrane). The thickness and density of the coat-
ing are not controlled and the coating thickness is about 400 µm, which
would give rise to a huge response time if applied on a sensor. Nothing
about selectivity or protein retention is treated. Nonetheless HA is known
to be effective for anti-biofouling and is an alternative to PPEGMA, as dis-
cussed in section 3.5.
The third one is the study of Lee et al. [20] since the same alumina
membrane was used (Whatman 20 nm). They grafted PEG on the surface
but their results is limited to a good reduction of BSA adsorption. They also
measured a reduction of diffusivity of ovalbumin but no protein retention
or selectivity is observed.
The last comparison is to the work of Asatekin et al. [153]. An ultrafiltra-
tion polyvinylidene fluoride (PVDF) membrane was coated with PEGMA
and they observed a reduction of biofouling by BSA, sodium alginate and
humic acid by water permeability measurements. Though no information
is given on small solutes diffusivity and protein retention, this work clearly
shows that PEGMA coating is effective for biofouling reduction.
An ultimate topic to be discussed about our selective interface is the
ConA retention. Our results have not concluded with a complete retention
of ConA. However we showed that the leakage is very slow (see table 5.7)
for membrane with De of about 0.4 · 10−4 mm2s . Since this value was lower
than the one necessary for BSA retention, we expect a successful retention
of ConA because the ConA dimers have similar MW to BSA and both are
globular proteins. We believe that dimers and tetramers of ConA were re-
tained and that only smaller fragments of the protein leaked through the
membrane. Wang et al. [83] demonstrated that ConA, obtained with the
very same method, contains different fragments. Therefore we performed
MALDI (Matrix-Assisted Laser Desorption/Ionization) mass spectrometry
of the ConA we used and observed fragments with similar sizes than in the
work of Wang. The resulted spectrum is given in figure 5.16. The struc-
ture and activity of the fragments are unknown but it is believed that the
fragments aggregate to the intact proteins and have a relative activity con-
cerning glucose binding. Therefore we believe that our selective membrane
retains the intact units of ConA and that the leakage of the fragments is suf-
ficiently slow in order to use the membrane as an interface on the IGLUS
demonstrator with a stable signal over 48h in vitro.
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As a comparison to ConA, we also performed MALDI mass spectrom-
etry of the BSA used for the retention test, as is shown in figure 5.16. We
determined a good purity of the BSA since no fragments were observed.
This result confirms the relevancy of BSA as a test protein.
5.8.2 PE films
The studied nanoporous PE films exhibit promising selective properties but
the effective diffusivity of glucose is still low compared to coated alumina
membranes. BSA retention could be observed with films prepared with a
short etching time but at the cost of a very low glucose diffusivity. Nonethe-
less we have to consider that this technology is new and that it was the first
time that such membranes were tested for glucose/BSA selectivity. In or-
der for these films to create a good selective interface for an implantable
sensor, an anti-fouling coating needs to be added. Besides, to function in
particular on the IGLUS, a rigid support is required.
5.8.3 The ideal selective interface
The ideal selective interface would combine the selective property of small
pores (steric) and the anti-non-specific protein adhesion properties of a thin
and very dense coating. The necessary selectivity can be obtained by steric
and/or electrostatic repulsion, however a charged membrane seems to be
efficient only for specific selectivity but not for preventing non-specific ad-
hesion of proteins. Therefore a very thin and dense (high grafting density)
coating is effective for preventing non-specific adhesion of proteins [149].
5.9 Conclusion
We have characterized both selected SIs: the hybrid nanoporous alumina-
PPEGMA membrane with reduced fouling properties and the nanoporous
PE films, with respect to the requirements of the IGLUS. The selectivity
of the PPEGMA coated 20 nm pores alumina membrane was shown for
the BSA-glucose couple over 48 hours. The ConA from Sigma being not
pure, we were not able to prove the complete retention of ConA, though
we believe that ConA dimers and tetramers are retained by our membrane
with a sufficiently thick coating. As long as we cannot produce a sensitive
fluid containing purified ConA, the long term retention of ConA cannot be
proved in diffusion cells using UV absorption spectroscopy.
PE films have been studied as an alternative technology with which non
flat selective interface could be designed. The BSA retention was shown
for small enough pore size but the glucose diffusivity remains too slow.
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Figure 5.16: MALDI mass spectra, obtained with a ABI 4800 MALDI
TOF/TOF Analyzer, of BSA A7906 and ConA C2010 from Sigma. The BSA
protein is pure and its MW is 66.6 kDa. The ConA exhibits many framents
and the intact units have a MW of 25.6 kDa.
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5.10. Outlook
Thinner films coupled to a rigid support should be designed in order to suit
the IGLUS. We believe that further developments could lead to a success.
5.10 Outlook
The actual selective interface still needs to be improved. As discussed pre-
viously, a better support would be a membrane having a selective layer
with smaller pores. A pore size of 3-5 nm and a thin coating would create
an efficient selective interface. Recently, alumina membranes with pores
down to 5 nm have been achieved. We tested an alumina membrane from
Synkera with 5-7 nm pores and BSA was retained. However the quality of
these membranes needs to be improved as they are too brittle and exhibit a
poor porosity. Nevertheless we can expect further improvement in the near
future because of the commercial need for such membranes in other fields.
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Chapter 6
Selective interface on the
IGLUS
6.1 Introduction
The selective interface (SI), resulting from the combination of an alumina
membrane and the PPEGMA coating, gave good results in terms of molec-
ular selectivity in the diffusion cells. In this chapter, we present the integra-
tion of the SI on a newer version of an IGLUS demonstrator developed in
the scope of this work. The forthcoming experiments allowed us to assess
the SI in in vitro conditions.
We present the improved version of the IGLUS demonstrator and the
preparation and integration of the SI, as well as the setup used for the in
vitro experimentations. Next, we present and discuss the in vitro results
obtained using the WA20-80-2 and WA20-80-3 SIs. These interfaces are
nanoporous alumina-PPEGMA hybrid membranes (refer to section 5.3.2.B
for nomenclature).
6.2 IGLUS demonstrator improvements
As presented in chapter 3.2, the microviscometer and the acquisition sys-
tem were studied in a previous work [22]. The IGLUS demonstrator used
in this work has been redesigned taking into account requirements issued
from the implementation of the SI. An exploded and a detailed views of
the newer demonstrator are presented in figure 6.1. The complete CAD
drawings are in the appendix C.
The exploded view of figure 6.1 shows the different parts of the demon-
strator. The housing is made of PMMA and is watertightly sealed with an
O-ring. The rotor is based on a Samarium-cobalt (SmCo5) cylindrical mag-
net, and at both ends a disc of brass is glued which holds the stainless steel
111
Chapter 6. Selective interface on the IGLUS
1
2
3
4
5
6
1. cap
2. O-ring
3. bearing
4. rotor
5. housing
6. bearing
Figure 6.1: IGLUS demonstrator. Exploded and detailed views. Dimen-
sions in mm.
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shafts. To prevent any corrosion and water contact, the rotor, excepted for
the ends of the shafts, is coated with parylene. The two miniature bearings
are made of sapphire and ensure that the mechanical friction is as low as
possible.
The newer demonstrator version is optimized for a faster response time
since the inner volume (SF volume) has been reduced to 4.1 µl compared
to 5.1 µl for the older version, and the open surface for the SI has been in-
creased from 1.7 mm2 to 3.6 mm2. This improvement has been achieved by
increasing the rotor magnet length by 1 mm and moving the interface closer
to the rotor at a distance of 0.175 mm (0.35 mm in the previous version).
The external dimensions of the housing have been enlarged in order
to improve the assembly because the previous version necessitated several
attempts before the demonstrator was usable. A larger housing led to a
90% successful assembly score and drastically improved two issues which
were related to the housing deformation when screwing the cap. The two
issues were the cracking of the SI and the jam of the rotor. The necessity
of a reproducible and one-step successful assembly procedure becomes es-
sential when considering in vivo testing. The assembly in sterile conditions
for an implantation does not offer the possibility of reopening the capsule
right before the implantation. The external size increase of the demonstra-
tor was thus implemented for practical reasons but does not compromise
the future miniaturization of the IGLUS sensor.
In order to assess the SF under repeated shear stress, a closed version
(without the opening for the SI) has also been used. In the next section, this
slitless version is referred to as the closed capsule and the regular version is
referred to as the sensing capsule.
6.3 Integration of the selective interface
6.3.1 Preparation
The SI is a nanoporous alumina membrane coated with PPEGMA as de-
scribed in section 4.6 and characterized in chapter 5. The alumina mem-
branes were provided as 13 mm diameter discs and were cut into smaller
rectangular pieces of 4.15 × 2.5 mm2. The PPEGMA coating was applied
prior to cutting.
The small membrane pieces were first pre-cut by laser ablation, leaving
0.4 mm wide bridges connecting to the initial membrane. The individual
pieces were then detached by breaking the bridges. The laser ablation was
performed using a LS-520G Nd:YAG 1064 nm laser from Laser Systems.
The initial porous alumina membrane was placed on a bulk alumina sub-
strate and the laser ablation was operated using the following parameters:
power 80%, pulses frequency 3 kHz and speed 1 mm/s.
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5 mma) b) c)
Figure 6.2: Integration of the alumina membrane onto the demonstrator:
a) the bare demonstrator and the laser cut membrane, b) the membrane is
disposed on the demonstrator opening, c) the membrane is glued onto the
demonstrator.
The so-prepared membranes were subsequently integrated onto the IG-
LUS demonstrator, described in section 6.2, by gluing it on the opening as
depicted in figure 6.2. We used the epoxy adhesive Eccobond 268 from
Emerson & Cuming because it is adapted to aqueous media, does not re-
lease solvents nor ions and has adapted creeping properties to sustain the
expansion difference of PMMA and alumina. The glue was polymerized
for 8 hours at 37◦C.
6.3.2 Filling procedure
In order to avoid the emergence of bubbles and to ensure the watertight-
ness of the demonstrator, we developed a specific filling and assembly pro-
cedure. A reproducible and efficient procedure is required to prepare the
demonstrator for in vivo testing. Indeed the assembly in sterile conditions
for an implantation requires the complete sealing of the capsule and elimi-
nates the possibility of reopening the capsule right before the implantation.
After the SI has been glued onto the sensing capsule, the rest of the
assembly procedure consists on filling the capsule with the sensitive fluid
(SF) and sealing the cap in order to avoid any leakage, mainly due to the
osmotic pressure. The concentration difference of a solute on both sides of
a selective membrane, in our case dextran and ConA, creates an osmotic
pressure which tends to equilibrate the concentrations.
Prior to filling the demonstrator, the housing and the cap are stored for
at least one day in the reference solution (RS) because PMMA can absorb
a very little amount of water and ions. Shortly before filling, the housing
and the cap in their RS bath, as well as 2 ml of SF, are outgassed at 0.05 mPa
for 15-30 min at ambient temperature. This step is necessary to avoid the
emergence of air bubbles. Next, the housing is filled with the outgassed SF
up to the edge, the rotor is inserted and the cap is screwed slowly in order
to avoid any excessive overpressure inside the capsule which could cause
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a) b)
Figure 6.3: IGLUS demonstrator. a) assembled, b) the evacuation channel
is sealed with a conically shaped pin.
the burst of the SI. The excess of SF inside the capsule flows out through
the overpressure channel in the cap. The last step is to seal the overpressure
channel using a conically shaped stainless steel pin, as depicted in figure
6.3.
6.4 In vitro test bench
6.4.1 Experimental setup
The experimental setup is composed of the acquisition system, which per-
mits the measurement of the damping factor as described in section 3.3,
and the simplified in vitro environment model (SITEM), which creates an
environment where the ionic physiological conditions are mimicked.
6.4.1.A Acquisition system and thermostatic chamber
The acquisition system is controlled by a multifunction DAQ board PCI-
6052E from National Instrument1. The sine and cosine waves to acceler-
ate the rotor are generated with the digital-to-analogue converter (DAC) of
the board. The setup is depicted in figure 6.4. The board is also used for
the acquisition of the two Hall effect sensors signals during the measure-
ment phase. The signals for the coil currents are generated by the DAC and
amplified by two current followers based on power operational amplifiers
OPA541.
The rotor is accelerated to an angular speed of 210 Hz, and, during the
speed decay, the position of the rotor is acquired through two Hall effect
sensors, oriented at 90◦ with respect to each other. The Hall effect sensors
used are of the type Honeywell SS94A1F. These sensors are highly inte-
grated and have all necessary electronics and amplification stages on one
chip. The output is an analog signal, proportional to the magnetic field
1http://www.ni.com/dataacquisition
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Figure 6.4: Experimental in vitro setup.
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component perpendicular to the sensor. The acquisition of the signal is
done via the DAQ board and Labview2 is then used to analyze and per-
form the calculations on the data.
Once the signal has been acquired from the hall effect sensors, the sec-
ond step is to extract the angular position from which the damping factor is
calculated. A previous work [22] determined an accurate and reproducible
method for this calculation. The rotor angular position θ(t) is obtained by
computing the arctangent from the sine and cosine signals of the hall effect
sensors. For reproducibility issues, the starting and ending values of θ(t)
are discarded. In facts, regarding the angular speed, the rotor is accelerated
up to 210 Hz and only the values between 200 and 70 Hz are used to calcu-
late the damping factor λ. The reasons are that the acceleration to 210 Hz is
not reproducible and that, for the lower angular speeds, the rotor rotation
is influenced by the terrestrial magnetic field.
The temperature of the thermostatic chamber is monitored with a PT100
high-precision thermometer GMH 3710 from Greisinger GmbH3. The ab-
solute temperature accuracy is ±0.03◦C with a reproducibility of ±0.01◦C.
The temperature is read via RS-232.
The chamber is heated and cooled by a Peltier element, which is pow-
ered with an Array 3645A4 power supply and controlled via RS-232. A
polarity inverter, actuated through the parallel port allows the computer
to switch the polarity of the power supply. Thus, only one power source
is sufficient for heating and cooling. The temperature control is performed
with a PID regulation implemented in Labview. The temperature can be
automatically set by the computer and the obtained long term stability is
better than ±0.02◦C.
6.4.1.B SITEM setup
As introduced in section 4.2, the SITEM has been deployed in order to as-
sess the IGLUS demonstrator with the SI. The SITEM is a chemical envi-
ronment where the interstitial fluid (IF) is mimicked by a RS which is an
isotonic solution of the SF for all of its constituents but dextran and ConA.
See table 6.1 for the detailed composition. In other words, the RS contains
equal concentrations of ions and has the same pH and buffer as the SF.
The only chemical constituents which differ on both sides of the membrane
are dextran and ConA. Using this model, the only constituent whose con-
centration is varied in and out of the demonstrator should be D-glucose,
because ConA and dextran are retained by the SI and all other chemical
constituents are already equilibrated on both sides of the interface.
2http://www.ni.com/labview
3www.greisinger.de
4www.array.sh/yq-3600e.htm
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Table 6.1: Solutions utilized for the simplified in vitro environment model
(SITEM). The RS is used to simulate the interstitial fluid and the concen-
trated glucose solution is injected in the RS in order to modify the glucose
concentration.
Solution Description Concentration
Reference solution RS Tris buffer (7.4) 10mM
NaN3 0.05%(w/w)
D-glucose 2 - 30 mM
MnCl2 1 mM
CaCl2 1 mM
NaCl 150 mM
H2O -
Glucose solution D-glucose 2M
NaN3 0.05%(w/w)
NaCl 150 mM
MnCl2 1 mM
CaCl2 1 mM
H2O -
The setup used to apply the SITEM is represented in the lower part
of figure 6.4. The sensing capsule is enclosed in a housing containing the
RS. The RS, which thus surrounds the sensing capsule, circulates with the
aid of a peristaltic pump in order to mix the RS. This allows us to have a
situation were both fluids, inside and outside the sensing capsule, are well
stirred and is therefore comparable to the diffusion cell situation. The SF is
mixed by the viscosity measurements since the rotor is actuated every 25
seconds.
The whole setup is disposed in the thermally regulated chamber so that
the system can be set to the required temperature. In order to be as close
as possible to the conditions of the human body, all the measurements are
performed at 37◦C.
The glucose concentrations were applied to the RS, either by injecting
small amounts of a concentrated (2 M) D-glucose solution with a microliter
syringe in order to increase stepwise the concentration, or by flushing the
RS and replacing it with another RS having the appropriate glucose con-
centration when a decrease is desired. The chemical composition of the
glucose concentrated solution is detailed in table 6.1.
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Figure 6.5: Calibration of the sensing capsule (black curve) and closed cap-
sule (blue curve). The damping factor is calibrated as a function of the
viscosity using calibration oils (D5 and N10) whose viscosity is varied by
adjusting the temperature.
6.4.2 Microviscometer calibration
The IGLUS demonstrator being a microviscometer, we calibrated the mea-
sured damping factor using calibration oils from Paragon Scientific Ltd5.
The viscosity of the calibration oils, being dependent on the temperature,
can be adjusted by varying the temperature. The drive capsule was filled
with the D5 oil and the damping factor λd was determined from 20 to 40◦C
with an increment of 2.5◦C. Subsequently the sensing capsule was filled
with the N10 and D5 oils in order to cover a broader viscosity range. The
total damping factor λt was measured for the same temperatures as pre-
viously and the damping factor of the sensing capsule λs was calculated
using the relation λs = λt − λd. The viscosity of the calibration oils as
a function of the temperature is given by the manufacturer and thus the
damping factor of the sensing capsule can be plotted as a function of the
viscosity. The results are shown in figure 6.5. The viscosity range of 3-
6 mPas is covered by the D5 oil and the 8-18 mPas range is covered by the
N10 oil.
Figure 6.5 also shows a calibration curve for the closed capsule since
this latter was used to assess our system as presented in the next section.
5http://www.paragon-sci.com
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Figure 6.6: Stability measurements of dextran solutions and SFs in the
closed capsule at 37◦C.
6.5 In vitro results
The results obtained with the IGLUS demonstrator are presented in three
sections. First we present stability measurement obtained with a closed
capsule. This study was required in order to verify the viscosity stability
of the SF over time when repeated measurements, i.e repeated shear stress,
are applied to the SF. In a second part, we studied the viscosity stability of
a dextran solution in the demonstrator with the SI (sensing capsule). The
third section deals with the response of the IGLUS demonstrator to glucose
concentration variations using the SITEM.
6.5.1 Stability in closed capsule
In order to evaluate the SI on the IGLUS demonstrator, the first step was
to determine whether the repeated viscosity measurements are supported
by the SF. Hence we measured the viscosity stability over time in a closed
capsule with four different fluids at 37◦C. A measurement was taken every
25 s. We tested two SFs, the SF36F and the SF24P, and two dextran 3 wt%
solutions prepared with Fluka and PSS dextrans respectively. The dextran
solutions were prepared by dissolving the dextran in the RS. The damping
factors as a function of the time are plotted in figure 6.6.
The viscosity remained constant for more than 40 hours for almost ev-
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Table 6.2: Effective diffusivity of the two selected SIs for the IGLUS
demonstrator.
Name De glucose [mm
2
s ]
WA20-80-3 0.0501± 0.0019 ×10−4
WA20-80-2 0.0628± 0.0006 ×10−4
ery solutions, only the SF36F showed a slight increase. The reason for this
increase is unknown but was observed in many experiments. As a compar-
ison, the SF24P, prepared with purified PSS dextran, exhibited a much bet-
ter stability, since the viscosity remained the same for more than 50 hours.
This observation lead us to use the SF prepared with the PSS dextran for
the assessment of the IGLUS demonstrator with the SI.
None of the two dextran types showed any weakness during the ex-
periment. Both dextran solutions had a very stable viscosity. We therefore
conclude that the repeated shear stress applied to the tested fluids does not
alter nor break the molecules of dextran or ConA. The slight increase of vis-
cosity of the SF36F is thought to be a reorganization of the dextran-ConA
network.
6.5.2 Stability in sensing capsule with SI
In the previous section, we demonstrated that the SF and the dextran so-
lutions have a stable viscosity over time in a closed capsule. The next step
was to assess the SI on the sensing capsule, both parts assembled together
creating the IGLUS demonstrator. Two SIs were selected, the WA20-80-
3 and WA20-80-2, because they exhibited an effective diffusivity of glu-
cose close to 0.06 · 10−4 mm2s , which is much below the maximum value of
0.6 · 10−4 mm2s for BSA retention. The detailed values are given in table 6.2.
Given the low values of De, the coating was relatively thick and this is re-
quired in order to retain the fragments of ConA as well as possible.
Prior to using a SF, we tested the demonstrator with the SI WA20-80-3
using a dextran solution in the SITEM setup. This interface had the thicker
coating (since De is smaller). In figure 6.7, we show the viscosity evolution
of a dextran solution in the demonstrator and we compared it to a non-
coated SI. The main outcome of this experiment is that the WA20-80-3 SI
retained the dextran over 24 hours (green curve), whereas the non-coated
version did not (red curve). The two jumps in the green curve are due to
the presence of a bubble.
This experiment taught us other things. Regarding the measurement
with the non-coated SI, the black curve was obtained without sealing the
sensing capsule with the pin and the red curve was obtained with the pin.
We observe that without a good sealing, the viscosity stabilizes faster but
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Figure 6.7: Stability measurements of dextran PSS 3% solutions in the
IGLUS demonstrator. Two Whatman 20nm membranes were tested, a non-
coated and a PPEGMA coated (WA20-80-3).
air bubbles appear after a few hours. After 10 hours, we clearly see on the
black curve the discontinuity of the signal due to the bubbles. We believe
that the faster stabilization of the viscosity was either due to the air bub-
bles preventing the dextran to leak out, or due to the very slow water flux
entering the demonstrator through the membrane, because of the osmotic
pressure, which slows down the leakage of dextran.
We also observed that pre-filling the sensing capsule with the dextran
solution gave rise to a better viscosity stability. The pre-filling means that
we filled the capsule with the dextran solution for 24 hours prior to per-
forming the measurements. Just before the measurements, the dextran so-
lution was renewed with a fresh and outgassed solution. It is known that
PMMA adsorbs certain solutes, especially proteins, and hence we expected
that dextran would also be adsorbed. By pre-filling the sensing capsule, we
created a layer of adsorbed dextran on the inside walls of the capsule which
prevents further adsorption. This is the difference between the blue curve
and the green curve in figure 6.7, where the latter curve was obtained after
pre-filling and we observed a better stability of the viscosity over 24 hours.
What happens with the blue curve is that the capsule was rinsed with ul-
trapure water before the measurement and we observe a slight decrease of
the viscosity, due to the slow adsorption of dextran on the walls.
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While studying the viscosity stability of the dextran solution in the sens-
ing capsule, we discovered that we could obtain a better stability by chang-
ing the rotating direction of the rotor for every measurement. This opera-
tion is named bidirectional mode and was used for the measurement of the
green curve in figure 6.7. The reason for the improved viscosity stability by
using the bidirectional mode is not yet determined. However we suspect
a rearrangement of the dextran molecules when the shear stress is repeat-
edly applied in the same direction, which creates a variation of the viscosity
over time, as it has been evidenced by Beyer et al. [154]. It is important to
note that we only observed this phenomenon with PSS dextran and in the
sensing capsule. It was not observed in the closed capsule. The reason for
this phenomenon is not understood yet. The bidirectional measurements
were adopted for the later experiments using the SF.
6.5.3 Demonstrator response to glucose variations
The ultimate step of the validation of the SI on the IGLUS demonstrator
was to implement the SF and test the response of the complete system to
glucose variations using the SITEM. The experiment was repeated only a
limited number of times because we only achieved to prepare two SIs with
a sufficient coating thickness, the WA20-80-2 and the WA20-80-3. Their
properties were detailed in section 6.5.2. In addition, we will see that their
use with the SF on the sensing capsule is limited in time.
The SI was glued on the sensing capsule as described in section 6.3.1
and the capsule was filled with the SF24P following the procedure detailed
in section 6.3.2. The capsule was pre-filled with the SF36P 48 h before the
measurements, as we also observed that it leads to a better viscosity stabil-
ity. All measurements were performed using the bidirectional mode.
6.5.3.A Experiment A
In figure 6.8, we present the result of a typical experiment with the SI
WA20-80-3. The system was first tested with a dextran solution in order
to verify the assembly and sealing of the capsule. The blue curve shows
the good stability. Subsequently, we used the SF, and during the first 24 h
the black curve shows a good stability of the viscosity at 2 mM of glucose
(region B). The region A corresponds to the signal stabilization which oc-
curs every time the demonstrator is started with a fresh SF. We remind that
the damping factor accuracy is increased for lower values since the rotor
speed decay takes place on more turns for lower viscosities. Therefore we
have a higher noise in region B.
At the start of region C, we set the sensing capsule environment at 4 mM
glucose. A viscosity decrease followed by stabilization is expected, but
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Figure 6.8: In vitro measurements of the IGLUS demonstrator with the
PPEGMA coated alumina membrane WA20-80-3 in the SITEM. The system
was first tested for stability with a dextran solution (blue curve). Subse-
quently, the SF24P was used and the external glucose concentration was
varied: A. stabilization, B. 2 mM, C. 4 mM, D. 2 mM, E. 30 mM, F. 2 mM, G.
30 mM, H. 7 mM and I. 2 mM.
124
6.5. In vitro results
instead of stabilizing, the viscosity keeps decreasing linearly. This phe-
nomenon is not clearly understood but we suppose that the SF is subjected
to a molecular reorganization due to the increase of the glucose concen-
tration. Indeed the viscosity of the SF at the beginning was unexpectedly
high at 36 mPas, refereing to the calibration of figure 6.5, whereas we mea-
sured 9.4 mPas for another preparation of the SF24P in section 3.4.3. This
highlights the non-reproducibility of the nominal viscosity at the prepa-
ration. In order to verify whether the SF was still chemically active, the
glucose was set back to 2 mM in region D. From region E to region I the
glucose concentration was varied two times up to 30 mM and back down
to 2 mM in order to assess the reversibility. For both regions with 30 mM
glucose (E and G), the same damping factor value was reached when sta-
bilizing. Whereas the stabilized damping factor values were different with
a decreasing tendency over time for every region at 2 mM (B, D, F and
I). The reversibility was thus not complete, but a partial reversibility was
observed.
The possible reasons for the incomplete reversibility of the viscosity
measurements under glucose concentration variations are various. The
ConA leakage is favored at higher glucose concentrations. At 2 mM glu-
cose, the network constituted by the dextran and ConA is highly linked
and, as a consequence, the ConA cannot leak through the SI. At higher glu-
cose concentration, i.e. at 30 mM, the network is untied and the ConA is
free to diffuse out of the sensing capsule through the SI. As previously dis-
cussed in section 5.8.1, the ConA contains fragments which can possibly
leak out of the SI. Another reason is the unstability of the SF upon glucose
variations. The SF24P was assessed in a closed capsule and the result, pre-
sented in section 6.5.1, demonstrated the viscosity stability over 50 hours,
but this experiment was operated at constant glucose concentration (2 mM)
and no data exists about the resistance of the SF under glucose variations.
In fact, the SF is not completely understood and many questions remain,
especially when the glucose concentration is varied. Investigations in a dif-
ferent system should be undertaken in order to give answers to these ques-
tions, because it is difficult to validate the SI and the SF simultaneously.
During this experiment, we observed that the response time of the de-
monstrator was higher for every supplementary glucose variation. At the
end of the experiment, regions H and I, the sensor showed only a very
slow response to the glucose concentration change. After 92 hours of run,
the demonstrator was rinsed and the SF replaced, but the sensor did not
respond to glucose variations anymore. The SI was fouled, because im-
permeable to glucose. We believe that dextran and/or ConA fragments
clog the pores. An investigation of this hypothesis is underway and results
will be presented in a later work. The decay of the sensor response time
throughout glucose variations is studied in details in experiment B.
We have to emphasize an important achievement. The SITEM setup
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Figure 6.9: in vitro measurements of the IGLUS demonstrator with the
PPEGMA coated alumina membrane WA20-80-2. The SF24P was used and
the external glucose concentration was varied: A. stabilization at 2 mM, B.
7 mM, C. 16 mM, D. 7 mM, E. 2 mM, F. 7 mM, G. 16 mM, H. 5 mM, I. 2 mM.
and J. 30 mM.
and IGLUS demonstrator completed a 92 hours run without the appear-
ance of a bubble, which shows the capability of the system to run over 4
days. This achievement is the result of the improvement of the preparation
and filling procedures described in sections 6.3.1 and 6.3.2.
6.5.3.B Experiment B
Experiment B is similar to experiment A. We replaced the SI by the WA20-
80-2 version which has very similar properties, as seen in table 6.2. The ex-
perimental and preparation conditions were identical. In this experiment,
we applied glucose concentration variations by renewing the RS around
the sensing capsule with a defined glucose concentration. Renewing the
RS is more precise regarding the glucose concentration than adding shots
of concentrated glucose. Hence, for every time region, named from A to J in
figure 6.9, the glucose concentration was precise and constant. Two cycles
of glucose concentration variation were applied by starting at 2 mM up to
16 mM with an intermediate step at 7 mM. The purpose of the cycles was
to test the viscosity reversibility. The result is presented in figure 6.9.
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As a result, the sensor followed the glucose variations, however the
complete reversibility was not observed. Indeed, the stabilized damping
factor values are not identical in regions A, E and I. We observed the similar
decreasing tendency when going back to 2 mM in the previous experiment.
The stabilized damping factor values for the high glucose concentration
are very close, see regions C, G and J. The stabilized value of region G
is a little lower than in region C, which is in accordance with the global
viscosity decrease over the entire experiment. The viscosity difference at 16
mM is smaller (between regions C and G) than at 2 mM (between regions A,
E and I) simply because the viscosity sensitivity to glucose is much higher
at lower concentrations, see viscosity variations of the SF24P in figure 3.12.
The last glucose variation to 30 mM (region J) was applied to verify the non-
fouling of the SI, and to show the poor sensitivity of the SF24P at higher
glucose concentration, above 16 mM.
After 48 hours of use, we stopped the experiment to preserve the demon-
strator in order to use it for the in vivo experiment presented in the next
chapter.
The response of the IGLUS demonstrator to the glucose variations was
analyzed and the response time for each time region was fitted using the
following equation
y = A(1− e− tτ ) + B (6.1)
which is derived from eq. (5.3) and where τ is the relaxation time. It is
common for sensors to give the τ90% value, which is the response time of the
sensor to reach 90% of the variation amplitude. The calculated values are
given in table 6.3. In addition, we calculated the extrapolated response time
τ90%* for the situation where the SI would totally surround the sensor. The
demonstrator presented in this work only has a partial opening for a flat SI,
as illustrated in figure 6.2, and a future version could integrate a tubular-
shaped SI which would surround the rotor. This situation would reduce
the response time since the surface is increased whilst the inner volume (SF
volume) remains equal. τ90%* is calculated using eq. (4.25).
In the results of table 6.3, we observe that the response time is higher
when the glucose concentration is decreased (regions D, E, H and I) than
when it is increased (regions B, C, F, G and J). Furthermore the response
time is lower when the glucose variation is in a higher concentration range,
i.e. τ is smaller when passing from 7 mM to 16 mM (regions C and G) than
from 2 mM to 7 mM (regions B and F). This observation is also valid for
the case of decreasing concentrations. The reason is that, at higher glucose
concentration, the SF viscosity is lower and thus the diffusion of glucose
is higher. The SF is supposed to be stirred by the rotor rotation, but we
suspect that a thin layer region on the inside face of the SI is not correctly
mixed and, in this region, the glucose is transported by pure diffusion. And
we know from the Stokes-Einstein relation (eq. (4.2)) that the diffusion
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Table 6.3: Response time of the IGLUS demonstrator according to the time
regions of figure 6.9. τ is the response time obtained by fitting with eq. (6.1),
τ90% is the time to reach 90% of the variation and τ90%* is the extrapolated
time for a surrounding SI.
Region Glucose variation τ [min] τ90% [min] τ90%* [min]
B 2 to 7 mM 48 110 18
C 7 to 16 mM 26 60 10
D 16 to 7 mM 156 359 59
E 7 to 2 mM 202 465 76
F 2 to 7 mM 64 147 24
G 7 to 16 mM 57 131 22
H 16 to 5 mM 227 522 86
I 5 to 2 mM 466 1072 176
J 2 to 30mM 37 85 14
coefficient of a solute is proportional to the viscosity of the medium.
As also observed in experiment A, the response time of the demonstra-
tor increases progressively throughout the experiment. As in experiment A
(section 6.5.3.A), the SI is progressively fouled when glucose variations are
applied.
The extrapolated response time τ90%* (assuming a cylindrical shaped
SI) is rapid, when increasing the glucose concentration, compared to the
20 min which is the required lag time from the medical point of view. The
response time remains important for decreasing glucose concentrations,
but the actual IGLUS demonstrator can be further optimized through vari-
ous modifications.
6.6 Discussion
The intrinsic performance of the SI on the demonstrator is difficult to as-
sess because many questions remain open concerning the SF. However the
SI showed good results since we could observe the glucose concentration
variations with the IGLUS demonstrator and the response time is promis-
ing. The only negative point is the incomplete reversibility of the SF viscos-
ity. At present, it is difficult to distinguish between a lack of performance
of the SI or the SF.
As previously discussed in section 5.8.1, ConA contains fragments which
could leak out of the SI, and would induce a progressive decrease of the SF
viscosity. The quantification of this effect is not in the scope of this work
and a further investigation on the SF could distinguish the performance of
the SI and SF. For instance, a SF should be prepared with purified ConA and
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the stability of the fluid be assessed. Another possibility would be the mod-
ification of ConA by pegylation since it increases its solubility. This mod-
ification consists of grafting PEG molecules to the protein. In fact, ConA
has a limited solubility in water which can be the cause of a slow precipi-
tation over time. In addition, the ConA pegylation increases its affinity to
D-glucose [150].
During the experimentation with the SF and the IGLUS demonstrator,
we observed a non-reproducibility from batch to batch and instability of the
nominal viscosity of the SF during storage, and this remains an important
source of unexplained behaviors of the demonstrator.
Regarding the SI, we previously discussed the progressive fouling. In
fact, the SI that were tested on the demonstrator showed a tendency to
improve their retention capability when used for a series of experiments.
We believe that a partial fouling of the membrane ameliorates the reten-
tion capabilities, while the glucose diffusion is altered. This conclusion is
highlighted by the fact that several SI got fouled after 4 to 6 days of use.
At present, we have not studied the details of the fouling process, but both
dextran and ConA can be the cause. Regarding dextran, we know that
both PEG (from PPEGMA) and dextran are very hydrophilic and polar
molecules. This makes them rather miscible and there is a possibility for
dextran to partially penetrate the PPEGMA coating. The possibility of a
simple adsorption of the dextran on the coating is minimum, if we refer to
the work of Singh et al. [155]. And, as discussed previously, the fragments
of ConA are also susceptible to foul the SI.
6.7 Conclusion and outlook
In this chapter, we demonstrated the promising performance of the SI com-
posed of an alumina membrane and a PPEGMA coating. We showed the
partial reversibility of the chemical process of the SF over two cycles of glu-
cose variations and demonstrated the use of the sensor over 92 hours. The
assessment of the SI on the IGLUS demonstrator is currently limited by the
SF performance.
At the present state of research, the IGLUS still needs improvements to
precisely monitor the glucose concentration. Nevertheless glucose varia-
tions can be clearly observed and the situation is very encouraging for a
proof of concept. Since the demonstrator presented in experiment B (see
section 6.5.3.B) showed a sufficient response to glucose variations, we used
it for an in vivo experiment which is presented in the next chapter.
Another way to assess our SI could be to use a different system than
the IGLUS since the performances of the SF, containing dextran and ConA,
are questioned. For example, a sensor recently developed by Lei et al. [63]
uses a phenylboronic acid based hydrogel to sense glucose. Alternatively, a
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possibility is to synthesize a stable and biocompatible SF based on phenyl-
boronic acid as proposed by Siqi et al. [156].
In 1994, Ballerstädt and Ehwald wrote in a scientific article [66] that
the SF is suitable and that "The technical challenge lies in miniaturization
by microengineering and microelectronics." At this point of our research,
we believe the microengineering and electronics not to be a challenge any-
more. For the IGLUS, the new challenge lies on the chemistry of the relation
between the SF and the SI and their long-term stability.
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IGLUS in vivo investigation
7.1 Introduction
As the IGLUS demonstrator showed promising results in vitro, we investi-
gated its sensing performance in vivo, since there are various differences in
the environmental conditions. The step from in vitro to in vivo experimen-
tation being a complex work, we did not intend to validate the functioning
of the sensor in vivo, but we investigated and established the necessary ba-
sis for further in vivo assessment of the IGLUS, with the aim to observe
glycemia variations of the animal. Prior to the sensor in vivo validation,
which is beyond the scope of this work, the new environment needs to be
investigated. Following this thread, we present the developed procedure
and the experiment in which an IGLUS demonstrator was implanted in an
animal over a period of five days. A Zucker Diabetic Fatty (ZDF) Type 2
diabetic rat was selected for the implantation. The ZDF rat model is appro-
priate since it is possible to control its glycemia either to hyper-, normo-, or
hypo-glycemia depending on the test requirements.
The implanted part of the demonstrator is a single capsule without elec-
tronics. It contains the sensitive fluid (SF) prepared with purified dextran
3200 kDa, ConA and phenol as an antiseptic. The demonstrator, used in this
experiment, is the version presented and tested in section 6.5.3.B, with the
selective interface (SI) WA20-80-2, i.e. an alumina membrane with 20 nm
pores with a PPEGMA coating. We used a in-house developed hand-held
reader to measure the signal of the sensor through the skin. The body tem-
perature of the rat was measured with a transponder located beneath the
skin right next to the sensor. The blood glycemia was monitored by com-
mercially available blood glucose meters, for which blood drop samples
were taken by pricking the tail, ear or tongue of the animal.
In this chapter, we present the assessment of the preparation and im-
plantation procedures of a working sensor device in a living animal. In
addition, we present and discuss the measurements obtained with the im-
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planted sensor. This experimentation was done in collaboration with the
Swiss Institute for Experimental Cancer Research (ISREC) and the Centre
d’Application du Vivant at EPFL.
7.2 Experimental description
7.2.1 Protocol
As the in vivo experimentation is a complex procedure. A protocol has been
written by our team and the main features are presented in the followings.
Objectives
• To validate the IGLUS demonstrator in-vivo, with semi-permeable mem-
brane
• To quantify the glucose variability of a ZDF rat and compare it to the sen-
sor response time
• To investigate the blood glucose behavior upon skipping an insulin bolus
Material
• 1 male rats of 8 weeks, ZDF
• 1 glucose sensor demonstrator, filled with SF with PSS dextran and phe-
nol, with semi-permeable membrane (WA20-80-2)
• One Plexx temperature transponder and reader
• One glucose meter for follow-up on glycemia
• Insulin Lantus Sanofi-Aventis R©, ultra-slow insulin, 100U / mL, injection
at 27U/kg
Sterilization
• Sensor capsule: γ radiation with 60Co, 29 kGy
• Sensitive fluid: contains 0.2% phenol
• Sterile assembly: in sterile laminar flow bench
ZDF rat glycemia regulation test. This series of experiments performed
prior to sensor implantation must help us understand how the rat glycemia
behaves when an insulin bolus is skipped.
Day 1:
• Evening: measure blood glycemia, insulin bolus injection, feed overnight
Day 2:
•Morning: remove food, measure rat blood glucose
• Evening: measure blood glycemia, skip insulin bolus, feed overnight
Day 3:
•Morning: remove food, measure blood glycemia
• Evening: measure blood glycemia, insulin bolus injection, feed ZDF rat
overnight
Implantation (see figure 7.7):
• Duration: 5 days, prolonged if successful
• Anesthesia: isoflurane, induction 4%, maintenance 2%
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•Analgesia: injectable buprenorphine, Temgésic R© SC, 0.0005 mg/ kg body
weight (BW) then Acetaminophen in drinking water, 300 mg/ kg BW
• Anti-infectious prophylaxis: Amoxicillin in drinking water, 100 mg/ kg
BW
• For surgery: skin disinfection with Betadine R©
• Location: on the flank
• Suture: with vicryl 4.0
• Temperature measurement: Shearing and disinfection with Betadiner
Rats identification:
• Rat #1: ZDF rat, grey and white fur and obese
• Rat #2: anti-depressive companion rat, white fur
Measurements with implant:
Day 1:
• Morning: sensor implantation, 2-3 measurements with implanted glu-
cose sensor to check its integrity
• Afternoon: measure blood glycemia (BG) and temperature (T), 10 mea-
surements under anesthetic with implanted glucose sensor, 1 min. interval
for checking coupling and sensor integrity
•Wait 1 hr: measure BG and temperature, 10 measurements with sensor
• Evening: slow-acting insulin bolus, feed
Day 2:
•Morning: 8:00 measure BG and T, 20 measurements with sensor; wait 2 h;
10:00 measure BG and T, 20 measurements with sensor
• Afternoon: 14:00 measure BG and T, 20 measurements with sensor; wait
2 h; 16:00 measure BG and T, 20 measurements with sensor
• Evening: skip insulin bolus (should be done as early as possible in the
experimental planning in case of sensor stability issues), feed
Day 3: With previous insulin delivery more than 36 hr before, the ZDF rat
should be reaching hyperglycemia
• Same as Day 2, however with insulin administration at 8:00
Day 4:
• Same as Day 3, however with insulin administration at 16:00
Day 5:
• Same as Day 3, i.e., with insulin administration at 8:00
From Day 6: Only if previous measurement campaign was successful
•Measure the blood glucose prior to insulin bolus and 3-4 h later, perform
a few measurements for statistics
Explantation:
• Keep the rat alive
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7.2.2 Implant and acquisition system
The IGLUS demonstrator was chosen for implantation after in vitro tests.
The demonstrator, detailed in chapter 6, with the SI WA20-80-2 showed the
best results in vitro (see section 6.5.3) in terms of reversibility and time sta-
bility, and was therefore appointed for the in-vivo experimentation. The
SF used for this experiment was obtained from SF36P prepared with puri-
fied dextran 3200 kDa from PSS, 0.2 wt% phenol, 2 mM glucose, and from
RS prepared with same concentrations of phenol and glucose. The mixing
ratio was 2:1 (SF:RS) in order to obtain an SF24P.
The acquisition system used to measure the damping factor is an in-
house developed system named "Glucorat System". It is a portable version
of the acquisition system presented in section 6.4.1.A. The hand-held reader
measures the damping factor of the implanted sensor through the skin and
sends the data wirelessly. The Glucorat is an electronic system which con-
sists of two parts: a hand-held electronic reader (Glucorat Reader) capable
of measuring the damping factor of the implanted sensor through the skin
and a remote base station (Glucorat Base Station) that, when connected to
a PC, gathers data from the reader for further analysis. The Glucorat has
been developed by Sadasing Kowlessur and Julien Chassot. The global sys-
tem is depicted in figure 7.1 and the hand-held reader is detailed in figure
7.2. The main gathered data are the damping factor and the temperature
of the drive. Contrary to in vitro measurements, the drive capsule has a
different temperature than the sensor capsule, which means that we need
to collect the damping factor and temperature for each capsule. For ev-
ery measurement we get the coupled damping factor of the two capsule λt
and, right after, the damping factor of the drive alone λd. Knowing that
λt = λd + λs [22], we can extract the damping factor of the implanted sen-
sor λs. The temperatures Td and Ts are acquired from the Glucorat Reader
and an implanted transponder respectively.
In order to monitor the rat body temperature we placed a IPTT-300 Pro-
grammable Temperature Transponder from PLEXX1 beneath the skin next
to the glucose sensor. The temperature acquisition was done with a DAS-
6007 Handheld Scanner also from PLEXX. The data acquisition with the
Glucorat Reader and the DAS-6007 Scanner are shown in figure 7.3. This
system allows temperature reading wirelessly and the transponder is cor-
rectly located for measuring the temperature of the implant. Rectal tem-
perature measurement is a standard for body temperature, but the temper-
ature beneath the skin is slightly lower (∼ −1˚C).
1www.plexx.eu
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Figure 7.1: Data acquisition from implanted sensor with the Glucorat Sys-
tem.
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Figure 7.2: Hand-held reader (Glucorat Reader) the in vivo data acquisi-
tion. a) the hand-held reader, b) the measuring probe.
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a) b)
Figure 7.3: Data acquisition on implant. a) temperature acquisition from
the subcutaneous transponder, b) damping factor acquisition through the
skin.
7.2.3 In vivo data acquisition assessment
The data acquisition with the implanted sensor and the Glucorat System
can suffer from misalignment when in-vivo. Therefore we studied the er-
rors caused by misalignment on the damping factor measurement in a prior
experiment. To this end, we implanted a closed capsule in a non-diabetic
rat and measured its damping factor with the Glucorat System, once vary-
ing the distance between the capsule and the reader lA (axial displacement),
and once shifting the reader perpendicularly to the alignment axis lL (lat-
eral displacement). The results are shown in figure 7.4 and are necessary
for in vivo measurement when a swelling appears around the implant and
makes the alignment difficult. The results shows that the axial displace-
ment must be >4 mm to affect the measurement, and the lateral displace-
ment >2 mm. The skin of the rat being only 1-2 mm thick, the axial dis-
placement is not an issue, but the lateral displacement is an error caused
by the practitioner and needs a guiding system to be avoided. Therefore
a series of guides has been designed and adapted to the Glucorat reader
head. The series of guides ranges from 10 mm to 19 mm inner diameter
and are shown in figure 7.5.
7.2.4 The ZDF rat
The ZDF (Zucker Diabetic Fatty) rat is an inbred rat model that, through
genetic mutation and a managed diet of Purina 5008, will closely mimic
human adult onset diabetes (Type 2) and related complications. When fed
with a diet of Purina 5008, homozygote recessive males (fa/fa) develop
obesity, hyperlipidemia, fasting hyperglycemia, and Type 2 diabetes. The
ZDF rat is an accurate model for Type 2 diabetes based on impaired glucose
tolerance caused by the inherited obesity gene mutation which leads to
136
7.2. Experimental description
drive
sensing
capsule
l
A
l
L
hand-held reader
- 1 0 1 2 3 4 5 6 7 8 9 1 0 1 11
2
3
4
5
6
7
 
 
Dam
ping
 fac
tor 
of t
he 
imp
ant
 [1/
s]
A x i a l  d i s p l a c e m e n t  l A  [ m m ]
0 1 2 3 4 56
7
8
9
1 0
1 1
1 2
1 3
1 4
1 5
 
 
Dam
ping
 fac
tor 
of t
he 
imp
ant
 [1/
s]
L a t e r a l  d i s p l a c e m e n t  l L  [ m m ]
Figure 7.4: Misalignment effect on damping factor reading.
a) b)
drive
13mm guide
Figure 7.5: a) Glucorat Reader head with 13 mm alignment guide.
b) 10 mm to 19 mm inner diameter guides.
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insulin resistance2. We acquired the ZDF rat at the age of 4 weeks and
fed it with a diet of Formulab Diet 5008 (Purina 5008 equivalent) from PMI
Feeds Inc.. Formulab Diet is a high-energy and high-protein formulation
diet.
The rat followup of its weight, blood glycemia, insulin injections and
nutrition evolution before implantation is presented in table 7.1. As ex-
pected, the rat developed obesity and a Type 2 diabetes at the age of 8
weeks. It also showed an insulino-resistance to the injected insulin. On day
33 in table 7.1, we started the glycemia regulation test described in section
7.2.1. We tried to control the blood glycemia of the rat, but the regulation
remains difficult.
7.2.5 Procedures for sensor preparation and implantation
Every step for sterilizing, assembling the sensor and implanting are listed
hereafter. The following procedure are essential for the well functioning of
the experiment.
Sterilization protocol:
• Demonstrator core with glued membrane in reference solution (RS) with
phenol, sterilized by γ-radiation 29 kGy
• Demonstrator cap in RS with phenol, sterilized by γ-radiation 29 kGy
• Rotor, sterilized with ethanol/water (70%/30%)
• Sensitive fluid, contains 0.2 wt% phenol
• Reference solution, contains 0.2 wt% phenol
• Physiological solution 0.9% NaCl and 2 mM glucose, filtration with
0.22 µm filter
The sterilization choices have been tested and compared with other
techniques. For example the sterilization by ethylene oxide vapor has been
discarded because it affects the membrane coating though it is easier to de-
ploy. And the SF cannot be sterilized by γ-radiation because both dextran
and ConA are destroyed. The γ-radiation dose is given by the sterilization
standard as a minimum of 25 kGy3 according to the International Atomic
Energy Agency [157]. After irradiation of the demonstrator core, the mem-
brane had a brown coloration, see figure 7.6. It is due to the partial degra-
dation of the phenol during the γ-radiation exposure.
Assembly protocol:
1. Fill demonstrator core with degassed SF
2. Insert rotor
3. Screw cap, slowly to avoid overpressure, keep membrane wet with de-
gassed RS
4. Check if rotor spins without resistance with a magnetic object, if not ad-
2Charles River Laboratories specification sheet.
3The gray (symbol: Gy) is the SI unit of absorbed radiation dose.
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Table 7.1: ZDF rat evolution of weight, blood glycemia (BG), injections of
insulin units (IU) and periods without food (Diet).
Insulin unit definition: The activity contained in 1/22 mg of the interna-
tional standard of zinc-insulin crystals.
Date Day Time Weight g BG mM BG mg/dl IU Diet
13.03.2008 1 09:00 198 7.9 142.2
17.03.2008 5 09:00 227 3.2 57.6
20.03.2008 8 09:00 247 5.3 95.4
25.03.2008 13 09:00 285 7.7 138.6
27.03.2008 15 09:00 300 7.6 136.8
01.04.2008 19 09:00 326 17.3 311.4
04.04.2008 22 09:00 337 16.2 291.6
06.04.2008 24 09:00 341 19 342
07.04.2008 25 09:00 346 17 306 9
08.04.2008 26 09:00 17.3 311.4 9
09.04.2008 27 09:00 354 17.8 320.4 12
10.04.2008 28 09:00 365 5.8 104.4 11
11.04.2008 29 09:00 371 14.9 268.2 12
12.04.2008 30 09:00 374 4.4 79.2 11
13.04.2008 31 09:00 380 6.7 120.6 10
14.04.2008 32 09:00 382 16.3 293.4 11
15.04.2008 33 09:00 398 15 270
16:00 14 252 12
16.04.2008 34 09:00 393 6.1 109.8 start
10:30 5.4 97.2 at 9:30
13:30 6.5 117
14:30 11.1 199.8
15:30 9.8 176.4
16:30 7.9 142.2 11 end
17.04.2008 35 09:00 402 4.8 86.4 start
17.04.2008 11:00 3.9 70.2 end
17.04.2008 16:00 10.8 194.4 12
18.04.2008 36 09:00 416 7.5 135 12
19.04.2008 37 16:00 397 2.6 46.8 9
20.04.2008 38 16:00 371 2.9 52.2 8
21.04.2008 39 10:00 371 3.4 61.2
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a) b)
Figure 7.6: Sensor assembly. a) the body of the sensor before assembly, b)
the assembled sensor right before implantation.
just cap tightening
5. Place PTFE sleeve over the demonstrator on the other side of the cap and
cover the membrane opening of the core, the membrane opening is filled
with degassed RS
6. Glue (Ecobond) the cap with the core and the cap overpressure hole in
order to seal the demonstrator
7. Glue (Ecobond) the support onto the demonstrator
8. Wait 3h at ambient temperature for the glue to polymerize
9. Check functioning of demonstrator with reader (repeat 2-3 acquisitions)
10. Rinse the demonstrator with degassed NaCl-glucose solution just be-
fore implantation
The assembly procedure is essential to avoid drying of the membrane,
and thus air bubbles formation in the sensor. The assembled sensor is
shown in figure 7.6.
Implantation procedure (see figure 7.7):
11. Shave and disinfect implantation site (flank)
12. Open of the skin and fat layer in order to see the abdominal muscle of
the flank
13. Stitch demonstrator onto the muscle and inject physiological solution
with 2mM glucose so that the membrane remains wet
14. Stitch the opening
15. Inject subcutaneously some more physiological solution with 2mM glu-
cose
7.3 Results and discussion
The results of the in vivo experiment are presented in two parts. The first
part deals with the preparation, the implantation procedure of the sensor
and the surgical observations. In the second part, we expose and discuss
the measurements obtained with the implanted demonstrator while the
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Figure 7.7: Implantation of the sensor demonstrator.
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rat’s glycemia evolves.
7.3.1 Preparation and implantation procedure
An important outcome of the in-vivo experimentation was to validate the
preparation and implantation procedure of the sensing device. In order to
prepare the in-vivo study, we have performed the necessary biocompatibil-
ity tests of different materials of which the implanted part of the sensor are
composed, i.e. PMMA, the Eccobond adhesive and the SI. The biocompat-
ibility tests implied the implantation of pieces of the materials for several
weeks and an histology of surrounding tissues. The tests are still underway
and hence the results are not presented in this work, and will be presented
in an upcoming study. However the present results show a positive ten-
dency and the PPEGMA coating shows an improved biocompatibility. We
have also tested the different sterilization ways for each component of the
implant.
The implantation of the sensor did not cause any complication (see fig-
ure 7.7). Since the ZDF rat is obese, the important fat layer needs to be
spread in order to stitch the sensor to the flank muscles. After implanta-
tion, we have observed the evolution of the scar and of the swelling around
the implant, as shown in figure 7.8. On day 1, the important swelling is
due to the physiological solution around the implant which was injected
to avoid drying the membrane as well as any air bubble appearance in the
implant. We used the 14 mm guide for the measurement (see 7.2.2). On day
2, the swelling became more important. The injected physiological solution
was not completely resorbed and apparently there was some inflammation
due to the surgery. The handling of the sensor was thus more difficult but
achievable with a 15 mm guide. It was difficult to hold the implant in such
conditions, but we were able to align the reader with the sensor. With good
alignment, the distance between the sensor and the reader is not an issue.
Day 3, the swelling started to reduce so the sensor handling became more
precise. Day 4, the swelling kept reducing so that the sensor shape under
the skin started to be visible and we used the 14 mm guide. Day 5, the
swelling disappeared and one sees distinctly the sensor shape under the
skin. We could even use the 13 mm guide.
In addition to the body reaction to the implant, the influence of the im-
plant on the ZDF rat was also an important point to be observed. As de-
scribed above, the sensor shape became visible through the skin after three
days of implantation. As long as we observed, the rat did not seem to be
bothered by the implant, thus didn’t eat its stitches either. Even though
the size of the implant was rather large compared to the ZDF rat, it was
not a disturbance for the rat. Indeed the implant was of the same thickness
as the fat layer, and the protuberance it created didn’t disturb the animal.
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Day 1: just implanted Day 3
Day 4 Day 5
Figure 7.8: Evolution of the scar. On day 1 the important swelling was due
to injection of physiological solution. Day 3, the swelling reduced so the
sensor handling became more precise. Day 4, the swelling kept reducing
so that one sees the sensor under the skin. Day 5, the swelling disappeared
and one sees distinctly the sensor.
Finally, the implantation site did not reveal any infection or important in-
flammation at explantation, as depicted in figure 7.9. After explantation,
we did not observe any damage of the sensor. The most fragile part of the
demonstrator, the SI, was unimpaired. Finally, as shown in section 7.2.5,
the SI became brownish after gamma irradiation, but this wasn’t an issue
since no extraordinary inflammation was observed.
7.3.2 Implanted sensor response
While the sensor demonstrator was implanted, the signal that we measured
is the damping factor of the implanted capsule. As previously discussed in
section 6.6, the glucose concentration cannot be systematically determined,
due to the non-reproducibility of the SF characteristics and the difficulty
to calibrate the damping factor to the glucose concentration. For these rea-
sons, we plotted the inverse of the damping factor in order to have the
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a) b) c)
Figure 7.9: Explantation of the sensor demonstrator: a) reopening of the
scar, b) there is no infection nor important inflammation, c) the sensor is
unimpaired.
same trends as the glucose concentration. The signal variations were com-
pared to blood glycemia measurements and plotted in figure 7.10. Since
the measurements with the implant require an operator, and the rat to be
anesthetized, the measurements have been planned as 3-4 sessions per day
(see protocol in section 7.2.1). In each session, 20 measurements were per-
formed (1 measurement/min). The plot in figure 7.10 shows the average
() and the standard deviation (error bars) of every session.
The blood samples were taken by pricking the tail, ear or tongue of the
animal and glycemia values were analyzed with a commercial blood glu-
cose meter. The results of blood glycemia measurements are presented in
figure 7.11. These measurements were not accurate, the reasons are the
precision of the glucose meter, which is only of 20%, and the fact that in-
tensive stinging on a skin area created hematomas which significantly al-
ter the blood measurements. We measured the blood glycemia before and
after each anesthesia and, in most of the cases, it was lower after the anes-
thesia. The anesthesia seemed to reduce the glycemia value though the
isofluran can cause a temporary increase of the blood glucose4. On the
contrary, the amoxicillin, which we administrated as anti-infectious, can
reduce the glycemia value result as amoxicillin interferes in the chemical
process5. Therefore it is difficult to determine a systematic reduction of the
glycemia because the variations are due to a combination of the following
factors: hematomas, drugs, anesthesia, stress, sampling site. We would
need a central venous catheter, no anesthesia and no drugs in order to have
reliable and comparable measurements. In figure 7.10, we chose as a refer-
ence the blood glucose measurements done before the anesthesia with the
Pharmacia meter. We usually did 2-3 measurements, thus we plot the mean
value and the error.
If one compares the data obtained with the sensor and the blood glu-
4Compendium suisse des médicaments, see Isofluran Baxter
5Compendium suisse des médicaments, see Amoxicillin-CIMEX
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day 1 day 4 day 5day 2 day 3
Figure 7.10: Superposition of the sensor measurements and the blood gly-
cemia evolution.
day 1 day 4 day 5day 2 day 3
Figure 7.11: Blood glycemia measurements obtained by pricking the tail,
ear or tongue. Two commercial blood glucose meters were used: the Phar-
macia and the Accu-Chek.
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cose measurements, we see a similar trend in the variations, see figure 7.10.
These results must be interpreted cautiously. In fact the damping factor
values are much lower than expected. This means that the viscosity of the
SF inside the sensor is very low. There are different hypothesis to explain
this low viscosity. The SF has been prepared with purified dextran and we
have noticed that it is an issue regarding the viscosity reproducibility with
such a preparation. Furthermore a solution can change its viscosity after a
few days when stored, without changing its composition. Another hypoth-
esis is that the ionic composition of the interstitial fluid around the sensor
is different from the in-vitro experimentation. For example, the Mn2+ con-
centration is very low in the body [158]. In fact, Mn2+ only appears as trace
element in the blood, in the order of 30 µg/l [159], but we found no data
on the interstitial fluid concentration. Because of the low concentration,
there is a chance that the Mn2+ ions leave the ConA protein. The site can
be replaced by Ca2+ without losing the glucose affinity [93], but we don’t
know the effect on the viscosity of the solution. This could partially explain
the drop of viscosity when the sensor was implanted. We also observed a
precipitation in the batch of SF prepared for this experiment one week after
dilution. It seems to resolubilize when shaken. The batch was prepared 3
days before the sensor assembly and its viscosity was much higher at this
moment. There has been a drop of viscosity over 3 days which we can’t
explain with our current knowledge. We have less experience with the use
of purified dextran 3200 kDa (PSS) than non-purified dextran 2000 kDa
(Fluka). For this experiment, we wanted a low viscosity in order to make
sure to be able to measure the damping factor with the reader, and to max-
imize the diffusion time of the glucose inside the sensor since the mixing
is not continuous as in vitro. Right before the implantation, the SF turned
out to have a lower viscosity than expected, probably due to a partial loss
of activity of ConA. Another observation is that the rotor started rusting
after explantation. We cannot tell if the corrosion process already started
when implanted. This can also induce a loss of viscosity because it can
change the pH and bring new ions in the solution. Corrosion of the rotor
can also affect its rotation, but the corrosion was not sufficient at explan-
tation. We cannot explain the deterioration of the rotor parylene coating.
With the aim to quantify the decrease of viscosity with respect to a loss of
ConA, we qualified a SF23P in the capillary viscometer (see figure 3.11).
We observe that a loss of 25% of ConA leads to a viscosity decrease of 25 -
35% at 35◦C (rat subcutaneous temperature). This shows that the leakage
and/or degradation of ConA have an important impact on the viscosity.
Considering all these unknown parameters, it is difficult to ensure that the
variations observed with the implanted sensor are solely due to glycemia
variations.
The results of day 5 show an important mismatch with the blood glycemia
measurements. We know from experiments that the membrane gets fouled
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after a few days of use on the sensor (see section 6.5.3). After explantation,
we tested the demonstrator in vitro again and noticed that the membrane
was fouled. This can explain the non-match for day 5.
7.3.3 Statistical analysis
As discussed previously, we cannot ensure that the observed signal vari-
ations with the implanted sensor are solely due to glucose variations. In-
deed, the damping factor values are <3 and, in this range, the dependence
of the damping factor as a function of the viscosity is not linear anymore
and is difficult to qualify as it exhibit a high error. Therefore we proposed
a statistical analysis to determine whether the signal variations are lost in
the noise and to qualify the correlation between the sensor signal and the
blood glycemia evolution.
7.3.3.A Correlation Test
In order to qualify the correlation between the two sets of data, one can per-
form a correlation test [18]. In probability theory and statistics, a correlation
(measured as a correlation coefficient) indicates the strength and direction
of a linear relationship between two random variables. A number of dif-
ferent coefficients are used for different situations. The best known is the
Pearson product-moment correlation coefficient, which is obtained by di-
viding the covariance of the two variables by the product of their standard
deviations:
r =
1
n
n
∑
i=1
(
Xi − X
σX
)(
Yi −Y
σY
)
(7.1)
where Xi−XσX , X, and σX are the standard score, population mean, and pop-
ulation standard deviation (calculated using n in the denominator).
The correlation result ranges from 0.1 to 1, 0.1 being the minimum and
1 the maximum (1 indicates that the two variables analyzed are equivalent
modulo scaling). When applied to both sets of data, we obtain the follow-
ing result6 :
Pearson’s product-moment correlation:
data: sensor and blood glycemia (day 1 to 4)
df = 225, p-value = 4.337e-06
alternative hypothesis: true correlation is not equal to 0
95 percent confidence interval: 0.1762 0.4136
sample estimates: r = 0.2995704
where df is the degree freedom and r the correlation coefficient. This result
6This has been done with the program R, www.r-project.org
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includes only day 1 to day 4. It is clear from figure 7.10 that the data from
day 5 don’t match. As the preliminary analysis, we want to qualify only the
data showing a correlation. A correlation of 0.3 means a small to medium
correlation. The interpretation of these values is arbitrary depending on
the context and purposes. Nevertheless we can conclude that we have an
existing correlation between the two sets of data, blood glucose and sensor
readings.
7.3.3.B Student T-test
Looking at the results on figure 7.10, one notices a grouping of the mea-
surements per day. As described in section 7.2.4, the glycemia of the rat
was regulated so that it varies from day to day. As a matter of fact, the
sensor had a slow response time as described in section 6. Moreover the
regular but not continuous mixing of the SF inside the sensor, as was the
case for in vitro experiments, leads to an even slower response time. The
first day, we started with a very low glycemia which increased continu-
ously until day 3, and then was reduced on day 4. We thus proposed to
compare the sensor data grouping them per day, making every day a data
set, from which we can analyze the data spreading. The analysis allows us
to tell if the variations from day to day are random (lost in the noise) or
distinct. We applied the Student T-Test [18] which is a test of the null hy-
pothesis that the means of two normally distributed populations are equal.
Given two data sets, each characterized by its mean, standard deviation
and number of data points, we can use a t-test to determine whether the
means are distinct, provided that the underlying distributions can be as-
sumed to be normal [18]. The equation for unequal sample sizes and equal
variance is
t =
X1 − X2√
(N1−1)σ21+(N2−1)σ22
N1+N2−2
(
1
N1
+ 1N2
) (7.2)
where Xi, σ2i and Ni are the mean, variance and number of participants
of the two samples. The statistical significance level associated with the t
value calculated in this way is the probability that, under the null hypothe-
sis of equal means, the absolute value of t could be that large or larger just
by chance.
The hypothesis required for this test are the following: a) normal dis-
tribution of data, b) equality of variances (determined by using a variance
test), c) determine if samples are independent or dependent (different equa-
tions). The data grouped per day are represented in a box plot in figure
7.12. Prior to the t-tests, we performed a variance test between data sets in
order to verify the hypothesis of equal variances. We chose the F-test [18]
with the null hypothesis being the equality between variances. The p-values
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are given in table 7.2. If the p-value is > 5%, the test is accepted, which
is the case for all cases of 7.2. The variances being equal, hypothesis b)
is fulfilled for the T-tests. Hypothesis a) is also fulfilled because we have
enough data to apply the central limit theorem [18], which tells us tha the
sum of a large number of independent random variables each with finite
mean and variance will be approximately normally distributed. Finally all
couples of data sets are independent. We can thus apply the t-tests with
the null hypothesis being the means of the two normally distributed populations
are equal and the p-values are given in table 7.3. If the p-value is < 5%,
the test is rejected and this proves the discrimination of the means of the
data sets. We can see that the means of day 2 and 3, and day 3 and 4 are
distinct, whereas the means of day 2 and 4 are equal. Assuming that the
sensor signal variation are coupled glucose variation, the sensor reacts to
glucose variations from day 1 to day 4.
Table 7.2: p-values for the variance test (F-test). If the p-value is >5%, one
can say that the variances are equal.
day 2 day 3 day 4
day 2 1 0.4357 0.88
day 3 0.4357 1 0.5579
day 4 0.88 0.5579 1
Table 7.3: p-values for the Student T-test. If the p-value is<5%, this proves
the discrimination of means of the data sets.
day 2 day 3 day 4
day 2 1 2.692e-10 0.2096
day 3 2.692e-10 1 4.898e-07
day 4 0.2096 4.898e-07 1
7.4 Conclusion and Outlooks
The preparation and the implantation procedure of a working sensor de-
vice in a living animal were well validated. We successfully implanted the
sensor demonstrator in the ZDF rat without any complication such as in-
fection and important inflammation. The sensor shape was visible through
the skin after three days of implantation which is a sign of minimal inflam-
mation. After explantation we did not observe any damage of the sensor.
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Figure 7.12: Box plot [18] of measured data per day. The center bold line
represents the median. The lower and upper limits of the box are the first
and third quartile and thus the box contains 50% of the distribution. The
"error bar" contains 99.3% of the distribution. The closed dots indicate
the outliers. The representation shows the discrimination of the data from
day 3 compared to day 2 and 4.
The in vivo demonstration of the sensor was also successfully carried
out. We could observe variations of the sensor signal corresponding to the
glycemia variations, but we cannot ensure that the signal variations are
solely due to glycemia variations. Several parameters needs to be better
controlled. A full success can be achieved by further in vivo experiments.
We need to know more about the ionic variations below the skin and
their effect on the SF viscosity. Detailed characterization of the sensitive
solution with PSS dextran will be necessary: a) Adjustment of viscosity (by
changing composition / dilution). b) Investigate the influence of much less
Mn2+ in the reference solution.
By means of these advances, we would improve, not only the demon-
strator itself, but also the blood glycemia measurements, more continuous
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measurements, better knowledge on sensor response time as a function of
inner mixing and a better knowledge of the SF behavior. For the next exper-
iments, we would need a rat with a central venous catheter to get reliable
blood glycemia measurements. An automated continuous measurement
using the demonstrator sensor and an implantable electronics would be a
must in order to study the in vivo response time. This would also avoid
recursive anesthesia and stress to the animals since these factors influence
the glycemia.
In order to get a fully working glucose sensor, the research has to be
emphasized on the chemistry of the SI and the SF. The actual methods to
characterize the SI allow a rough determination of the retention proper-
ties. Efforts need to be deployed on analytical chemistry to measure very
slow leakage of polypeptides and polysaccharides. The permeate resulting
of the leakage needs to be analyzed to determine its nature and molecular
weight. The fouling of the membrane is also an issue. The SF still has un-
known behaviors and its characterization with purified dextran needs to
be studied in details. As a matter of fact, the micro-engineering and elec-
tronic parts of the project are sufficiently advanced at this research stage.
The implantation protocol meets also the requirements.
For a long term implant, a suitable coating is needed on the entire outer
surface in order to prevent an encapsulation. Because the encapsulation
tissue have a threefold slower diffusion time for small species like glucose
compared to regular subcutis tissue [160], which would drastically increase
the lag time of glucose concentration between blood and the implant site.
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Conclusion
After a literature search and theoretical considerations, based on the IGLUS
requirements, we selected two selective interfaces among the most actual
technologies: hybrid membranes composed of a nanoporous alumina mem-
brane coated with PPEGMA brushes and nanoporous polyethylene films,
which have different advantages from each other. The presented theoretical
model for the transient diffusion of a solute through membranes permitted
us to quantify the membrane performance.
Both selective interfaces were characterized systematically and their se-
lectivity to a test protein was thoroughly demonstrated. Furthermore, we
highlighted the link between the diffusion rate of glucose and the protein
retention threshold, which enabled us to determine the membrane perfor-
mance without complex analysis. The optimized hybrid porous alumina-
PPEGMA selective interface revealed sufficient retention properties of dex-
tran and ConA in diffusion cells over 48 hours.
In a second step, we integrated the hybrid selective interface to a newer
IGLUS demonstrator in order to investigate the performance of the hybrid
selective interface under an environment mimicking the real working con-
dition of the sensor. The integrated IGLUS demonstrator showed its good
ability to respond to glucose variations in vitro, and we transferred all the
knowledge obtained from in vitro experiments to in vivo experimentation.
The in vivo test was carried out over 5 days in a rat model, and the im-
plantation as well as the transcutaneous data acquisition were successfully
demonstrated. On the other hand, there are still many points to be im-
proved. One of the most important hurdle to overcome is the sensitive
fluid. The assessment of the selective interface on the IGLUS demonstrator
is currently limited by the performance of the sensitive fluid. For realiza-
tion of a long-term implant, a suitable coating is needed on the entire outer
surface in order to prevent any encapsulation, which should be achievable
once such materials are available.
The technologies for a selective interface which we investigated are not
restricted to the glucose-sensitive fluid composed of dextran and ConA.
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Indeed the actual well-known chemicals capable of selectively recognize D-
glucose are ConA and boronic acid, and a sensitive fluid containing boronic
acid may also be used for our system.
We have developed a characterization procedure of the selective inter-
face for the IGLUS, experimentally and by theoretical analysis, which now
offers a solid basis for the realization of a long-term implantable continu-
ous glucose sensor. We believe to have paved an important part of the road
to a working device.
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Acronyms and Glossary
AAO Anodic Aluminium Oxide.
BSA Bovine Serum Albumin.
CA Cellulose Acetate.
CE Cellulose Ester.
CGM Continuous Glucose Monitoring.
ConA Concanavalin A.
IF Interstitial Fluid.
IGLUS Implantable GLUcose Sensor.
MALDI Matrix-Assisted Laser Desorption/Ionization.
MW Molecular Weight.
MWCO Molecular Weight Cut-Off.
PE PolyEthylene.
PEG PolyEthylene Glycol.
PES PolyEtherSulfone.
PET PolyEthylene Terephtalate.
PMMA Poly(Methyl MethAcrylate).
PPEGMA Poly PolyEthylene Glycol MethAcrylate.
PS PolySlufone.
PSS Polymer Standard Service GmbH.
PTFE PolyTetraFluoroEthylene.
PVDF PolyVinyliDene Fluoride.
RC Regenerated Cellulose.
RF Radio Frequency.
rI refraction Index.
RS Reference Solution.
SEC Size-Exclusion Chromatography.
SEM Scanning Electron Microscopy.
SF Sensitive Fluid.
SITEM Simplified In-viTro Environment Model.
TEM Transmission Electron Microscopy.
ZDF Zucker Diabetic Fatty.
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c(x, t) Concentration as a function of position and time [M]
∆c(t) Concentration difference between the two chambers as a
function of time [M]
D Bulk diffusion coefficient [mm
2
s ]
De Effective diffusivity [mm
2
s ]
Dm Modified diffusion coefficient [mm
2
s ]
K Partition coefficient [n.u.]
k Partitioning coefficient [n.u.]
l Thickness of selective interface [mm]
lc Chambers depth of the diffusion cell [mm]
S Surface of selective interface [mm2]
Va Volume of chamber A [mm3]
Vb Volume of chamber B [mm3]
φ Porosity [n.u.]
υ0 Bulk molar volume [ m
3
mol ]
υ Molar volume [ m
3
mol ]
τ1 Relaxation time of quasistationary case [s]
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PPEGMA coated alumina membranes
Nomenclature in thesis Nomenclature in experiments
WA20-NC Whatman non-coated
WA20-10-1 lolo079-S5
WA20-20-1 lolo083-A
WA20-30-1 lolo083-D
WA20-40-1 lolo083-E
WA20-60-1 lolo080-S7
WA20-180-1 lolo79-S13
WA20-40-2 lolo79-S5
WA20-40-3 lolo83-A
WA20-40-4 lolo83-D
WA20-40-5 lolo85-5
WA20-40-7 lolo85-2
WA20-40-8 lolo85-4
WA20-40-9 lolo85-7
WA20-40-10 lolo80-S7
WA20-40-11 lolo85-3
WA20-40-12 lolo85-6
WA20-40-13 lolo80-S3
WA20-40-14 lolo85
WA20-80-1 SLL011-4
WA20-80-2 SLL6-5
WA20-80-3 SLL6-6
WA20-160-1 SLL016-3
PE films
Nomenclature in thesis Nomenclature in experiments
PE-30-20 20060801-A
PE-30-30 20060801-B
PE-30-40 20060801-C
PE-15-05 20061222-05min
PE-15-10 20061222-10min
PE-15-30 20061222-30min
PE-15-60 20061222-60min
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